Marrone Bio Innovations (MBII) 10-K 25 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 14, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-K	'
Amendment Flag	'false	'
Document Period End Date	31-Dec-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'FY	'
Trading Symbol	'MBII	'
Entity Registrant Name	'MARRONE BIO INNOVATIONS INC	'
Entity Central Index Key	'0001441693	'
Current Fiscal Year End Date	'--12-31	'
Entity Well-known Seasoned Issuer	'No	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Filer Category	'Non-accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	19,616,399
Entity Public Float	$139,355,337	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$24,455	$10,006
Restricted cash	'	9,139
Short-term investments	13,677	'
Accounts receivable	6,215	2,834
Accounts receivable from related parties	903	136
Inventories, net	11,666	4,872
Prepaid expenses and other current assets	1,737	478
Total current assets	58,653	27,465
Property, plant and equipment, net	9,420	3,528
Other assets	806	2,785
Total assets	68,879	33,778
Current liabilities:	'	'
Accounts payable	4,460	2,104
Accrued liabilities	4,380	3,023
Deferred revenue, current portion	1,209	193
Deferred revenue from related parties, current portion	131	131
Capital lease obligations, current portion	1,401	207
Debt, current portion	157	8,572
Convertible notes payable, current portion	'	22,518
Total current liabilities	11,738	38,933
Deferred revenue, less current portion	744	937
Deferred revenue from related parties, less current portion	628	759
Capital lease obligations, less current portion	1,134	195
Debt, less current portion	12,280	7,766
Convertible notes payable, less current portion	'	19,342
Other liabilities	571	481
Total liabilities	27,095	68,413
Commitments and contingencies (Note 15)	'	'
Preferred stock	'	'
Stockholders' equity (deficit):	'	'
Common stock: $0.00001 par value; 250,000 shares authorized and 19,323 shares issued and outstanding at December 31, 2013; 12,936 shares authorized and 1,267 shares issued and outstanding at December 31, 2012	'	'
Additional paid in capital	147,220	1,322
Accumulated deficit	-105,436	-75,569
Total stockholders' equity (deficit)	41,784	-74,247
Total liabilities, convertible preferred stock and stockholders' equity (deficit)	68,879	33,778
Series A convertible preferred stock [Member]	'	'
Current liabilities:	'	'
Preferred stock	'	3,747
Series B convertible preferred stock [Member]	'	'
Current liabilities:	'	'
Preferred stock	'	10,758
Series C convertible preferred stock [Member]	'	'
Current liabilities:	'	'
Preferred stock	'	25,107
Preferred stock [Member]	'	'
Current liabilities:	'	'
Warrant liability	'	1,884
Common stock [Member]	'	'
Current liabilities:	'	'
Warrant liability	'	$301

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
In Thousands, except Per Share data, unless otherwise specified			Series A convertible preferred stock [Member]	Series A convertible preferred stock [Member]	Series B convertible preferred stock [Member]	Series B convertible preferred stock [Member]	Series C convertible preferred stock [Member]	Series C convertible preferred stock [Member]
Preferred stock, par value	$0.00	'	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Preferred stock, shares authorized	20,000	0	0	1,489	0	2,252	0	5,082
Preferred stock, shares issued	0	0	0	1,484	0	2,242	0	4,778
Preferred stock, shares outstanding	0	0	0	1,484	0	2,242	0	4,778
Common stock, par value	$0.00	$0.00	'	'	'	'	'	'
Common stock, shares authorized	250,000	12,936	'	'	'	'	'	'
Common stock, shares issued	19,323	1,267	'	'	'	'	'	'
Common stock, shares outstanding	19,323	1,267	'	'	'	'	'	'

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues:	'	'	'
Product	$12,657	$6,777	$5,044
License	193	179	57
Related party	1,693	184	150
Total revenues	14,543	7,140	5,251
Cost of product revenues, including cost of product revenues to related parties of $984, $126 and $50 for the years ended December 31, 2013, 2012 and 2011, respectively	10,736	4,333	2,172
Gross profit	3,807	2,807	3,079
Operating expenses:	'	'	'
Research, development and patent	17,814	12,741	9,410
Non-cash charge associated with a convertible note	'	3,610	'
Selling, general and administrative	15,018	10,294	6,793
Total operating expenses	32,832	26,645	16,203
Loss from operations	-29,025	-23,838	-13,124
Other income (expense):	'	'	'
Interest income	49	16	22
Interest expense	-5,997	-2,466	-88
Change in estimated fair value of financial instruments	6,717	-12,461	1
Gain on extinguishment of debt	49	'	'
Other (expense) income, net	-282	-45	9
Total other income (expense), net	536	-14,956	-56
Loss before income taxes	-28,489	-38,794	-13,180
Income taxes	'	'	'
Net loss	-28,489	-38,794	-13,180
Deemed dividend on convertible notes	-1,378	-2,039	'
Net loss attributable to common stockholders	($29,867)	($40,833)	($13,180)
Net loss per common share:	'	'	'
Basic	($3.42)	($32.48)	($10.64)
Diluted	($3.94)	($32.48)	($10.64)
Weighted-average shares outstanding used in computing net loss per common share:	'	'	'
Basic	8,731	1,257	1,239
Diluted	8,911	1,257	1,239

Consolidated_Statements_of_Ope1

Consolidated Statements of Operations (Parenthetical) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Statement [Abstract]	'	'	'
Cost of product revenues to related parties	$984	$126	$50

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Amounts Reclassified Out Of Accumulated Other Comprehensive Income Loss [Abstract]	'	'	'
Net loss	($28,489)	($38,794)	($13,180)
Other comprehensive loss	'	'	'
Comprehensive loss	($28,489)	($38,794)	($13,180)

Consolidated_Statements_of_Con

Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (USD $)	Total	Convertible preferred stock [Member]	Convertible preferred stock [Member]	Convertible preferred stock [Member]	Convertible preferred stock [Member]	Common stock [Member]	Additional paid-in capital [Member]	Accumulated deficit [Member]
In Thousands			Series A [Member]	Series B [Member]	Series C [Member]
Beginning balance at Dec. 31, 2010	($21,204)	$26,452	$3,747	$10,758	$11,947	'	$352	($21,556)
Beginning balance, shares at Dec. 31, 2010	'	6,012	1,484	2,242	2,286	1,234	'	'
Net loss	-13,180	'	'	'	'	'	'	-13,180
Exercise of stock options, shares	'	'	'	'	'	13	'	'
Exercise of stock options	13	'	'	'	'	'	13	'
Share-based compensation	271	'	'	'	'	'	271	'
Issuance of Series C convertible preferred stock, net of issuance costs, Shares	'	2,492	'	'	2,492	'	'	'
Issuance of Series C convertible preferred stock	'	13,160	'	'	13,160	'	'	'
Ending balance at Dec. 31, 2011	-34,100	39,612	3,747	10,758	25,107	'	636	-34,736
Ending balance, shares at Dec. 31, 2011	'	8,504	1,484	2,242	4,778	1,247	'	'
Net loss	-38,794	'	'	'	'	'	'	-38,794
Exercise of stock options, shares	'	'	'	'	'	20	'	'
Exercise of stock options	24	'	'	'	'	'	24	'
Share-based compensation	662	'	'	'	'	'	662	'
Deemed dividend, convertible notes	-2,039	'	'	'	'	'	'	-2,039
Ending balance at Dec. 31, 2012	-74,247	39,612	3,747	10,758	25,107	'	1,322	-75,569
Ending balance, shares at Dec. 31, 2012	'	8,504	1,484	2,242	4,778	1,267	'	'
Net loss	-28,489	'	'	'	'	'	'	-28,489
Exercise of stock options, shares	217	'	'	'	'	217	'	'
Exercise of stock options	250	'	'	'	'	'	250	'
Share-based compensation	2,300	'	'	'	'	'	2,300	'
Deemed dividend, convertible notes	-1,378	'	'	'	'	'	'	-1,378
Cash exercise of preferred stock warrants, shares	'	10	'	10	'	'	'	'
Cash exercise of preferred stock warrants	'	47	'	47	'	'	'	'
Net exercise of preferred stock warrants, shares	'	'	'	'	'	71	'	'
Net exercise of preferred stock warrants	'	'	'	'	'	'	'	'
Conversion of preferred stock into common stock, shares	'	-8,514	-1,484	-2,252	-4,778	8,514	'	'
Conversion of preferred stock into common stock	'	-39,659	-3,747	-10,805	-25,107	'	'	'
Conversion of preferred stock into common stock	39,659	'	'	'	'	'	39,659	'
Convertible notes converted into common stock, shares	'	'	'	'	'	3,741	'	'
Convertible notes converted into common stock	44,890	'	'	'	'	'	44,890	'
Cash exercise of common stock warrants, shares	'	'	'	'	'	3	'	'
Cash exercise of common stock warrants	25	'	'	'	'	'	25	'
Net exercise of common stock warrants, shares	'	'	'	'	'	47	'	'
Net exercise of common stock warrants	'	'	'	'	'	'	'	'
Reclassification of warrants from liability to equity	2,669	'	'	'	'	'	2,669	'
Issuance of common stock upon initial public offering, net of offering costs and underwriter commission, shares	'	'	'	'	'	5,463	'	'
Issuance of common stock upon initial public offering, net of offering costs and underwriter commission	56,105	'	'	'	'	'	56,105	'
Ending balance at Dec. 31, 2013	$41,784	'	'	'	'	'	$147,220	($105,436)
Ending balance, shares at Dec. 31, 2013	'	'	'	'	'	19,323	'	'

Consolidated_Statements_of_Con1

Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2011
Issuance of Series C convertible preferred stock, issuance costs	$91
Convertible preferred stock [Member]	'
Issuance of Series C convertible preferred stock, issuance costs	$91

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities	'	'	'
Net loss	($28,489)	($38,794)	($13,180)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Depreciation and amortization	976	613	499
Loss on disposal of equipment	231	'	'
Share-based compensation	2,300	662	271
Non-cash interest expense	4,315	1,224	4
Reduction of revenue associated with a convertible note (Note 9)	'	245	'
Non-cash charge associated with a convertible note (Note 9)	'	3,610	'
Change in estimated fair value of financial instruments	-6,717	12,461	-1
Gain on equipment sale leaseback	'	'	-6
Gain on extinguishment of debt	-49	'	'
Amortization of investment securities premiums/discounts, net	18	'	'
Net changes in operating assets and liabilities:	'	'	'
Accounts receivable	-3,381	-2,464	484
Accounts receivable from related parties	-767	-59	-54
Inventories	-6,794	-1,625	-1,703
Prepaid expenses and other assets	991	-2,097	-663
Accounts payable	1,682	1,174	438
Accrued and other liabilities	987	1,381	710
Deferred revenue	823	354	776
Deferred revenue from related parties	-131	890	'
Net cash used in operating activities	-34,005	-22,425	-12,425
Cash flows from investing activities	'	'	'
Purchases of property, plant and equipment	-4,025	-2,757	-423
Proceeds from sale of equipment	41	'	'
Purchase of short-term investments	-17,477	'	-2,000
Maturities of short-term investments	3,782	2,000	'
Net cash used in investing activities	-17,679	-757	-2,423
Cash flows from financing activities	'	'	'
Proceeds from initial public offering, net of offering costs and underwriter commissions	56,105	'	'
Proceeds from issuance of convertible preferred stock, net of issuance costs	'	'	13,160
Proceeds from issuance of convertible notes payable	6,529	24,076	'
Proceeds from issuance of debt, net of financing costs	3,700	17,375	'
Proceeds from line of credit	'	500	500
Repayment of line of credit	'	-500	-500
Repayment of debt	-9,433	-1,154	-206
Repayment of capital leases	-229	-209	-191
Proceeds from secured borrowing	2,880	'	'
Reductions in secured borrowing	-2,880	'	'
Change in restricted cash	9,139	-9,139	'
Proceeds from exercise of stock options	250	24	13
Proceeds from exercise of preferred stock warrants	47	'	'
Proceeds from exercise of common stock warrants	25	'	'
Net cash provided by financing activities	66,133	30,973	12,776
Net increase (decrease) in cash and cash equivalents	14,449	7,791	-2,072
Cash and cash equivalents, beginning of year	10,006	2,215	4,287
Cash and cash equivalents, end of year	24,455	10,006	2,215
Supplemental disclosure of cash flow information	'	'	'
Cash paid for interest, net of capitalized interest of $695, $106 and $0 for the years ended December 31, 2013, 2012 and 2011, respectively	1,682	1,136	84
Supplemental disclosure of non-cash investing and financing activities	'	'	'
Property, plant and equipment included in accounts payable and accrued liabilities	1,009	'	'
Equipment acquired under capital leases	2,106	317	93
Interest added to the principal of convertible notes	1,623	837	'
Reclassification of warrants from liabilities to equity	2,669	'	'
Conversion of convertible notes to common stock	44,890	'	'
Conversion of preferred stock to common stock	$39,659	'	'

Consolidated_Statements_of_Cas1

Consolidated Statements of Cash Flows (Parenthetical) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Statement Of Cash Flows [Abstract]	'	'	'
Cash paid for interest, capitalized interest	$695	$106	$0

Summary_of_Business

Summary of Business	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Summary of Business	'
	1. Summary of Business
	Marrone Bio Innovations, Inc. (Company), formerly Marrone Organic Innovations, Inc., was incorporated under the laws of the State of Delaware on June 15, 2006, and is located in Davis, California. In July 2012, the Company formed a wholly-owned subsidiary, Marrone Michigan Manufacturing LLC (MMM LLC), which holds the assets of a manufacturing plant the Company purchased in July 2012 as discussed in Note 3. The Company makes bio-based pest management and plant health products. The Company targets the major markets that use conventional chemical pesticides, including certain agricultural and water markets where its bio-based products are used as substitutes for, or in connection with, conventional chemical pesticides. The Company also targets new markets for which there are no available conventional chemical pesticides, the use of conventional chemical pesticides may not be desirable or permissible, or the development of pest resistance has reduced the efficacy of conventional chemical pesticides. The Company delivers EPA-approved and registered biopesticide products and other bio-based products that address the global demand for effective, safe and environmentally responsible products.
	In August 2013, the Company closed its initial public offering of 5,462,500 shares of its common stock (inclusive of 712,500 shares of common stock sold upon the exercise of the underwriters’ option to purchase additional shares) (IPO). The public offering price of the shares sold in the offering was $12.00 per share. The total gross proceeds from the offering to the Company were $65,550,000, and after deducting underwriting discounts and commissions and offering expenses payable by the Company, the aggregate net proceeds received by the Company totaled approximately $56,105,000. Upon the closing of the IPO, all shares of the Company’s outstanding convertible preferred stock and convertible notes automatically converted into shares of common stock and outstanding warrants to purchase convertible preferred stock and certain warrants to purchase common stock were exercised for shares of common stock (See Note 20).
	The Company is an early stage company with a limited operating history and has only recently begun commercializing its products. As of December 31, 2013, the Company had an accumulated deficit of $105,436,000 and expects to continue to incur losses for the foreseeable future. Until the IPO in August 2013, the Company had funded operations primarily with the net proceeds from the private placements of convertible preferred stock, convertible notes, promissory notes, term loans, as well as proceeds from the sale of its products and payments under strategic collaboration agreements and government grants. The Company will need to generate significant revenue to achieve and maintain profitability. As of December 31, 2013, the Company had working capital of $46,915,000, cash and cash equivalents of $24,455,000, and short-term investments of $13,677,000.
	On August 1, 2013, the Company amended and restated its certificate of incorporation to effect a reverse split of shares of its common stock at a 1-for-3.138458 ratio (See Note 19).
	The Company participates in a heavily regulated and highly competitive crop protection industry and believes that adverse changes in any of the following areas could have a material effect on the Company’s future financial position, results of operations, or cash flows: inability to obtain regulatory approvals, increased competition in the pesticide market, market acceptance of the Company’s products, weather and other seasonal factors beyond the Company’s control, litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors, and the Company’s ability to support increased growth.

Significant_Accounting_Policie

Significant Accounting Policies

12 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

'

Significant Accounting Policies

'

2. Significant Accounting Policies

Basis of Presentation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers all highly liquid financial instruments purchased with a maturity of three months or less to be cash equivalents. Cash and cash equivalents consist of cash on deposit, money market funds and certificates of deposit accounts (CDs) with U.S. financial institutions. The Company is exposed to credit risk in the event of default by financial institutions to the extent that cash and cash equivalents balances with financial institutions are in excess of amounts that are insured by the Federal Deposit Insurance Corporation. The Company has not experienced any losses on these deposits.

Restricted Cash

The Company’s restricted cash consisted of cash that the Company was contractually obligated as of December 31, 2012 to use to pay off the entire indebtedness of the promissory note entered into in April 2012 with an original principal balance of $10,000,000. The Company paid the outstanding balance of the promissory note in January 2013, and as of December 31, 2013, had no remaining contractual obligations which restricted the use of cash. See Note 8 for further discussion.

Short-Term Investments

The Company’s short-term investments consist of certificates of deposit with original maturities less than one year but greater than three months which are classified as held-to-maturity. Certificates of deposit are stated at their amortized cost with realized gains or losses, if any, reported as other income or expenses in the consolidated statements of operations. The Company routinely evaluates the realizability of its short-term investments and recognizes an impairment charge when a decline in the estimated fair value of a short-term investment is below the amortized cost and determined to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the duration of time and the severity to which the fair value has been less than amortized cost, any adverse changes in the investee’s financial condition, and the Company’s intent and ability to hold the short-term investment for a period of time sufficient to allow for any anticipated recovery in market value. To date, the Company has not recognized any losses on its short-term investments.

The amortized cost and estimated fair values of short-term investments are summarized in the following table (in thousands):

31-Dec-13

AMORTIZED

GROSS

GROSS

ESTIMATED

COST

UNREALIZED

UNREALIZED

FAIR VALUE

GAINS

LOSSES

Securities Held-to-Maturity

Certificates of deposit, with maturities less than 1 year

$

13,677

$

—

$

(4

)

$

13,673

The short-term investments at December 31, 2013 were in inactive markets and, therefore, the estimated fair value is measured based on the Level 2 valuation hierarchy. The Company did not have any investments in securities as of December 31, 2012.

Fair Value of Financial Instruments

ASC 820, Fair Value Measurements (ASC 820), clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.

ASC 820 requires that the valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 establishes a three tier value hierarchy, which prioritizes inputs that may be used to measure fair value as follows:

•

Level 1—Quoted prices in active markets for identical assets or liabilities.

•

Level 2—Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

•

Level 3—Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability.

The following table presents the Company’s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2013 and 2012 (in thousands):

31-Dec-13

TOTAL

LEVEL 1

LEVEL 2

LEVEL 3

Assets

Money market funds

$

16,268

$

16,268

$

—

$

—

31-Dec-12

TOTAL

LEVEL 1

LEVEL 2

LEVEL 3

Assets

Money market funds

$

7,668

$

7,668

$

—

$

—

Liabilities

Common stock warrant liability

$

301

$

—

$

—

$

301

Preferred stock warrant liability

1,884

—

—

1,884

Convertible notes payable

41,860

—

—

41,860

Total liabilities at fair value

$

44,045

$

—

$

—

$

44,045

The money market funds held as of December 31, 2013 and 2012 were in active markets and, therefore, are measured based on the Level 1 valuation hierarchy.

The Company estimated the fair value of the common and preferred stock warrant liabilities as of December 31, 2012 using the Probability Weighted Expected Return Method (PWERM), which analyzes the returns afforded to common equity holders under multiple future scenarios. Under the PWERM, share value is based upon the probability-weighted present value of expected future net cash flows (distributions to stockholders), considering each of the possible future events and giving consideration to the rights and preferences of each share class. This method is most appropriate when the long-term outlook for an enterprise is largely known and multiple future scenarios can be reasonably estimated.

The common and preferred stock warrant liabilities were valued by a PWERM valuation using six scenarios, which included three initial public offering scenarios, two merger scenarios and a sale of the Company’s intellectual property. An annual discount rate of 35% was applied to the PWERM valuations as of December 31, 2012. The common stock warrant liability valuation also included an 18% discount for lack of marketability as of December 31, 2012. As the PWERM estimates the fair value of the common and preferred stock warrant liabilities using unobservable inputs, it is considered to be a Level 3 fair value measurement.

Effective on the date of the IPO, under ASC 815-40-15, Contracts in Entity’s Own Equity (ASC 815-40-15), the common and preferred stock warrant liabilities were considered to be indexed to the Company’s stock, and accordingly, the total warrants liability of $2,669,000 was reclassified and included in stockholders’ equity (deficit) as of December 31, 2013. The Company revalued the warrants immediately prior to the IPO. The fair value of the warrants which would have expired on the date of the IPO unless exercised was determined using the intrinsic method based on the IPO price of $12.00 per share, which is deemed a Level 2 fair value measurement. The fair value of the warrants that would not have expired on the date of the IPO regardless of whether or not they were exercised was determined using the Black-Scholes-Merton option-pricing model, which is deemed a Level 3 fair value measurement.

As a result of the change in estimated fair value between December 31, 2012 or the issuance dates of the warrants issued during the year ended December 31, 2013 and the closing of the IPO, the Company recognized a net gain from the total change in estimated fair value of the common and preferred stock warrant liabilities as shown in the tables below.

The following table provides a reconciliation of the beginning and ending balances for the common and preferred stock warrant liabilities measured at fair value using significant unobservable inputs (Level 3). The amounts included in the “Transfers out of Level 3” represent the beginning balance in the interim quarter during which it was transferred (in thousands):

COMMON

STOCK

WARRANT

LIABILITY

Fair value at December 31, 2012

$

301

Warrants issued

900

Change in fair value recorded in change in fair value of financial instruments

377

Transfers out of Level 3

(434

)

Reclassified to stockholders’ equity (deficit)

(1,144

)

Fair value at December 31, 2013

$

—

PREFERRED

STOCK

WARRANT

LIABILITY

Fair value at December 31, 2012

$

1,884

Change in fair value recorded in change in fair value of financial instruments

(823

)

Transfers out of Level 3

(140

)

Reclassified to stockholders’ equity (deficit)

(921

)

Fair value at December 31, 2013

$

—

Effective on the date of the IPO, all of the Company’s convertible notes were converted into shares of common stock. Prior to the IPO, convertible notes were valued by a PWERM valuation utilizing inputs similar to those used for estimating fair values of the common and preferred stock warrant liabilities described above. A discount rate of 25% was used for valuing the March and October 2012 Convertible Notes, defined in Note 9, as of December 31, 2012. A discount rate of 18% was used for valuing the October 2012 Subordinated Convertible Notes and the December 2012 Convertible Note, both defined in Note 9, as of December 31, 2012. These annual discount rates were applied in the PWERM valuation as of December 31, 2012. The Company revalued the convertible notes immediately prior to the IPO. As a result of the IPO, the number of shares to be issued became known and the Company estimated the fair value of the convertible notes using the intrinsic method based on the IPO price of $12.00 per share, which is deemed a Level 2 fair value measurement. Due to the change in estimated fair values between December 31, 2012 or the issuance dates of the convertible notes issued during the year ended December 31, 2013 and the closing of the IPO, the Company recognized a gain from the change in estimated fair value of the convertible notes as shown in the table below.

The following table provides a reconciliation of the beginning and ending balances for the convertible notes measured at fair value using significant unobservable inputs (Level 3). The amounts included in the “Transfers out of Level 3” represent the beginning balance in the interim quarter during which it was transferred (in thousands):

Fair value at December 31, 2012

$

41,860

Convertible notes issued

9,069

Convertible notes cancelled

(1,360

)

Accrued interest

1,299

Change in fair value recorded in change in fair value of financial instruments

(2,634

)

Transfers out of Level 3

(48,234

)

Fair value at December 31, 2013

$

—

During the year ended December 31, 2013, as noted above, there were $574,000 of preferred and common stock warrants and $48,234,000 of convertible notes transferred from the Level 3 to Level 2 category. There were no such transfers from the Level 3 to Level 2 category during the year ended December 31, 2012. Further, there were no transfers from the Level 2 to Level 1 category during the years ended December 31, 2013 or 2012.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, short-term investments, accounts receivable and debt. The Company deposits its cash, cash equivalents and short-term investments with high credit quality domestic financial institutions with locations in the U.S. Such deposits may exceed federal deposit insurance limits. The Company believes the financial risks associated with these financial instruments are minimal.

The Company’s customer base is dispersed across many different geographic areas, and currently most customers are pest management distributors in the U.S. Generally, receivables are due up to 120 days from the invoice date and are considered past due after this date, although the Company may offer extended terms from time to time.

During the years ended December 31, 2013, 2012 and 2011, 8%, 20% and 7%, respectively, of the Company’s revenues were generated from international customers.

From inception through December 31, 2012, the Company’s principal source of revenues was its Regalia product line. During the year ended December 31, 2013, Grandevo and Regalia were the principal sources of the Company’s total revenues. During the years ended December 31, 2013, 2012 and 2011, these two product lines accounted for 97%, 96% and 96%, respectively, of the Company’s total revenues.

Customers with 10% or more of the Company’s total revenues consist of the following:

CUSTOMER

CUSTOMER

CUSTOMER

CUSTOMER

CUSTOMER

A

B (1)

C

D

E

For the years ended December 31,

2013

28

%

10

%

*

*

*

2012

33

%

*

13

%

12

%

*

2011

39

%

*

*

17

%

10

%

*

Represents less than 10% of total revenues

(1)

Represents related party revenues. See Note 18 for further discussion.

Customers with 10% or more of the Company’s outstanding accounts receivable consist of the following:

CUSTOMER

CUSTOMER

CUSTOMER

CUSTOMER

CUSTOMER

CUSTOMER

CUSTOMER

A

B (1)

C

D

E

F

G

December 31, 2013

19

%

13

%

12

%

11

%

*

*

*

December 31, 2012

*

*

*

33

%

17

%

11

%

11

%

*

Represents less than 10% of accounts receivable.

(1)

Represents accounts receivable from related parties. See Note 18 for further discussion.

Concentrations of Supplier Dependence

The active ingredient in the Company’s Regalia product line is derived from the giant knotweed plant, which the Company obtains from China. The Company’s single supplier acquires raw knotweed from numerous regional sources and performs an extraction process on this plant, creating a dried extract that is shipped to the Company’s third- party manufacturer in the U.S. A disruption at this supplier’s manufacturing site or a disruption in trade between the U.S. and China could negatively impact sales of Regalia. The Company currently uses one supplier and does not have a long-term supply contract with this supplier. Although the Company has identified additional sources of knotweed, there can be no assurance that the Company will continue to be able to obtain dried extract from China at a competitive price.

Accounts Receivable

The carrying value of the Company’s receivables represents their estimated net realizable values. The Company generally does not require collateral and estimates any required allowance for doubtful accounts based on historical collection trends, the age of outstanding receivables, and existing economic conditions. If events or changes in circumstances indicate that specific receivable balances may be impaired, further consideration is given to the collectibility of those balances and the allowance is recorded accordingly. Past-due receivable balances are written-off when the Company’s internal collection efforts have been unsuccessful in collecting the amount due. During the years ended December 31, 2013 and 2012, no receivable balances were written-off. As of December 31, 2013 and 2012, the Company had no allowance for doubtful accounts.

Inventories

Inventories are stated at the lower of cost or market value (net realizable value or replacement cost) and include the cost of material and external labor and manufacturing costs. Cost is determined on the first-in, first-out basis. The Company provides for inventory reserves when conditions indicate that the selling price may be less than cost due to physical deterioration, obsolescence, changes in price levels, or other factors. Additionally, the Company provides reserves for excess and slow-moving inventory on hand that is not expected to be sold to reduce the carrying amount of excess slow-moving inventory to its estimated net realizable value. The reserves are based upon estimates about future demand from the Company’s customers and distributors and market conditions. As of December 31, 2013, the Company had $45,000 in reserves against its inventories. As of December 31, 2012, the Company had no reserves against its inventories. During the year ended December 31, 2013, the Company recorded, as a component of cost of product revenues, an inventory write-off of $205,000 primarily due to abnormal scrap and the identification of inventory that was not suitable for sale and an adjustment of $194,000 to write-down its Zequanox inventory to net realizable value. During the year ended December 31, 2012, the Company recorded, as a component of cost of product revenues, an inventory write-off of $913,000 primarily due to an early formulation of the Zequanox line of products that was not suitable for sale.

Inventories, net consist of the following (in thousands):

DECEMBER 31

2013

2012

Raw materials

$

5,355

$

3,204

Work in progress

2,917

607

Finished goods

3,394

1,061

$

11,666

$

4,872

Deferred Cost of Product Revenues

Deferred cost of product revenues are stated at the lower of cost or net realizable value and include product sold where title has transferred but the criteria for revenue recognition have not been met. As of December 31, 2013, the Company recorded current deferred cost of product revenues of $418,000 which is included in prepaid expenses and other current assets in the consolidated balance sheets. As of December 31, 2012, the Company had no deferred cost of product revenues. During the year ended December 31, 2013, the Company recorded an adjustment of $174,000 to write down the carrying value of deferred cost of product revenues to net realizable value.

Property, Plant and Equipment

Property, plant and equipment are recorded at cost and are depreciated using the straight-line method over their estimated useful lives. The Company generally uses the following estimated useful lives for each asset category:

ASSET CATEGORY

ESTIMATED USEFUL LIFE

Building

30 years

Computer equipment

2-3 years

Machinery and equipment

3-20 years

Office equipment

3-5 years

Furniture

3-5 years

Leasehold improvements

Shorter of lease term or useful life

Software

3 years

Amortization of assets under capital leases is included in depreciation expense. Maintenance, repairs and minor renewals are expensed as incurred. Expenditures that substantially increase an asset’s useful life are capitalized.

Deferred Financing Costs

Deferred financing costs, net include fees and costs incurred to obtain long-term financing. The costs are being amortized over the terms of the respective loans on a basis that approximates level yield. Unamortized deferred financing fees are written-off when debt is retired before the maturity date. Upon the amendment or termination of debt, unamortized deferred financing fees are accounted for in accordance with ASC 470-50-40, Debt Modifications and Extinguishments (ASC 470-50-40). As of December 31, 2013, $458,000 and $148,000 of the deferred financing costs were recorded as a component of current and non-current other assets, respectively, and are being amortized to interest expense. As of December 31, 2012, $145,000 and $261,000 of the deferred financing costs were recorded as a component of current and non-current other assets, respectively, and are being amortized to interest expense.

Impairment of Long-Lived Assets

Impairment losses related to long-lived assets are recognized in the event the net carrying value of such assets is not recoverable and exceeds fair value. The Company evaluates the recoverability of its long-lived assets whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. The carrying amount of a long-lived asset (asset group) is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset (asset group). If an asset is considered is not recoverable, the impairment loss is measured as the amount by which the carrying value of the asset group exceeds its estimated fair value. To date, the Company has not recognized any such impairment loss associated with its long-lived assets.

Preferred Stock Warrant Liability

The Company accounted for outstanding warrants exercisable into shares of its preferred stock as liability instruments as the preferred stock into which these warrants were convertible were contingently redeemable upon the occurrence of certain events or transactions. The Company adjusted the warrant instruments to fair value at each reporting period with the change in fair value recorded as a component of change in estimated fair value of financial instruments in the consolidated statements of operations. Effective on the date of the IPO, under ASC 815-40-15, the preferred stock warrant liabilities were considered to be indexed to the Company’s stock, and accordingly, the total warrants liability was reclassified and included in stockholders’ equity (deficit) as of December 31, 2013.

Common Stock Warrant Liability

The Company issued detachable common stock warrants in connection with the October 2012 and April 2013 Junior Secured Promissory Notes as defined and discussed in Note 8 to purchase a variable number of the Company’s shares of common stock based on a fixed monetary amount. As the predominant settlement feature of these common stock warrants was to settle a fixed monetary amount in a variable number of shares, these common stock warrants fell within the scope of ASC 480, Distinguishing Liabilities from Equity (ASC 480). Accordingly, these common stock warrants were recorded at estimated fair value on their issuance date and were adjusted to their estimated fair value as of each reporting date with the change in estimated fair value recorded as a component of change in estimated fair value of financial instruments in the accompanying consolidated statements of operations. Effective on the date of the IPO, under ASC 815-40-15, the common stock warrant liabilities were considered to be indexed to the Company’s stock, and accordingly, the total warrants liability was reclassified and included in stockholders’ equity (deficit) as of December 31, 2013.

Revenue Recognition

The Company recognizes revenues when persuasive evidence of an arrangement exists, delivery and transfer of title has occurred or services have been rendered, the price is fixed or determinable, and collectability is reasonably assured, unless contractual obligations, acceptance provisions or other contingencies exist. If such obligations or provisions exist, revenue is recognized after such obligations or provisions are fulfilled or expire.

Product revenues consist of revenues generated from sales to distributors and from sales of the Company’s products to direct customers, net of rebates and cash discounts. For sales of products made to distributors, the Company considers a number of factors in determining whether revenue is recognized upon transfer of title to the distributor, or when payment is received. These factors include, but are not limited to, whether the payment terms offered to the distributor in comparison to the Company’s historical terms are considered to be longer than normal payment terms, the distributor history of adhering to the terms of its contractual arrangements with the Company, whether the Company has a pattern of granting concessions for the benefit of the distributor, and whether there are other conditions that may indicate that the sale to the distributor is not substantive. When the Company offers payment terms that are considered to be extended in comparison to the Company’s historical terms, the Company considers the arrangement not to be fixed or determinable, and accordingly, revenue is deferred until payment is due. The costs associated with such deferral are also deferred and classified in prepaid expenses and other current assets in the consolidated balance sheets. The Company currently recognizes revenue primarily on the sell-in method with its distributors. Distributors do not have price protection or return rights.

As of December 31, 2013, the Company recorded current deferred product revenues of $1,016,000. As of December 31, 2012, the Company had no deferred product revenues.

From time to time, the Company offers certain product rebates, which are recorded as reductions to product revenues. An accrued liability for these product rebates is recorded at the time the revenues are recorded.

The Company recognizes license revenues pursuant to strategic collaboration and distribution agreements under which the Company receives payments for the achievement of testing validation, regulatory progress and commercialization events. As these activities and payments are associated with exclusive rights that the Company provides in connection with strategic collaboration and distribution agreements over the term of the agreements, revenues related to the payments received are deferred and recognized over the term of the exclusive distribution period of the respective agreement. For the years ended December 31, 2012 and 2011, the Company received payments totaling $1,533,000 and $833,000, respectively, of which $1,000,000 was received from a related party for the year ended December 31, 2012. No payments were received under these agreements during the year ended December 31, 2013. For the years ended December 31, 2013, 2012 and 2011, the Company recognized $193,000, $179,000 and $57,000, respectively, as license revenues, excluding related party revenues, in the accompanying consolidated statements of operations.

For the year ended December 31, 2013, the Company recognized $131,000 of related party revenues under these agreements based on the terms of the Company’s commercial agreement with Syngenta, an affiliate of one of our 5% stockholders. In addition, in connection with the December 2012 Convertible Note issued to a related party in December 2012, which is described in Note 9, the Company recorded a reduction of license revenues included in related party revenues of $110,000 for the year ended December 31, 2012. There were no related party license revenues recognized for the years ended December 31, 2012 and 2011.

At December 31, 2013, the Company recorded current and non-current deferred revenues of $324,000 and $1,372,000, respectively, related to payments received under these agreements, of which $131,000 and $628,000, respectively, related to deferred revenues from related parties based on the terms of the Company’s commercial agreement with Syngenta. At December 31, 2012, the Company recorded current and non-current deferred revenues of $324,000 and $1,696,000, respectively, related to payments received under these agreements, of which $131,000 and $759,000, respectively, related to deferred revenues from related parties based on the terms of the Company’s commercial agreement with Syngenta.

Research, Development and Patent Expenses

Research and development expenditures, which primarily consist of payroll-related expenses, toxicology costs, regulatory costs, consulting costs and lab costs, and patent expenses, which primarily consist of legal costs relating to the patents and patent filing costs, are expensed to operations as incurred. For the years ended December 31, 2013, 2012 and 2011, research and development expenses totaled $16,827,000, $12,140,000 and $9,133,000, respectively, and patent expenses totaled $987,000, $601,000 and $277,000, respectively. Grants received from third parties for research and development activities are recorded as reductions of expense over the term of the agreement as the related activities are conducted. For the years ended December 31, 2012 and 2011, the Company received payments under grants totaling $140,000 and $164,000, respectively. There were no grants received for the year ended December 31, 2013. Of these amounts, $31,000 was recorded in accrued liabilities as accrued grant proceeds for which the underlying grant services had not been provided as of December 31, 2011. There were no accrued grant proceeds for the years ended December 31, 2013 and 2012. For the years ended December 31, 2012 and 2011, the Company reduced research and development expenses by $171,000 and $195,000, respectively, as services were performed under the grants. There was no reduction to research and development expenses for services performed under grants for the year ended December 31, 2013.

Shipping and Handling Costs

Amounts billed for shipping and handling are included as a component of product revenues. Related costs for shipping and handling have been included as a component of cost of product revenues.

Advertising

The Company expenses advertising costs as incurred. Advertising costs for the years ended December 31, 2013, 2012 and 2011, were $760,000, $609,000 and $286,000, respectively.

Share-Based Compensation

The Company recognizes share-based compensation expense for all stock options made to employees and directors based on estimated fair values.

The Company estimates the fair value of stock options on the date of grant using an option-pricing model. The value of the portion of the stock options that is ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

For purposes of determining the Company’s historical share-based compensation expense, it used the Black-Scholes-Merton (BSM) option-pricing model to calculate the estimated fair value of stock options on the measurement date (generally, the grant date). This model requires inputs for the expected life of the stock options, estimated volatility factor, risk-free interest rate, and expected dividend yield. The Company’s estimates of forfeiture rates also affect the amount of aggregate compensation expense. These inputs are subjective and generally require significant judgment. For the years ended December 31, 2013, 2012 and 2011, the Company calculated the fair value of stock options granted using the following assumptions:

YEAR ENDED DECEMBER 31

2013

2012

2011

Expected life (years)

5.29-7.71

5.00-6.08

5.00-6.28

Estimated volatility factor

0.70-0.75

0.72-0.76

0.7

Risk-free interest rate

1.27%-2.11%

0.74%-1.16%

0.86%-2.40%

Expected dividend yield

—

—

—

Expected Life—The Company’s expected life represents the period that its share-based payment awards are expected to be outstanding. The Company uses the “simplified method” in accordance with Staff Accounting Bulletin (SAB) No. 107, Share-Based Payment, and SAB No. 110, Simplified Method for Plain Vanilla Share Options, to develop the expected term of options determined to be “plain vanilla.” Under this approach, the expected term is presumed to be the midpoint between the vesting date and the contractual end of the option grant. For stock options granted with an exercise price not equal to the determined fair market value, the Company estimates the expected life based on historical data and management’s expectations about exercises and post-vesting termination behavior.

Estimated Volatility Factor—The Company uses the calculated volatility based upon the trading history and calculated volatility of the common stock of comparable agricultural biotechnology companies in determining an estimated volatility factor.

Risk-Free Interest Rate—The Company bases the risk-free interest rate on the implied yield currently available on U.S. Treasury constant-maturity securities with the same or substantially equivalent remaining term.

Expected Dividend Yield—The Company has not declared dividends nor does it expect to in the foreseeable future. Therefore, a zero value was assumed for the expected dividend yield.

Estimated Forfeitures—When estimating forfeitures, the Company considers voluntary and involuntary termination behavior and actual option forfeitures.

If in the future the Company determines that other methods are more reasonable, or other methods for calculating these assumptions are prescribed by authoritative guidance, the fair value calculated for the Company’s stock options could change significantly. Higher volatility and longer expected lives result in an increase to share-based compensation expense determined at the grant date. Share-based compensation expense affects the Company’s research, development and patent expense and selling, general and administrative expense.

Other Income (Expense), Net

Other income (expense), net included net losses resulting from foreign currency transactions in the amount of $53,000 and $54,000 for the years ended December 31, 2013 and 2012, respectively. There were no losses from foreign currency transactions for the year ended December 31, 2011. In addition, in 2013, other income (expense), net included a loss on disposal of fixed assets totaling $231,000. There were no losses on disposals of fixed assets during the years ended December 31, 2012 and 2011.

Income Taxes

The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. To the extent deferred tax assets cannot be recognized under the preceding criteria, the Company establishes valuation allowances as necessary to reduce deferred tax assets to the amounts expected to be realized. As of December 31, 2013 and 2012, all deferred tax assets were fully offset by a valuation allowance. Realization of deferred tax assets is dependent upon future federal, state, and foreign taxable income. The Company’s judgments regarding deferred tax assets may change as the Company expands into international jurisdictions, due to future market conditions, changes in U.S. or international tax laws, and other factors. These changes, if any, may require possible material adjustments to these deferred tax assets, resulting in a reduction in net income or an increase in net loss in the period when such determinations are made.

The Company recognizes liabilities for uncertain tax positions based upon a two-step process. To the extent a tax position does not meet a more-likely-than-not level of certainty; no benefit is recognized in the consolidated financial statements. If a position meets the more-likely-than-not level of certainty, it is recognized in the consolidated financial statements at the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company’s policy is to analyze the Company’s tax positions taken with respect to all applicable income tax issues for all open tax years (in each respective jurisdiction). As of December 31, 2013 and 2012, the Company has concluded that no uncertain tax positions were required to be recognized in its consolidated financial statements. It is the Company’s practice to recognize interest and penalties related to income tax matters in income tax expense. No amounts were recognized for interest and penalties during the years ended December 31, 2013, 2012 and 2011.

Comprehensive Loss

Comprehensive loss represents the net loss for the period plus the results of certain changes to stockholders’ equity (deficit) that are not reflected in the consolidated statements of operations, if applicable. The only component of the Company’s comprehensive loss for the periods presented is net loss.

Net Loss Per Share

Basic net loss per share, which excludes dilution, is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock, such as stock options, convertible notes, convertible preferred stock and warrants, result in the issuance of common stock which share in the losses of the Company. Certain potential shares of common stock have been excluded from the computation of diluted net loss per share for certain periods as their effect would be anti-dilutive. Such potentially dilutive shares are excluded when the effect would be to reduce the loss per share. The treasury stock method has been applied to determine the dilutive effect of warrants. See Note 4 for further discussion.

Segment Information

The Company is organized as a single operating segment, whereby its chief operating decision maker assesses the performance of and allocates resources to the business as a whole.

Recently Issued Accounting Pronouncements

There have been no new accounting pronouncements issued during the year ended December 31, 2013 that are of significance, or potential significance, to the Company.

Reclassifications

Certain amounts in 2012 and 2011 have been reclassified to conform with the 2013 financial statement presentations. These reclassifications have no effect on previously reported net income.

Property_Plant_and_Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2013
Property Plant And Equipment [Abstract]	'
Property, Plant and Equipment	'
	3. Property, Plant and Equipment
	Property, plant and equipment consist of the following (in thousands):
		31-Dec
		2013			2012
	Land	$	1		$	1
	Buildings		—			—
	Computer equipment and software		459			355
	Furniture, fixtures and office equipment		293			192
	Machinery and equipment		4,624			2,446
	Leasehold improvements		497			472
	Construction in progress		6,503			2,103
			12,377			5,569
	Less accumulated depreciation		(2,957	)		(2,041	)
		$	9,420		$	3,528
	The Company has granted to third parties interests in specific property and equipment as part of certain financing arrangements (see Note 8).
	Depreciation and amortization expense for the years ended December 31, 2013, 2012 and 2011, was $976,000, $613,000 and $499,000, respectively, which included amortization expense related to capital leases for those periods (see Note 14).
	On July 19, 2012 (Acquisition Date), the Company purchased land, building and equipment (Manufacturing Plant) for $1,459,000, including $341,000 of transaction costs. The Manufacturing Plant is located in Bangor, Michigan. Prior to the acquisition, the Manufacturing Plant was owned by a bank and sold in a foreclosure auction. Accordingly, the purchase price for the Manufacturing Plant was less than the estimated fair value of the assets acquired by $257,000. The excess of fair value of the assets acquired over the purchase price was allocated on a relative fair value basis to all assets acquired. The acquisition of the Manufacturing Plant will allow the Company to manufacture certain products internally and improve the overall operating efficiencies and margins of the business as the production of these products historically has been outsourced.
	The acquisition was accounted for as an asset acquisition in accordance with ASC 805, Business Combinations (ASC 805). The assets acquired under the Manufacturing Plant acquisition have been included in the Company’s consolidated financial statements from the Acquisition Date. The purchase price was allocated to assets acquired as of the Acquisition Date.
	Prior to the allocation of the excess of fair value of the assets acquired over the purchase price, the assets acquired are first measured at their fair values. The Company engaged a third-party valuation firm to assist with its estimated fair value of the assets acquired. The following methods and assumptions are used to estimate the fair value of each class of asset acquired:
	Land—Market approach based on similar, but not identical, transactions in the market. Adjustments to comparable sales are based on both the quantitative and qualitative data.
	Building—The cost approach, market approach and income approach were used to assess fair value. Cost approach is based on replacement cost new less depreciation adjusted for physical deterioration, functional obsolescence and external/economic obsolescence, as applicable. The market approach is based on similar, but not identical, transactions in the market using both quantitative and qualitative data. The income approach is based on the direct capitalization method using similar but not identical lease rates and making an assessment of net operating income.
	Equipment—Both the cost approach and the market approach were used to assess fair value. Cost approach is based on replacement cost new less depreciation adjusted for physical deterioration, functional obsolescence and external/economic obsolescence, as applicable. The market approach is based on similar, but not identical, transactions in the market using both quantitative and qualitative data.
	The following table summarizes the estimated fair value of the assets acquired as of the Acquisition Date, which were determined using Level 2 and 3 inputs as described above (in thousands):
		JULY 19,
		2012
	Land	$	1
	Building		314
	Equipment		1,144
	Assets acquired	$	1,459
	As the Manufacturing Plant had not yet been placed in service as of December 31, 2013, the assets acquired, except the land, were recorded as construction in progress as a component of property, plant and equipment in the accompanying consolidated balance sheets as of December 31, 2013 and 2012. In addition, interest expense in the amount of $801,000 and $106,000 was recorded in construction in progress as of December 31, 2013 and 2012, respectively.

Net_Loss_Per_Share

Net Loss Per Share	12 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Net Loss Per Share	'
	4. Net Loss Per Share
	Basic net loss per share, which excludes dilution, is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock, such as stock options, convertible notes, convertible preferred stock and warrants, result in the issuance of common stock which share in the losses of the Company.
	The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented (in thousands). Such potentially dilutive shares are excluded when the effect would be to reduce the loss per share. The treasury stock method has been applied to determine the dilutive effect of warrants.
			DECEMBER 31
			2013			2012			2011
	Convertible preferred stock			—			8,504			8,504
	Convertible notes (1)			—			—			—
	Stock options outstanding			2,608			2,067			1,384
	Warrants to purchase convertible preferred stock			—			207			36
	Warrants to purchase common stock (2)			151			—			5
	(1)	As of December 31, 2012, the Company had approximately $41,860,000, in contingently convertible notes payable and related accrued interest for which the contingencies related to conversion had not been met as of December 31, 2012. Therefore, it would have no dilutive or anti-dilutive impact until the contingency had been met effective upon the IPO in August 2013. All convertible notes converted to common stock in connection with the IPO. See Note 9 for further discussion.
	(2)	In October 2012 and April 2013, the Company issued warrants to purchase a number of shares of common stock equal to 15% of the funded principal amount of the October 2012 and April 2013 Junior Secured Promissory Notes as defined in Note 8, divided by 70% of the value of common stock in a sale of the Company or a qualified initial public offering (Qualified IPO), with an exercise price of 70% of the value of common stock in a sale of the Company or a Qualified IPO. In June 2013, the Company issued warrants to purchase a number of shares of common stock equal to 10% of the total committed amount of the June 2013 Credit Facility as defined in Note 8, divided by 70% of the value of common stock in a sale of the Company or a Qualified IPO, with an exercise price of 70% of the value of common stock in a sale of the Company or a Qualified IPO. These warrants were contingently exercisable for which the contingencies related to exercise had not been met until the IPO in August 2013. Therefore, they would have no dilutive or anti-dilutive impact until the contingency had been met in August 2013. See Note 8 for further discussion.
	The numbers of shares of common stock issuable upon the exercise of warrants to purchase convertible preferred stock and upon the conversion of convertible preferred stock were at a ratio of one-to-one.
			YEAR ENDED DECEMBER 31
			2013			2012			2011
			(In thousands, except per share data)
	Numerator:
	Net loss		$	(28,489	)	$	(38,794	)	$	(13,180	)
	Deemed dividend on convertible notes			(1,378	)		(2,039	)		—
	Net loss attributable to common stockholders		$	(29,867	)	$	(40,833	)	$	(13,180	)
	Effect of potentially dilutive securities:
	Convertible notes			(4,392	)		—			—
	Warrants to purchase preferred stock			(840	)		—			—
	Net loss for diluted net loss per share		$	(35,099	)	$	(40,833	)	$	(13,180	)
	Denominator
	Weighted average shares used for basic net loss per share			8,731			1,257			1,239
	Effect of potentially dilutive securities:
	Convertible notes			127			—			—
	Warrants to purchase preferred stock			53			—			—
	Weighted average shares outstanding for diluted net loss per share			8,911			1,257			1,239
	Basic net loss per share:		$	(3.42	)	$	(32.48	)	$	(10.64	)
	Diluted net loss per share:		$	(3.94	)	$	(32.48	)	$	(10.64	)

Other_Assets

Other Assets	12 Months Ended
	Dec. 31, 2013
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]	'
Other Assets	'
	5. Other Assets
	Other assets consist of the following (in thousands):
		DECEMBER 31
		2013		2012
	Prepaid initial public offering costs	$	—	$	2,257
	Prepaid distribution fees		125		134
	Deferred financing costs, less current portion		148		261
	Deposits for equipment		256		—
	Deposits on equipment leases		177		43
	Other assets		100		90
		$	806	$	2,785

Accrued_Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2013
Payables And Accruals [Abstract]	'
Accrued Liabilities	'
	6. Accrued Liabilities
	Accrued liabilities consist of the following (in thousands):
			DECEMBER 31
			2013		2012
	Accrued compensation		$	2,040	$	1,342
	Accrued severance			100		—
	Accrued expenses			1,630		1,295
	Accrued inventory costs			610		—
	Accrued product rebates			—		386
			$	4,380	$	3,023
	On November 7, 2013, the Company announced that its Chief Financial Officer, Donald Glidewell, had decided to retire from the Company. To facilitate the transition, Mr. Glidewell agreed to remain as the Company’s Chief Financial Officer for up to five months while the Company searched for a successor Chief Financial Officer, and the Company entered into a transition agreement with Mr. Glidewell that provides, among other things, for continued vesting of his outstanding equity awards through his retirement date and that upon his separation from the Company, Mr. Glidewell is eligible to receive:
		•		an amount equal to six months of his then-current annual base salary payable monthly for a period of six months from his retirement date in the form of salary continuation;
		•		medical and dental coverage, plus disability and life insurance premiums, for a period of six months following his retirement; and
		•		full acceleration of vesting of his outstanding equity awards that are unvested as of his retirement date.
	The Company recorded accrued severance expenses in the amount of $100,000 based on the terms of the transition agreement for salary, COBRA, and transition service related costs. See Note 13 for further discussion regarding the acceleration of vesting of Mr. Glidewell’s outstanding equity awards.

Factoring_and_Security_Agreeme

Factoring and Security Agreement	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Factoring and Security Agreement	'
	7. Factoring and Security Agreement
	On June 13, 2013, the Company entered into a factoring and security agreement (Factoring and Security Agreement) with a third-party that would enable the Company to sell the entire interest in certain accounts receivable up to $5,000,000. Under the Factoring and Security Agreement, 15% of the sales proceeds will be held back by the purchaser until collection of such receivables. Such holdbacks are not considered legal securities, nor are they certificated. Upon the sale of the receivable, the Company will not maintain servicing. The purchaser may require the Company to repurchase accounts receivable if (i) the payment is disputed by the account debtor, with the purchaser being under no obligation to determine the bona fides of such dispute; (ii) the account debtor has become insolvent or (iii) upon the effective date of the termination of the Factoring and Security Agreement. The purchaser will retain its security interest in any accounts repurchased by the Company. The Factoring and Security Agreement is secured by all of the Company’s personal property and fixtures, and proceeds thereof, including accounts receivable, inventory, equipment and general intangibles other than intellectual property. Upon sale of the receivable, the Company may elect to set up a reserve where upon the cash for the sale remains with the third-party and the Company can draw on the available amount on the reserve account at any time. The Company elected to utilize the reserve account. On November 11, 2013, the Company terminated the Factoring and Security Agreement effective January 10, 2014.
	The Company accounted for sales of accounts receivable under the Factoring and Security Agreement as a secured borrowing in accordance with ASC 860, Transfers and Servicing (ASC 860). As of December 31, 2013, the Company had $479,000 included in accounts receivable that were transferred under this arrangement. As of December 31, 2013, the Company did not have excess funds available on the reserve account and did not have secured borrowings outstanding under the arrangement.

Debt

Debt	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Debt	'
	8. Debt
	Debt consists of the following (in thousands):
			31-Dec
			2013			2012
	Promissory note bearing interest at 6.25% per annum, which is payable monthly through May 2013, collateralized by all of the Company’s inventories, chattel paper, accounts receivable, equipment and general intangibles (excluding certain financed equipment and intellectual property). The Promissory Note was repaid in May 2013 (1)		$	—		$	35
	Term Loan (Term Loan) bearing interest at 7.00% per annum which is payable monthly through April 2016. The Term Loan is collateralized by all of the Company’s inventories, chattel paper, accounts receivable, equipment and general intangibles (excluding certain financed equipment and intellectual property) pledged as collateral under the Term Loan, subordinated (1)			309			426
	Promissory note bearing interest at 7.00% per annum which is payable monthly through November 2014, collateralized by all of the Company’s inventories, chattel paper, accounts receivable, equipment and general intangibles (excluding certain financed equipment and intellectual property), net of unamortized debt discount at December 31, 2013 of $2, subordinated (1)			123			261
	Senior secured promissory note (April 2012 Senior Secured Promissory Note) bearing interest at 15.00% per annum which is payable monthly through April 2017, collateralized by substantially all of the Company’s assets. The April 2012 Senior Secured Promissory Note was repaid in January 2013			—			8,374
	Junior secured promissory notes (October 2012 and April 2013 Junior Secured Promissory Notes) bearing interest at 12.00% per annum which are payable monthly through October 2015, collateralized by substantially all of the Company’s assets, net of unamortized debt discount at December 31, 2013 of $445 (1)			12,005			7,242
	Debt			12,437			16,338
	Less current portion			(157	)		(8,572	)
			$	12,280		$	7,766
	(1)	The lender’s security interest was subordinate to the holders of the April 2012 Senior Secured Promissory Note with the exception of its interest in equipment.
	As of December 31, 2013, aggregate contractual future principal payments on the Company’s debt, by year, are due as follows (in thousands):
	Years ending December 31:
	2014		$	251
	2015			12,585
	2016			48
	Total future principal payments		$	12,884
	The fair value of the Company’s outstanding debt obligations was $13,950,000 as of December 31, 2013, which was estimated based on a discounted cash flow model using an estimated market rate of interest of 7.0% and is classified as Level 3 within the fair value hierarchy. The Company believes the carrying values of its debt approximate their fair values at December 31, 2012 based on the interest rates as of those dates compared to similar debt instruments.
	Promissory Notes, Term Loan, Revolving Line of Credit and Credit Facility
	In May 2008, the Company borrowed $400,000 pursuant to a promissory note with a bank which had an interest rate of 6.25% per annum and was payable in 60 equal monthly installments of $7,785 commencing June 1, 2008. This promissory note was repaid in May 2013.
	In March 2009, October 2010 and October 2011, the Company and the bank agreed to modify the terms of its existing revolving line of credit (Revolver). Under the modified terms of the Revolver, the Company’s borrowings under the Revolver were limited to 75% of qualifying accounts receivable with a maximum borrowing limit of $500,000. In March 2012, the Company entered into a change in terms agreement with the bank under which the existing Revolver was replaced by the Term Loan in the amount of $500,000 with a rate of 7.00% per annum, maturing April 1, 2016. The Company’s inventories, chattel paper, accounts receivable, equipment and general intangibles (excluding certain financed equipment and intellectual property) have been pledged as collateral under the Term Loan. The Revolver was terminated in March 2012.
	In March 2009, the Company borrowed $650,000 pursuant to a promissory note with the bank which bears interest at the rate of 7.00% per annum and is repayable in six monthly interest only payments starting May 1, 2009, followed by 60 equal monthly installments of $13,000 commencing November 1, 2009, with the final payment due on November 1, 2014. All of the Company’s inventories, chattel paper, accounts receivable, equipment and general intangibles (excluding certain financed equipment and any intellectual property) have been pledged as collateral for the promissory notes.
	On April 13, 2012, the Company borrowed $10,000,000 pursuant to a senior secured promissory note (April 2012 Senior Secured Promissory Note) which had an interest rate of 15.00% per annum and required the Company to pay the lender non-refundable loan fees of $625,000. The April 2012 Senior Secured Promissory Note was payable in 59 monthly installments of $238,000 beginning in May 2012 with all unpaid principal and interest due in April 2017. The April 2012 Senior Secured Promissory Note was secured by a first priority security interest in substantially all of the Company’s present and future assets. The Company also issued a warrant (Series C Warrant) to the lender to purchase 191,000 shares of the Company’s Series C convertible preferred stock with an exercise price of $7.846 per share. Under its terms, the Series C Warrant would expire, unless exercised, on the earlier to occur of April 2022 or one year after the Company successfully completes a Qualified IPO, however the Series C Warrant was exercised effective upon the completion of the IPO (See Note 20). Until the effective date of the IPO, the Company estimated the fair value of the Series C Warrant using a PWERM valuation based on unobservable inputs and, therefore, the Series C Warrant was considered to be a Level 3 liability.
	The loan fees and the fair value of the Series C Warrant at the date of issuance of $625,000 and $306,000, respectively, were recorded as a debt discount to the April 2012 Senior Secured Promissory Note and were being amortized to interest expense over the term of the arrangement.
	Under the terms of the April 2012 Senior Secured Promissory Note, the Company could have elected to prepay the entire outstanding principal balance upon thirty days written notice to the lender. In the event the Company decided to prepay the entire loan balance, the Company would incur a termination fee that would be calculated based on the April 2012 Senior Secured Promissory Note’s outstanding principal balance as of the effective date of termination notice. The termination fee is 0% to 3% of the April 2012 Senior Secured Promissory Note’s outstanding balance as of the effective date of the termination notice, depending on the timing of the termination.
	Under the terms of the December 2012 Convertible Note issued in December 2012 (Note 9), the Company was required to use the proceeds from this convertible note to repay all outstanding balance of the April 2012 Senior Secured Promissory Note within 35 days of closing. The Company repaid the outstanding balance of the April 2012 Senior Secured Promissory Note in January 2013 and classified the outstanding balance of the April 2012 Senior Secured Promissory Note as of December 31, 2012 as a current liability. The total amount of the payout was $9,451,000 which consisted of $9,139,000 in principal, $34,000 in accrued interest, and an early termination fee of $278,000. The termination fee was recorded as incremental interest expense in the accompanying consolidated statements of operations for the year ended December 31, 2013.
	Activity related to the April 2012 Senior Secured Promissory Note from December 31, 2012 through December 31, 2013 consisted of the following (in thousands):
			DECEMBER 31,			AMORTIZATION			PRINCIPAL			DECEMBER 31,
			2012			OF DEBT			PAYMENTS			2013
						DISCOUNT
	Principal		$	9,139		$	—		$	(9,139	)	$	—
	Discount related to Series C Warrant (1)			(251	)		251			—			—
	Discount related to financing costs (1)			(514	)		514			—			—
			$	8,374		$	765		$	(9,139	)	$	—
	(1)	The amortization of this account is included in interest expense in the consolidated statements of operations and non-cash interest expense in the consolidated statements of cash flows.
	On October 2, 2012, the Company borrowed $7,500,000 pursuant to senior notes (October 2012 Junior Secured Promissory Notes) with a group of lenders. The October 2012 Junior Secured Promissory Notes have an initial term of three years and can be extended for an additional two years in one year increments. During the initial three-year term, the October 2012 Junior Secured Promissory Notes bear interest at 12% per annum. If the term of the October 2012 Junior Secured Promissory Notes is extended an additional year, the interest rate increases to 13% during the fourth year. If the term of the October 2012 Junior Secured Promissory Notes is extended for an additional two years, the interest rate is 14% during the fifth year. Interest on the October 2012 Junior Secured Promissory Notes is payable monthly through the initial maturity date of the loan which is October 2, 2015 or through any extension period. The principal and all unpaid interest are due on the maturity date, as may be extended.
	As part of the terms of the October 2012 Junior Secured Promissory Notes, the Company is required to pay a fee of 5% of the funded principal amount to the agent that facilitated the borrowing and provides management of the relationship with the group of lenders (Agent Fee). This Agent Fee is payable within 30 days after all interest and principal have been paid. For each year the Company extends the maturity date of the October 2012 Junior Secured Promissory Notes beyond the initial term, the agent will receive an additional 1% fee based on the funded principal amount. The present value of the unpaid Agent Fee, based on 5% of the funded principal amount, or $261,000, as of the closing date of the October 2012 Junior Secured Promissory Notes was recorded as both deferred financing costs as a component of current and non-current other assets and non-current other liabilities. The amortization of the deferred financing costs and the accretion of the Agent Fee are recorded to interest expense over the term of the arrangement. As of December 31, 2013 and 2012, $502,000 and $270,000, respectively, of the Agent Fee, including the amounts relating to the additional funds received from the issuance of the April 2013 Junior Secured Promissory Notes discussed below, was recorded under non-current other liabilities. In addition, the Company incurred an additional $66,000 in financing-related costs, primarily legal fees. These costs were recorded as deferred financing costs as a component of current and non-current other assets and are being amortized to interest expense over the term of the arrangement.
	The October 2012 Junior Secured Promissory Notes are secured by the Company’s ownership interest in MMM LLC, a security interest in the assets of the Manufacturing Plant, and all of the Company’s other assets, subject to certain permitted liens. This security interest was subordinate to the security interest held by the holders of the April 2012 Senior Secured Promissory Note as described above, which also had a security interest in MMM LLC.
	The Company also issued warrants (Common Stock Warrants) to the group of lenders to purchase a number of shares of common stock equal to 15% of the funded principal amount of the October 2012 Junior Secured Promissory Notes divided by 70% of the value of common stock in a sale of the Company or a Qualified IPO, with such Common Stock Warrants having an exercise price of 70% of the value of common stock in a sale of the Company or a Qualified IPO. The Common Stock Warrants would be automatically exercised immediately prior to expiration on the earlier to occur of a Qualified IPO or a sale of the Company or the maturity of the October 2012 Junior Secured Promissory Notes. The October 2012 Junior Secured Promissory Notes could be prepaid six months after the initial funding date or earlier if a Qualified IPO or a sale of the Company occurs. As the predominant settlement feature of the Common Stock Warrants is to settle a fixed monetary amount in a variable number of shares, the Common Stock Warrants were accounted for under ASC 480. Accordingly, the Common Stock Warrants were recorded at estimated fair value on their issuance date and were adjusted to their estimated fair value as of each reporting date with the change in estimated fair value recorded as a component of change in estimated fair value of financial instruments in the Company’s consolidated statements of operations. The fair value of the Common Stock Warrants at the date of issuance of $282,000 was recorded as a discount to the October 2012 Junior Secured Promissory Notes and is being amortized to interest expense over the term of the arrangement. Until the effective date of the IPO, the Company estimated the fair value of the Common Stock Warrants using a PWERM valuation based on unobservable inputs, and, therefore, the Common Stock Warrants were considered to be Level 3 liabilities. Upon closing of the IPO, the exercise price of the Common Stock Warrants was determined to be $8.40 per share and the number of shares to be issued upon exercise of the warrants was no longer variable. As a result of the IPO, the Common Stock Warrants were considered to be indexed to the Company’s stock, and accordingly, the common stock warrants liability was reclassified and included in stockholders’ equity (deficit) during the year ended December 31, 2013.
	The October 2012 Junior Secured Promissory Notes contain certain covenant requirements which include a requirement to maintain a minimum cash balance of the lesser of the April 2012 Senior Secured Promissory Note indebtedness described above or $5,000,000. As discussed above, the April 2012 Senior Secured Promissory Note was fully paid off in January 2013. The Company is also precluded from adding additional debt without lender approval unless such debt is subordinated to the October 2012 Junior Secured Promissory Notes and not more than $2,000,000. In the event of default on the October 2012 Junior Secured Promissory Notes, the lenders may declare the entire unpaid principal and interest immediately due and payable.
	On April 10, 2013 (Conversion Date), the Company entered an amendment to increase, by up to $5,000,000, the amount available under the terms of the loan agreement with respect to the October 2012 Junior Secured Promissory Notes. Under this amendment, an additional $4,950,000 was issued in partial consideration for $3,700,000 in cash received and in partial conversion for the cancellation of $1,250,000 of the total principal balance of the October 2012 Subordinated Convertible Note described below (collectively, April 2013 Junior Secured Promissory Notes). The total amount borrowed under the amended loan agreement for the October 2012 Junior Secured Promissory Notes and the April 2013 Junior Secured Promissory Notes increased from $7,500,000 to $12,450,000 as of the Conversion Date. The accrued interest of $74,000 for the partially converted October 2012 Subordinated Convertible Note as of the Conversion Date shall be repaid or converted on the applicable maturity date of the October 2012 Subordinated Convertible Note.
	In connection with the issuance of the April 2013 Junior Secured Promissory Notes, the Company issued additional warrants (Additional Common Stock Warrants) to purchase a number of shares of common stock equal to 20% of the funded principal amount of the April 2013 Junior Secured Promissory Notes divided by 70% of the value of common stock in a sale of the Company or a Qualified IPO, with such Additional Common Stock Warrants to have an exercise price of 70% of the value of common stock in a sale of the Company or a Qualified IPO. As the predominant settlement feature of the Additional Common Stock Warrants was to settle a fixed monetary amount in a variable number of shares, the Common Stock Warrants were accounted for under ASC 480. Accordingly, the Additional Common Stock Warrants were recorded at estimated fair value on their issuance date and were adjusted to their estimated fair value as of each reporting date with the change in estimated fair value recorded as a component of change in estimated fair value of financial instruments in the Company’s consolidated statements of operations. The fair value of the Additional Common Stock Warrants at the date of issuance was estimated to be $465,000. The Company estimated the fair value of the Additional Common Stock Warrants using a PWERM valuation based on unobservable inputs and, therefore, the Additional Common Stock Warrants were considered to be Level 3 liabilities. Upon closing of the IPO, the exercise price of the Common Stock Warrants was determined to be $8.40 per share and the number of shares to be issued upon exercise of the warrants was no longer variable. As a result of the IPO, the Common Stock Warrants were considered to be indexed to the Company’s stock, and accordingly, the common stock warrants liability was reclassified and included in stockholders’ equity (deficit) during the year ended December 31, 2013.
	The debt holder who converted $1,250,000 principal balance of the October 2012 Subordinated Convertible Note (with a fair value of $1,360,000 on the date of conversion) also loaned an additional $2,500,000 in cash as part of the April 2013 Junior Secured Promissory Notes (collectively, the $3,750,000 Notes). The Company accounted for the conversion as an extinguishment of debt in accordance with ASC 470-50-40. The $1,360,000 fair value of the partially converted October 2012 Subordinated Convertible Note on the Conversion Date was derecognized and the fair value of the $3,750,000 Notes with the portion of the fair value of the Additional Common Stock Warrants issued to this debt holder on the date of issuance was recorded. The Company recorded the $49,000 excess of the total fair value of the $3,750,000 Notes and the related Additional Common Stock Warrants on the issuance date over total consideration received as a gain on extinguishment of debt in the accompanying consolidated statements of operations for the year ended December 31, 2013.
	The following table shows the consideration received, fair values of the notes and common stock warrants issued and calculation of the gain on extinguishment of debt for the $3,750,000 Notes (in thousands):
	Consideration received
	Fair Value of October 2012 Subordinated Convertible Note		$	1,360
	Cash			2,500
	Total Consideration Received (a)		$	3,860
	Notes and Warrants Issued
	Principal Balance of Notes Issued		$	3,750
	Debt Discount (1)			(291	)
	Fair Value of Notes Issued			3,459
	Fair Value of Additional Common Stock Warrants Issued			352
	Total Fair Value of Notes and Warrants Issued (b)		$	3,811
	Gain on Extinguishment of Debt (a—b)		$	49
	(1)	The amortization of this account is being recorded in interest expense in the consolidated statements of operations over the term of the arrangement.
	The remaining fair value to the Additional Common Stock Warrants of $113,000, net of the fair value of the Additional Common Stock Warrants issued of $352,000 related to the $3,750,000 Notes discussed above, was recorded as a debt discount to the April 2013 Junior Secured Promissory Notes and is being amortized to interest expense over the term of the arrangement.
	As a result of the amendment described above, the Company is also required to pay the Agent Fee, 5% of the $3,700,000 in cash received from the April 2013 Junior Secured Promissory Notes, under the same terms as the October 2012 Junior Secured Promissory Notes. In addition, the portion of the Agent Fee relating to the converted October 2012 Subordinated Convertible Note that would be due under the terms of the October 2012 Subordinated Convertible Note will be paid under the terms of the October 2012 and April 2013 Junior Secured Promissory Notes. The present value of the unpaid Agent Fee of $172,000, based on 5% of the funded principal amount of $4,950,000, as of the closing date of the April 2013 Junior Secured Promissory Notes was recorded as both deferred financing costs as a component of current and non-current other assets and non-current other liabilities. The amortization of the deferred financing costs and the accretion of the Agent Fee are being amortized to interest expense over the term of the arrangement.
	In addition, the Company incurred an additional $24,000 in financing-related costs, primarily legal fees. These costs were recorded as deferred financing costs as a component of current and non-current other assets and are being amortized to interest expense over the term of the arrangement.
	The amendment to the loan agreement also amended the interest provision applicable to the October 2012 and April 2013 Junior Secured Promissory Notes to allow any holder of the October 2012 and April 2013 Junior Secured Promissory Notes to request the Company to defer all interest due monthly to the applicable maturity date, and the optional prepayment provision applicable to the October 2012 and April 2013 Junior Secured Promissory Notes to allow the Company to repay the outstanding amount of the October 2012 and April 2013 Junior Secured Promissory Notes, either (i) with the written consent of the lender or the agent on such lenders’ behalf or (ii) without such consent provided that the Company pays the interest that would have been due from the prepayment date to the initial maturity date.
	Activity related to the October 2012 and April 2013 Junior Secured Promissory Notes from December 31, 2012 through December 31, 2013 consisted of the following (in thousands):
		DECEMBER 31,			ADDITIONS			AMORTIZATION			PRINCIPAL		DECEMBER 31,
		2012						OF DEBT			PAYMENTS		2013
								DISCOUNT
Principal		$	7,500		$	4,950		$	—		$	—	$	12,450
Debt discount related to issuance of common stock warrants (1)			(258	)		(113	)		130			—		(241	)
Discount related to the $3,750,000 Notes (1)			—			(291	)		87			—		(204	)
		$	7,242		$	4,546		$	217		$	—	$	12,005
(1)	The amortization of this account is included in interest expense in the consolidated statements of operations and as non-cash interest expense in the consolidated statements of cash flows.
On June 14, 2013, the Company entered into a credit facility agreement (June 2013 Credit Facility) with a group of lenders that are, or that are affiliated with, existing investors in the Company. Under the June 2013 Credit Facility, the lenders have committed to permit the Company to draw an aggregate of up to $5,000,000, and, subject to the Company’s obtaining additional commitments from lenders, such amount may be increased to up to $7,000,000. The June 2013 Credit Facility expires on June 30, 2014. During the term of the June 2013 Credit Facility, the Company may request from the lenders up to four advances, with each advance equal to one-quarter of each lender’s aggregate commitment amount. The Company will issue a promissory note in the principal amount of each such advance that will accrue interest at a rate of 10% per annum. The principal and all unpaid interest under the promissory notes are due on the maturity date, and the Company may not prepay the promissory notes prior to the maturity date without consent of at least a majority in interest of the aggregate principal amount of the promissory notes then outstanding under the credit facility. In connection with the June 2013 Credit Facility, the Company agreed to pay a fee of 2% of the total commitment amount to the lenders. In addition, the Company incurred an additional $10,000 in financing-related costs, primarily legal fees. These costs were recorded as deferred financing costs as a component of current other assets and are being amortized to interest expense over the term of the arrangement.
In connection with the June 2013 Credit Facility, the Company issued warrants (June 2013 Warrants) to purchase a number of shares of common stock equal to 10% of the total committed amount of the June 2013 Credit Facility divided by 70% of the value of common stock in a sale of the Company or a Qualified IPO, with such June 2013 Warrants to have an exercise price of 70% of the value of common stock in a sale of the Company or a Qualified IPO. The June 2013 Warrants expire upon the earlier of June 14, 2023 or the sale of the Company. As the predominant settlement feature of the June 2013 Warrants was to settle a fixed monetary amount in a variable number of shares, the June 2013 Warrants were accounted for under ASC 480. Accordingly, the June 2013 Warrants were recorded at estimated fair value on their issuance date and were adjusted to their estimated fair value as of each reporting date with the change in estimated fair value recorded as a component of change in estimated fair value of financial instruments in the Company’s consolidated statements of operations. The fair value of the June 2013 Warrants at the date of issuance of $435,000 was recorded as a deferred financing cost as a current other asset and is being amortized to interest expense over the term of the arrangement. Until the effective date of the IPO, the Company estimated the fair value of the June 2013 Warrants using a PWERM valuation based on unobservable inputs and, therefore, the June 2013 Warrants were considered to be Level 3 liabilities. Upon closing of the IPO, the exercise price of the June 2013 Warrants was determined to be $8.40 per share and the number of shares to be issued upon exercise of the warrants was no longer variable. As a result of the IPO, the June 2013 Warrants were considered to be indexed to the Company’s stock, and accordingly, the common stock warrants liability was reclassified and included in stockholders’ equity (deficit) during the year ended December 31, 2013.
During the year ended and as of December 31, 2013, there were no amounts outstanding under the June 2013 Credit Facility.
The Company is also required to comply with certain affirmative and negative covenants under the debt agreements discussed above. In the event of default on the debt, the lender(s) may declare the entire unpaid principal and interest immediately due and payable. As of December 31, 2013, the Company was in compliance with all of the affirmative and negative covenants, and there were no events of default, as defined in the agreements, related to the debt.

Convertible_Notes_Payable

Convertible Notes Payable	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Convertible Notes Payable	'
	9. Convertible Notes Payable
	Convertible notes payable consists of the following (in thousands):
		MATURITY	DECEMBER 31
		DATE	2013		2012
	Convertible notes (March 2012 Convertible Notes) bearing interest at 10.00% per annum issued in March and April 2012. The convertible notes were converted to common stock in August 2013.	September 2013	$	—	$	20,204
	Convertible note (October 2012 Convertible Note) bearing interest at 10.00% per annum issued in October 2012. The convertible note was converted to common stock in August 2013	September 2013		—		2,314
	Convertible notes payable, current portion			—		22,518
	Convertible note (October 2012 Subordinated Convertible Note) bearing interest at 12.00% per annum issued in October 2012. The convertible note was converted to common stock in August 2013	Oct-15		—		2,797
	Convertible note (December 2012 Convertible Note) bearing interest at 10.00% per annum issued in December 2012. The convertible note was converted to common stock in August 2013	Oct-15		—		16,545
	Convertible notes (First May 2013 Convertible Notes) bearing interest at 10.00% per annum issued in May 2013. The convertible notes were converted to common stock in August 2013	May-16		—		—
	Convertible note (Second May 2013 Convertible Note) bearing interest at 10.00% per annum issued in May 2013. The convertible note was converted to common stock in August 2013	May-16		—		—
	Total convertible notes payable		$	—	$	41,860
	March 2012 and October 2012 Convertible Notes
	During March 2012 through April 2012, the Company issued and sold in a series of closings $8,076,000 of convertible notes (March 2012 Convertible Notes) to existing preferred stockholders. During October 2012, the Company issued an additional $1,000,000 convertible note (October 2012 Convertible Note) to another existing preferred stockholder. Collectively, the March 2012 Convertible Notes and the October 2012 Convertible Note are referred to as the “March and October 2012 Convertible Notes,” and they accrued interest at 10% per annum. The principal and accrued interest then outstanding under the March and October 2012 Convertible Notes (Outstanding Balance) would mature on September 30, 2013 (Maturity Date) or earlier, at which time all such Outstanding Balance would automatically convert into a new series of preferred stock to be authorized immediately prior to the Maturity Date.
	Under the terms of the notes, if the Company closed an initial public offering in which the Company received gross cash proceeds, before underwriting discounts, commissions and fees, of at least $30,000,000 (a Qualified IPO) or a sale of substantially all of the Company’s assets or a series of transactions that result in the transfer of more than 50% of the Company’s outstanding voting power (an Acquisition), the Outstanding Balance of the March 2012 Convertible Notes would automatically convert into shares of the Company’s common stock at a rate of 70% of the per share price of the Company’s common stock sold in the Qualified IPO or the Acquisition. In the event of a Qualified IPO or Acquisition, the Outstanding Balance of the October 2012 Convertible Note would automatically convert into shares of the Company’s common stock at a rate of 80% of the per share price of the Company’s common stock sold in the Qualified IPO or the Acquisition. Upon the closing of the IPO on August 7, 2013, all outstanding principal and accrued interest of the March and October 2012 Convertible Notes converted into shares of the Company’s common stock at a rate of 70% and 80% of the per share price, respectively (See Note 20).
	Alternatively, the Outstanding Balance would have been automatically converted into other new securities, as follows, if prior to closing the Qualified IPO or the Acquisition, the Company had closed an equity financing for an aggregate consideration of at least $5,000,000 (a Qualified Equity Financing). If prior to closing the Qualified IPO or the Acquisition, the Company had closed a Qualified Equity Financing, the Outstanding Balance of the March 2012 Convertible Notes would have converted into the equity securities issued in the equity financing at 80% of the purchase price of such securities. In the event of a Qualified Equity Financing, the Outstanding Balance of the October 2012 Convertible Note would have converted into the equity securities issued in the equity financing at 85% of the purchase price of such securities.
	On the issuance date and at each reporting date prior to the conversion, the Company assessed the probability of the potential conversion scenarios under the terms of the March and October 2012 Convertible Notes and determined that the predominant settlement feature of the March and October 2012 Convertible Notes would have been the conversion of the March and October 2012 Convertible Notes into shares of the Company’s common stock issuable at a 30% or 20% discount to the per share price payable in connection with the completion of the Qualified IPO or Acquisition during the term of the arrangement. As the predominant settlement feature of the March and October 2012 Convertible Notes was to settle a fixed monetary amount in a variable number of shares, the March and October 2012 Convertible Notes fell within the scope of ASC 480. Accordingly, the March and October 2012 Convertible Notes were recorded at estimated fair value on their respective issuance dates and were adjusted to their estimated fair value as of each reporting date with the change in estimated fair value recorded as a component of change in estimated fair value of financial instruments in the Company’s consolidated statements of operations. As a result of the IPO, the number of shares to be issued became known and the Company estimated the fair value of the convertible notes immediately prior to the conversion using the intrinsic method based on the IPO price of $12.00 per share.
	The Company estimated the fair value of the March and October 2012 Convertible Notes as of the issuance dates to be $9,343,000 and $1,772,000, respectively. As the Company received total cash proceeds of $9,076,000 through the issuance of the March and October 2012 Convertible Notes, the Company determined that $2,039,000 of the excess of the estimated fair value of the March and October 2012 Convertible Notes on the issuance dates over cash proceeds to the Company represented a deemed dividend to preferred stockholders, and this amount was reflected in the net loss attributable to common stockholders for the year ended December 31, 2012 in the Company’s consolidated statements of operations.
	As of December 31, 2012 and immediately prior to the closing of the IPO on August 7, 2013, the estimated fair value of the March and October 2012 Convertible Notes was $22,518,000 and $14,599,000, respectively. Between December 31, 2012 and August 7, 2013, the estimated fair value of the March and October 2012 Convertible Notes decreased by $8,516,000, which was recognized as additional income in change in estimated fair value of financial instruments in the Company’s consolidated statements of operations for the year ended December 31, 2013.
	For the year ended December 31, 2012, due to changes in the probability and timing of the completion of a Qualified IPO or an Acquisition between the dates of issuance and December 31, 2012, the estimated fair value of the March and October 2012 Convertible Notes increased by $10,721,000, which was recognized as additional expense in change in estimated fair value of financial instruments in the Company’s consolidated statements of operations for the year ended December 31, 2012.
	As discussed above, the Company was not required to pay interest on the March and October 2012 Convertible Notes, but interest accrued as part of the principal balance under the March and October 2012 Convertible Notes and was converted, along with the initial principal, into common stock upon closing of the IPO in August 2013.
	October 2012 Subordinated Convertible Note
	On October 16, 2012, the Company borrowed $2,500,000 pursuant to a convertible note (October 2012 Subordinated Convertible Note) from a lender. The October 2012 Subordinated Convertible Note had an initial term of three years. During the initial three-year term, the October 2012 Subordinated Convertible Note accrued interest at 12% per annum.
	In April 2013, the Company entered an amendment to convert $1,250,000 of the outstanding principal balance of the October 2012 Subordinated Convertible Note to the April 2013 Junior Secured Promissory Notes, as defined and further discussed in Note 8. The accrued interest of $74,000 for the partially converted October 2012 Subordinated Convertible Note as of the Conversion Date was to be repaid or converted on the applicable maturity date of the October 2012 Subordinated Convertible Note. The Company accounted for the conversion as an extinguishment of debt in accordance with ASC 470-50-40 and derecognized the $1,360,000 fair value of the October 2012 Subordinated Convertible Note and recorded a $49,000 gain on extinguishment of debt which was reflected in the Company’s consolidated statements of operations. In addition, the portion of the Agent Fee relating to the converted October 2012 Subordinated Convertible Note that would be due under the terms of the October 2012 Subordinated Convertible Note will be paid under the terms of the October 2012 and April 2013 Junior Secured Promissory Notes. The amount of the unamortized converted Agent Fee on the date of conversion recorded under non-current other liabilities of $48,000 and the amount recorded as a component of current and non-current other assets of $39,000 was written-off and recorded as an adjustment to interest expense (See Note 8).
	As part of the terms of the October 2012 Subordinated Convertible Note, the Company was required to pay the Agent Fee of 5% of the funded principal amount to the agent that facilitated the borrowing and provided management of the relationship with the lender and who also facilitated the October 2012 Junior Secured Promissory Notes discussed in Note 8 above. This Agent Fee was payable within 30 days after all interest and principal had been paid. For each year the Company extended the maturity date of the October 2012 Subordinated Convertible Note beyond the initial term, the agent would have received an additional 1% fee based on the funded principal amount. The present value of the unpaid Agent Fee, based on 5% of the funded principal amount, or $87,000, as of the closing date of the October 2012 Subordinated Convertible Note was recorded as both deferred financing costs as a component of current and non-current other assets and non-current other liabilities. The amortization of the deferred financing costs and the accretion of the Agent Fee were being amortized to interest expense over the term of the arrangement. As of December 31, 2013, the Agent Fee was fully amortized and paid. As of December 31, 2012, $89,000 of the Agent Fee, including the effect of the amendment of the October 2012 Subordinated Convertible Note discussed above, was recorded in current and non-current other liabilities, respectively. In addition, the Company incurred an additional $22,000 in financing-related costs, primarily legal fees. These costs were recorded as deferred financing costs as a component of current and non-current other assets and were amortized to interest expense over the term of the arrangement. As of December 31, 2013, these deferred financing costs were fully amortized.
	Under the terms of the note, if the Company closed a Qualified IPO or an Acquisition, the October 2012 Subordinated Convertible Note and any accrued interest would automatically convert into shares of the Company’s common stock at a rate of 85% of the purchase price of common stock sold, provided the closing occurred on or prior to eighteen months from the issuance date of the October 2012 Subordinated Convertible Note. The conversion rate would have adjusted to 80% of the purchase price of such securities, if the closing had occurred on or after eighteen months from the issuance date of the October 2012 Subordinated Convertible Note through the date of maturity. Upon the closing of the IPO in August 2013, all outstanding principal and accrued interest of the October 2012 Subordinated Convertible Note were converted into shares of the Company’s common stock at a rate of 85% of the per share price (See Note 20).
	On the issuance date and at each reporting date prior to the conversion, the Company assessed the probability of potential conversion under its terms of the October 2012 Subordinated Convertible Note and determined that the predominate settlement feature of the October 2012 Subordinated Convertible Note would have been the conversion of the October 2012 Subordinated Convertible Note into shares of the Company’s common stock issuable at a 15% or 20% discount to the per share price payable upon the completion of a Qualified IPO, an Acquisition, or Qualified Equity Financing. As the predominant settlement feature of the October 2012 Subordinated Convertible Note was to settle a fixed monetary amount into a variable number of shares, the October 2012 Subordinated Convertible Note fell within the scope of ASC 480. Accordingly, the October 2012 Subordinated Convertible Note was recorded at estimated fair value on its issuance date and was adjusted to its estimated fair value as of each reporting date with the change in estimated fair value recorded as a component of change in estimated fair value of financial instruments in the Company’s consolidated statements of operations. As a result of the IPO, the number of shares to be issued became known and the Company estimated the fair value of the convertible notes immediately prior to the conversion using the intrinsic method based on the IPO price of $12.00 per share.
	The Company estimated the fair value of the October 2012 Subordinated Convertible Note as of the issuance date to be $2,662,000. As the Company received cash proceeds of $2,500,000 through the issuance of the October 2012 Subordinated Convertible Note, $162,000 of the excess of the estimated fair value of the October 2012 Subordinated Convertible Note on the issuance date over cash proceeds was recorded as additional interest expense for the year ended December 31, 2012 in the Company’s consolidated statements of operations.
	As of December 31, 2012, the principal balance and the estimated fair value of the October 2012 Subordinated Convertible Note was $2,500,000 and $2,797,000, respectively. Immediately prior to the closing of the IPO in August 2013, the principal balance and the estimated fair value of the October 2012 Subordinated Convertible Note was $1,250,000 and $1,703,000, respectively. Between December 31, 2012 and August 7, 2013, the estimated fair value of the October 2012 Subordinated Convertible Note increased by $133,000, which was recognized as additional expense in change in estimated fair value of financial instruments in the Company’s consolidated statements of operations for the year ended December 31, 2013.
	December 2012 Convertible Note
	On December 6, 2012, the Company borrowed $12,500,000 pursuant to a convertible note (December 2012 Convertible Note) from an existing preferred stockholder that also is an affiliate of one of the Company’s distributors. The December 2012 Convertible Note had an initial maturity date of October 16, 2015. During the initial approximately three-year (two-year and ten-month) term, the December 2012 Convertible Note accrued interest at 10% per annum.
	Under the terms of the note, the December 2012 Convertible Note could not have been pre-paid unless such prepayment was mandated by a sale event. A sale event as defined in the agreement was the transfer of substantially all of the Company’s assets, a transaction or series of transactions that result in the transfer of more than 50% voting power of the Company, or transactions that result in gross proceeds of at least $120,000,000 (Sale Event). In the case of a Sale Event, the holder could have elected to either convert all outstanding principal and accrued interest into shares of common stock in accordance with the conversion terms of this agreement or receive cash equal to the principal and accrued interest then outstanding multiplied by 133.33% if the Sale Event occurred prior to or as of June 30, 2013 or multiplied by 142.86% if the Sale Event occurred after June 30, 2013.
	Under the terms of the note, a Qualified Financing meant an equity financing for which the gross proceeds were at least $20,000,000 and at least 50% of the amount invested comes from sources other than holders of the Company’s equity, strategic investors, or affiliates (Qualified Financing). In the event of a Qualified Financing, all outstanding principal and unpaid interest on the December 2012 Convertible Note would automatically convert into new securities issued and sold in such qualified financing at a rate of 75% of the purchase price of such new securities provided the closing occurred on or prior to June 30, 2013. The conversion rate would adjust to 70% of the purchase price of such new securities, if the closing occurred after June 30, 2013. Upon the closing of the IPO on August 7, 2013, all outstanding principal and accrued interest of the December 2012 Convertible Note was converted into shares of the Company’s common stock at a rate of 70% of the per share price (See Note 20).
	In the event of a non-qualified financing (Non-Qualified Financing) or the Sale Event, the holder of the December 2012 Convertible Note would have had the right, but not the obligation, to convert all or a part of the outstanding principal and unpaid interest on the December 2012 Convertible Note into the same type of securities issued in the Non-Qualified Financing. A Non-Qualified Financing included either a convertible note financing or an equity transaction that did not qualify as a Qualified Financing.
	If the Non-Qualified Financing related to an equity financing or Sale Event, the number of shares of common stock or common stock equivalents to be received by the holder of the December 2012 Convertible Note would have been calculated by dividing the principal and unpaid accrued interest elected to be converted by the holder by a price per share equal to the price per share paid in the Non-Qualified Financing multiplied by a conversion discount.
	If the Non-Qualified Financing related to a debt financing, the December 2012 Convertible Note holder would have received new convertible notes convertible into shares of common stock or common stock equivalents at a per share price equal to the conversion price per share applicable to the other convertible debt issued in the Non-Qualified Financing multiplied by a conversion discount. In each case, if the Non-Qualified Financing had occurred on or before June 30, 2013, the conversion rate would have been equal to 75%, and thereafter the conversion rate would have been equal to 70%.
	On the issuance date and at each reporting date prior to the conversion, the Company assessed the probability of the potential conversion scenarios under the terms of the December 2012 Convertible Note and determined that the predominant settlement feature of the December 2012 Convertible Note was the conversion of the December 2012 Convertible Note into shares of the Company’s common stock issuable at a 25% or 30% discount to the per share price payable in connection with the completion of a Qualified Financing or a Sale Event during the term of the arrangement. As the predominant settlement feature of the December 2012 Convertible Note was to settle a fixed monetary amount into a variable number of shares, the December 2012 Convertible Note fell within the scope of ASC 480. Accordingly, the Company determined that the December 2012 Convertible Note should be recorded at estimated fair value on its issuance date and adjusted to its estimated fair value as of each reporting date with the change in estimated fair value recorded as a component of change in estimated fair value of financial instruments in the Company’s consolidated statements of operations. As a result of the IPO, the number of shares to be issued became known and the Company estimated the fair value of the convertible notes immediately prior to the conversion using the intrinsic method based on the IPO price of $12.00 per share.
	Following the issuance of the December 2012 Convertible Note, the Company estimated the fair value of the December 2012 Convertible Note as of the issuance date using a PWERM valuation consisting of six scenarios. This valuation included three initial public offering scenarios, two merger scenarios and a sale of the Company’s intellectual property along with the applicable conversion ratios based on the estimated timing of each scenario. Based on this valuation, the Company estimated the fair value of the December 2012 Convertible Note to be $16,355,000 as of the issuance date. As the holder of the December 2012 Convertible Note was an affiliate of one of the Company’s distributors, the $3,855,000 excess of the estimated fair value of the December 2012 Convertible Note on the date of issuance over gross cash proceeds was recorded as a reduction of related party revenues to the extent of revenue recognized from the distributor totaling $245,000 ($110,000 related to license revenues and $135,000 related to product revenues), and the remaining excess of $3,610,000 was recorded separately to an operating expense in accordance with ASC 605-50, Customer Payments and Incentives (ASC 605-50), in the Company’s consolidated statements of operations for the year ended December 31, 2012.
	As of December 31, 2012 and immediately prior to conversion on August 7, 2013, the estimated fair value of the December 2012 Convertible Note was $16,545,000 and $19,072,000, respectively. Between December 31, 2012 and August 7, 2013, the estimated fair value of the December 2012 Convertible Note increased by $1,767,000, which was recognized as additional expense in change in estimated fair value of financial instruments in the Company’s consolidated statements of operations for the year ended December 31, 2013.
	For the year ended December 31, 2012, due to changes in the probability and timing of the completion of a Qualified IPO or an Acquisition between the dates of issuance and December 31, 2012, the estimated fair value of the December 2012 Convertible Note increased by $100,000, which was recognized as additional expense in change in estimated fair value of financial instruments in the Company’s consolidated statements of operations for the year ended December 31, 2012.
	The December 2012 Convertible Note purchase agreement also required the Company to use the proceeds from this note to repay all outstanding obligations under the April 2012 Senior Secured Promissory Note within 35 days of closing as discussed in Note 8.
	First and Second May 2013 Convertible Notes
	On May 22, 2013, the Company completed the sale of convertible notes under a convertible note purchase agreement in the amount of $3,529,000 in a private placement to 22 investors (First May 2013 Convertible Notes). The First May 2013 Convertible Notes accrued interest at a rate of 10% per annum and would have matured on May 22, 2016.
	In addition, on May 28, 2013, the Company completed the sale of a convertible note under a separate convertible note purchase agreement in the amount of $3,000,000 in a private placement (Second May 2013 Convertible Note). The Second May 2013 Convertible Note accrued interest at a rate of 10% per annum and would have matured on May 30, 2016.
	Under the terms of the notes, no payments were due under the First and Second May 2013 Convertible Notes until maturity. In an event of a Qualified Financing, all outstanding principal and accrued interest due under the First and Second May 2013 Convertible Notes would automatically convert into the number of shares of the Company’s common stock determined by dividing such unpaid amounts by 70% of the per share price of the Company’s common stock sold in such qualified financing. Upon the closing of the IPO in August 2013, all outstanding principal and accrued interest of the First and Second May 2013 Convertible Notes were converted into shares of the Company’s common stock at a rate of 70% of the per share price (See Note 20).
	Alternatively, in the earlier event of a Non-Qualified Financing of equity or debt securities, the First and Second May 2013 Convertible Notes could have been converted, at the option of the holder, into the same type of securities issued in such financing, and in the earlier of a Sale Event, the First and Second May 2013 Convertible Notes would have been either, at the option of the holder, repaid in the amount of the principal and accrued interest then outstanding multiplied by 142.86% or converted at a discount into shares of the Company’s common stock.
	If the Qualified Financing, Non-Qualified Financing, or Sale Event had not occurred from the date of issuance of the convertible note through January 14, 2014, the holder of the Second May 2013 Convertible Note would have been able to elect to convert all outstanding principal and accrued interest into a number of shares of common stock determined by dividing this amount by the greater of (i) the per share price into which the Outstanding Balance under the Second May Convertible Note would be converted at their maturity in the event a Qualified Financing had not occurred as of September 30, 2013 or (ii) the purchase price paid per share for the most recent Non-Qualified Financing that occurred prior to a Sale Event, provided such Non-Qualified Financing would have been at least $2,000,000 and at least 50% of the proceeds of such Non-Qualified Financing would have been from persons or entities who were not common stockholders, or common share equivalents or affiliates of the Company.
	On the issuance date and at each reporting date prior to the conversion, the Company assessed the probability of potential conversion under its terms of the First and Second May 2013 Convertible Notes and determined that the predominate settlement feature of the First and Second May 2013 Convertible Notes was the conversion of the First and Second May 2013 Convertible Notes into shares of the Company’s common stock issuable at a 30% discount to the per share price payable upon the completion of a Qualified IPO, an Acquisition, or Qualified Equity Financing. As the predominant settlement feature of the First and Second May 2013 Convertible Notes was to settle a fixed monetary amount in a variable number of shares, the First and Second May 2013 Convertible Notes fell within the scope of ASC 480. Accordingly, the First and Second May 2013 Convertible Notes were recorded at estimated fair value on their issuance dates and were adjusted to estimated fair value as of each reporting date with the change in estimated fair value recorded as a component of change in estimated fair value of financial instruments in the Company’s consolidated statements of operations. As a result of the IPO, the number of shares to be issued became known and the Company estimated the fair value of the convertible notes immediately prior to the conversion using the intrinsic method based on the IPO price of $12.00 per share.
	The Company estimated the fair value of the First May 2013 Convertible Notes as of the issuance date to be $4,907,000. As the Company received cash proceeds of $3,529,000 through the issuance of the First May 2013 Convertible Notes, the Company determined that $1,378,000 of the excess of the estimated fair value of the First May 2013 Convertible Notes on the issuance date over cash proceeds to the Company represented a deemed dividend to preferred stockholders, and this amount was reflected in the net loss attributable to common stockholders for the year ended December 31, 2013 in the Company’s consolidated statements of operations.
	Immediately prior to conversion in connection with the closing of the IPO on August 7, 2013, the estimated fair value of the First May 2013 Convertible Notes was $5,147,000. The estimated fair value of the First May 2013 Convertible Notes increased by $166,000 from the issuance date, which was recognized as additional expense in change in estimated fair value of financial instruments in the Company’s consolidated statements of operations for the year ended December 31, 2013.
	The Company estimated the fair value of the Second May 2013 Convertible Note as of the issuance date to be $4,162,000. As the Company received cash proceeds of $3,000,000 through the issuance of the Second May 2013 Convertible Note, $1,162,000 of the excess of the estimated fair value of the Second May 2013 Convertible Note on the issuance date over cash proceeds to the Company was recorded as additional interest expense for the year ended December 31, 2013 in the Company’s consolidated statements of operations.
	Immediately prior to conversion in connection with the closing of the IPO on August 7, 2013, the estimated fair value of the Second May 2013 Convertible Note was $4,369,000. The estimated fair value of the Second May 2013 Convertible Note increased by $149,000 from the issuance date, which was recognized as additional expense in change in estimated fair value of financial instruments in the Company’s consolidated statements of operations for the year ended December, 2013.

Preferred_Stock

Preferred Stock	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Preferred Stock	'
	10. Preferred Stock
	The Company sold 1,484,000 shares of its Series A convertible preferred stock in private placements in April 2007 for $2.608 per share, including conversion of certain convertible notes payable, 2,242,000 shares of its Series B convertible preferred stock in August 2008 for $4.849 per share, including conversion of convertible notes payable, and 4,778,000 shares of its Series C convertible preferred stock from March 2010 to June 2011 for $5.317 per share, including conversion of the $514,000 of convertible notes payable plus accrued interest of $5,000. The Company recorded the issuance of its Series A, B, and C convertible preferred stock, net of issuance costs.
	In May 2012, in connection with the issuance of the Series C Warrant, the Company amended certificate of incorporation to increase the number of shares of common stock the Company is authorized to issue from 12,745,000 shares to 12,936,000 shares and to increase the number of shares of convertible preferred stock the Company is authorized to issue from 8,632,000 shares to 8,823,000, of which 1,489,000 shares were designated as Series A convertible preferred stock, 2,252,000 shares were designated as Series B convertible preferred stock, and 5,082,000 shares were designated as Series C convertible preferred stock.
	Upon the closing of the IPO, all shares of the Company’s outstanding convertible preferred stock automatically converted into shares of common stock. Further, in August 2013, the Company amended and restated its certificate of incorporation to effect the conversion of its outstanding convertible preferred stock into common stock on a 1-for-1 basis. The amendment also increased the number of shares of preferred stock authorized for issuance to 20,000,000.
	Investors in the Company’s Series C convertible preferred stock were entitled to receive noncumulative dividends, before and in preference to any amounts paid to Series A and Series B convertible preferred stockholders and common stockholders, and investors in the Company’s Series A and B convertible preferred stock were entitled to receive noncumulative dividends, on a pari passu basis, before and in preference to any amounts paid to common stockholders. Dividends would be paid only when and if declared by the board of directors. In addition, these investors were entitled to voting rights equal to the number of shares of the Company’s common stock into which the Series A, B and C convertible preferred stock were convertible as of the close of business on the record date fixed for each stockholder’s meeting. No dividends were declared during the years ended December 31, 2013 and 2012.
	As the Company’s Series A, B and C convertible preferred stock contained redemption features that were outside of the Company’s control, all shares of Series A, B and C convertible preferred stock were presented outside of permanent equity as of December 31, 2012.

Warrants

Warrants	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Warrants	'
	11. Warrants
	The following table summarizes information about the Company’s common stock warrants outstanding as of December 31, 2013 (in thousands, except exercise price data):
	DESCRIPTION		ISSUE DATE	EXPIRATION	NUMBER OF		EXERCISE
				DATE (1)	SHARES		PRICE
					SUBJECT TO
					WARRANTS
					ISSUED
	In connection with April 2013 Junior Secured Promissory Note (Additional Common Stock Warrants)		April 2013	October 2015		118	$	8.4
	In connection with June 2013 Credit Facility (June 2013 Warrants)		Jun-13	Jun-23		33	$	8.4
						151
	(1)	Both the common stock warrants expire upon the earlier to occur of (i) the date listed above; (ii) the acquisition of the Company by another entity by means of any transaction or series of related transactions (including, without limitation, any transfer of more than 50% of the voting power of the Company, reorganization, merger or consolidation, but excluding any merger effected exclusively for the purpose of changing the domicile of the Company) or (iii) a sale of all or substantially all of the assets of the Company; unless the Company’s stockholders of record as constituted immediately prior to such acquisition or sale will, immediately after such acquisition or sale (by virtue of securities issued as consideration for the Company’s acquisition or sale or otherwise) hold at least fifty percent (50%) of the voting power of the surviving or acquiring entity.
	The Additional Common Stock Warrants are exercisable 18 months after the consummation of the IPO and the June 2013 Warrants became exercisable on the date of the IPO.
	The following table summarizes information about the Company’s convertible preferred stock and common stock warrants outstanding as of December 31, 2012 (in thousands, except exercise price data):
	DESCRIPTION		ISSUE DATE	EXPIRATION	NUMBER OF		EXERCISE		ESTIMATED
				DATE	SHARES		PRICE		FAIR
					SUBJECT TO				VALUE AS
					WARRANTS				OF
					ISSUED				DECEMBER
									31, 2012 (2)
	In connection with loan agreement (Series A convertible preferred stock)		April 2007	April 2014		6	$	2.608	$	68
	In connection with promissory note and revolving line of credit (Series B convertible preferred stock)		August 2008	May 2013		3	$	4.849		34
	In connection with promissory note (Series B convertible preferred stock)		March 2009	March 2014		7	$	4.849		72
	In connection with April 2012 Senior Secured Promissory Note (Series C convertible preferred stock)		Apr-12	Apr-22		191	$	7.846		1,710
	In connection with October 2012 Junior Secured Promissory Note (Common stock) (1)		October 2012	October 2015		—	$	—		301
						207			$	2,185
	(1)	As of December 31, 2012, the Company had issued warrants to purchase shares of common stock equal to 15% of the funded principal amount of the October 2012 Junior Secured Promissory Notes (See Note 8) divided by 70% of the value of common stock in a sale of the Company or an IPO, with an exercise price of 70% of the value of common stock in a sale of the Company or IPO. These warrants were contingently exercisable for which the contingencies related to exercise had not been met as of December 31, 2012.
	(2)	See Note 2 for discussion of the methods used to determine the estimated fair values of the preferred stock warrants and common stock warrants.
	All of the preferred stock warrants and the common stock warrants issued in connection with the October 2012 Junior Secured Promissory Notes were exercised in 2013 in connection with the IPO. In addition, a portion of the warrants issued in connection with the June 2013 Warrants were exercised in 2013 in connection with the IPO (See Note 20).

Common_Stock

Common Stock	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Common Stock	'
	12. Common Stock
	In August 2013, the Company amended and restated its certificate of incorporation to increase the number of shares of common stock authorized for issuance to 250,000,000 shares with $0.00001 par value. As of December 31, 2013, the Company had reserved shares of common stock for future issuances as follows (in thousands):
		SHARES
	Stock options available for future grant		1,194
	Stock options outstanding		2,608
	Warrants to purchase common stock		151
			3,953

Stock_Option_Plans

Stock Option Plans	12 Months Ended
	Dec. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stock Option Plans	'
	13. Stock Option Plans
	In July 2006, the Company authorized the 2006 Equity Incentive Plan, as amended, (2006 Plan). The 2006 Plan provided for the issuance of up to 1,434,000 shares of common stock underlying awards. The 2006 Plan was terminated in December 2011. As of December 31, 2013 and 2012, there were no shares available to be granted under the 2006 Equity Incentive Plan.
	The 2006 Plan allowed holders to exercise stock options prior to their vesting. The common stock received by the employee is restricted and follows the same vesting schedule as the originally granted option. In the event the employee terminates employment from the Company (whether voluntary or involuntary), the Company retains a right to repurchase the unvested common stock at the original option exercise price. As of December 31, 2013 and 2012, no options had been exercised that would be subject to repurchase.
	As of December 31, 2013, options to purchase 705,000 shares of the Company’s common stock at a weighted-average exercise price of $1.04 per share were outstanding under the 2006 Plan, of which 624,000 were vested at December 31, 2013. During the year ended December 31, 2013, 204,000 and 116,000 options were exercised and canceled, respectively, under the 2006 Plan.
	In July 2011 and as amended in September 2012, the Company authorized the 2011 Stock Plan (2011 Plan). The 2011 Plan provided for the issuance of up to 1,167,000 shares of common stock underlying awards, plus any shares of common stock underlying awards previously issued under the 2006 Plan that terminate or expire after the date of authorization of the 2011 Plan, subject to certain adjustments. In addition, the 2011 Plan provided that the Company not deliver more than 2,446,000 shares upon the exercise of incentive stock options issued under both the 2006 Plan and 2011 Plan. The 2011 Plan was terminated in August 2013 and no new stock awards may be granted under the 2011 Plan. As of December 31, 2013, there were no shares available to be granted under the 2011 Plan.
	As of December 31, 2013, options to purchase 1,131,000 shares of the Company’s common stock at a weighted-average exercise price of $7.67 per share were outstanding under the 2011 Plan, of which 420,000 were vested at December 31, 2013. During the year ended December 31, 2013, 13,000 and 120,000 options were exercised and canceled, respectively, under the 2011 Plan.
	In August 2013, the Company’s Board of Directors adopted the 2013 Stock Incentive Plan (2013 Plan) covering officers, employees, directors of, and consultants to, the Company. The 2013 Plan allows for the granting of the following types of “stock awards”: incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units and dividend equivalent rights. At the time the 2013 Plan was established, the maximum aggregate number of shares of the Company’s common stock that could be issued pursuant to the 2013 Plan was 1,600,000 plus the number of shares of common stock reserved for issuance pursuant to future grants under the 2011 Plan. The number of shares authorized for issuance pursuant to the 2013 Plan is automatically increased by any additional shares that would have otherwise returned to the 2011 Plan as a result of the forfeiture, termination or expiration of awards previously granted under the 2011 Plan. In addition, the number of shares authorized for issuance pursuant to the 2013 Plan will increase by a number equal to the least of (i) 3.5% of the number of shares of the Company’s common stock outstanding on the last day of the immediately preceding fiscal year or (ii) a lesser number of shares determined by the administrator.
	As of December 31, 2013, options to purchase 772,000 shares of the Company’s common stock at a weighted-average exercise price of $16.74 per share were outstanding under the 2013 Plan, of which 11,000 were vested at December 31, 2013. During the year ended December 31, 2013, no options were exercised and 42,000 options were canceled under the 2013 Plan.
	Generally, options vest 25% on the first anniversary from the date of grant and 1/48 per month thereafter; however, options may be granted with different vesting terms as determined by the Company’s Board of Directors.
	The following table summarizes the activity under the Company’s stock option plans for the year ended December 31, 2013 (in thousands, except exercise price and remaining contractual life data):
		SHARES			SHARES			WEIGHTED-		WEIGHTED-		AGGREGATE
		AVAILABLE			OUTSTANDING			AVERAGE		AVERAGE		INTRINSIC
		FOR						EXERCISE		REMAINING		VALUE
		GRANT						PRICE		CONTRACTUAL
										LIFE
										(IN YEARS)
	Balances at December 31, 2012		352			2,067		$	3.86		7.7	$	14,380
	Options authorized		1,600			—
	Options granted		(1,036	)		1,036		$	15.76
	Options exercised		—			(217	)	$	1.18
	Options canceled		278			(278	)	$	6.24
	Balances at December 31, 2013		1,194			2,608		$	8.56		8.1	$	24,158
	Vested and expected to vest at December 31, 2013					2,409		$	8.25		8	$	23,061
	Exercisable at December 31, 2013					1,054		$	2.97		6.5	$	15,610
	The total intrinsic value of options exercised for the years ended December 31, 2013, 2012 and 2011 were $2,801,000, $93,000 and $7,000, respectively.
	The estimated fair value of options vested during the years ended December 31, 2013, 2012 and 2011, was $1,314,000, $489,000 and $228,000, respectively. The weighted-average estimated fair value of options granted during the years ended December 31, 2013, 2012 and 2011 was $10.35 per share, $4.24 per share and $0.78 per share, respectively.
	During the years ended December 31, 2013, 2012 and 2011, the Company recorded share-based compensation expense of $2,300,000, $662,000 and $271,000, respectively. For the years ended December 31, 2013, 2012 and 2011, the Company did not realize any tax benefit associated with its share-based compensation expense. No tax benefit was recognized because a portion of the option grants were ISOs for which stock-based compensation expense is not deductible and also due to the full valuation allowance on the Company’s deferred tax asset that is further discussed in Note 16.
	As of December 31, 2013, with the exception of unvested options granted to Donald Glidewell for which the vesting will be accelerated through his retirement date of March 31, 2013 (see below), the total share-based compensation expense related to unvested options granted to employees under the Company’s stock option plans but not yet recognized was $10,454,000. These costs will be amortized to expense on a straight-line basis over a weighted-average remaining term of 3.3 years.
	In connection with Mr. Glidewell’s retirement, the Company entered into a transition agreement with Mr. Glidewell (See Note 6) which provides, among other things, for the vesting of his outstanding equity awards through the retirement date. For the year ended December 31, 2013, the Company recorded share-based compensation expense of $266,000 relating to the acceleration of vesting of Mr. Glidewell’s option awards. The total share-based compensation expense related to unvested options granted to Mr. Glidewell under the Company’s stock option plans but not yet recognized was $444,000. These costs will be amortized to expense on a straight-line basis over a weighted-average remaining term of 0.3 years.

Capital_Leases

Capital Leases	12 Months Ended
	Dec. 31, 2013
Leases [Abstract]	'
Capital Leases	'
	14. Capital Leases
	The Company accounts for certain equipment acquired under financing arrangements as capital leases. This equipment is included in property, plant and equipment and related amortization is included in depreciation expense.
	As of December 31, 2013 and 2012, the cost of this equipment was $3,046,000 and $939,000, respectively, and the related accumulated amortization was $935,000 and $465,000, respectively.
	Amortization of capital leases for the years ended December 31, 2013, 2012 and 2011 was $470,000, $175,000 and $143,000, respectively.
	As of December 31, 2013, aggregate contractual future minimum lease payments on the capital leases are due as follows (in thousands):
		CAPITAL
		LEASES
	Years ending December 31:
	2014	$	1,520
	2015		1,120
	2016		54
	Total minimum payments required		2,694
	Less: amount representing interest		(159	)
	Present value of future payments		2,535
	Less: current portion		(1,401	)
		$	1,134

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	15. Commitments and Contingencies
	Operating Leases
	The Company has a non-cancelable lease for an aggregate of approximately 24,500 square feet of non-contiguous office space in an office complex in Davis, California under which a portion of the covered space terminates between February 2014 and October 2016. A portion of the lease that terminates in February 2015 provides for an option to extend the term for five years at the then prevailing market rent. The lease includes negotiated annual increases in the monthly rental payments.
	On September 9, 2013, the Company entered into a lease agreement for a new 28,700 square foot office and laboratory facility located in Davis, California. The initial term of the lease is for a period of 60 months commencing on the later of the date of substantial completion of initial improvements to the leased property, or May 1, 2014. The monthly base rent is $46,000 for the first 12 months with a 3% increase each year thereafter. The Company will have the option to extend the lease term twice for a period of five years each.
	The Company recognizes expense under its leases on a straight-line basis over the lease terms. At December 31, 2013, the Company’s aggregate commitment under non-cancelable lease agreements is as follows (in thousands):
		OPERATING
		LEASES
	Years ending December 31:
	2014	$	965
	2015		753
	2016		666
	2017		606
	2018 and beyond		822
	Total minimum payments required	$	3,812
	Rental expense charged to operations for all operating leases was $691,000, $484,000 and $412,000 for the years ended December 31, 2013, 2012 and 2011, respectively.
	Contingencies
	The Company is subject to legal proceedings and claims that arise in the normal course of business. As of December 31, 2013, there were no current proceedings or litigation involving the Company that management believes would have a material adverse impact on its business, financial position, results of operations or cash flows.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	16. Income Taxes
	As of December 31, 2013, the Company had net operating loss carry-forwards for federal income tax reporting purposes of $77,682,000, which begin to expire in 2026, and California and various other state net operating loss carry-forwards of $59,829,000 and $13,656,000, respectively, which begin to expire in 2016 and 2031, respectively. Additionally, as of December 31, 2013, the Company had federal research and development tax credit carry-forwards of $1,414,000, which begin to expire in 2026, and state research and development tax credit carry-forwards of $1,274,000, which have no expiration date.
	As of December 31, 2013, deferred tax assets of $34,250,000, arising principally as a result of the Company’s net operating loss carry-forwards, tax credits, and certain costs capitalized for tax purposes during the Company’s development stage, were fully offset by a valuation allowance. The valuation allowance increased by $11,850,000, $8,134,000 and $5,211,000 for the years ended December 31, 2013, 2012 and 2011, respectively.
	Federal and state laws impose substantial restrictions on the utilization of net operating loss and tax credit carry-forwards in the event of an “ownership change,” as defined in Section 382 of the U.S. Internal Revenue Code of 1986, as amended. The Company completed a Section 382 analysis as of December 31, 2013 and concluded that $493,000 in federal net operating losses and $151,000 in federal research and development credits are expected to expire prior to utilization as a result of the Company’s previous ownership changes and corresponding annual limitations.
	The temporary timing differences that give rise to the deferred tax assets are as follows (in thousands):
		31-Dec
		2013			2012
	Components of deferred taxes:
	Net operating loss carryforwards	$	30,258		$	19,966
	Research and development tax credit		1,577			1,002
	Other, net		2,415			1,432
	Net deferred tax assets		34,250			22,400
	Less: valuation allowance		(34,250	)		(22,400	)
	Net deferred tax assets	$	—		$	—
	The Company had no deferred tax liabilities at December 31, 2013 and 2012.
	The Company recognized no income tax expense, and did not receive a benefit from income taxes for the years ended December 31, 2013, 2012 and 2011.
	The provision for income taxes is different than the amount computed using the applicable statutory federal income tax rate with the difference for each year summarized below:
		DECEMBER 31
		2013			2012
	Federal tax benefit at statutory rate		34	%		34	%
	State tax benefit, net of federal benefit		5			5
	Interest expense		(5	)		—
	Mark-to-market accounting		9			(12	)
	Deemed dividend		(2	)		(6	)
	Share-based compensation expense		(2	)		—
	Other		1			(1	)
	Adjustment due to change in valuation allowance		(40	)		(20	)
	Provision for income taxes		—	%		—	%
	As of December 31, 2013, the Company had unrecognized tax benefits of $525,000. The unrecognized tax benefits, if recognized, would not impact the Company’s effective tax rate as the recognition of these tax benefits would be offset by changes in the Company’s valuation allowance. The Company does not believe there will be any material changes in its unrecognized tax position over the next twelve months.
	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):
		2013			2012
	Balance at January 1	$	340		$	305
	Increase related to prior year tax positions		79			—
	Increase related to current year tax positions		106			35
	Balance at December 31	$	525		$	340
	The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. The Company is subject to U.S. federal and state income tax examination for 2006 through 2013 due to unutilized net operating losses and research credits.

Employee_Benefit_Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2013
Compensation And Retirement Disclosure [Abstract]	'
Employee Benefit Plan	'
	17. Employee Benefit Plan
	The Company has a defined contribution plan offered to all eligible employees, which is qualified under Section 401(k) of the Internal Revenue Code. The Company currently provides a matching contribution. Matching contributions are based on a formula which provides for a dollar-for-dollar matching contribution of the employee’s 401(k) contribution up to 3% of eligible pay plus a 50% matching contribution on the employee’s 401(k) contribution between 3% and 5% of eligible pay. Each participant is 100% vested in elective contributions and the Company’s matching contribution. The Company provided 401(k) matching contributions for the years ended December 31, 2013, 2012 and 2011 were $294,000, $229,000 and $190,000, respectively.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	18. Related Party Transactions
	Les Lyman, a member of the Company’s board of directors, is the chairman and significant indirect shareholder of The Tremont Group, Inc. During the year ended December 31, 2013, The Tremont Group, Inc. purchased $1,446,000 of the Company’s products for further distribution and resale. As of December 31, 2013, the Company had outstanding accounts receivable due from The Tremont Group, Inc. of $903,000, all of which are due in April 2014. Although the Company anticipates sales of its products to The Tremont Group, Inc. to continue through 2014, the Company cannot estimate the amount of those sales.
	In December 2012, the Company issued a $12,500,000 convertible note to Syngenta Ventures Pte. LTD. (Syngenta), an affiliate of one of the Company’s distributors (See Note 9), for which there was no outstanding balance as of December 31, 2013 as the convertible note converted into shares of the Company’s common stock immediately following the completion of the IPO in August 2013. During the year ended December 31, 2013, the Company recorded revenue of $116,000 relating to sales of product to Syngenta and $131,000 relating to license revenue recognized based on the terms of the Company’s commercial agreement with Syngenta. As of December 31, 2013, the Company had no outstanding accounts receivable due from Syngenta.

Reverse_Stock_Split

Reverse Stock Split	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Reverse Stock Split	'
	19. Reverse Stock Split
	On August 1, 2013, the Company amended and restated its certificate of incorporation to effect the conversion of its outstanding convertible preferred stock into common stock on a 1-for-1 basis followed immediately by a reverse split of shares of its common stock (including the common stock issued upon conversion of the convertible preferred stock) at a 1-for-3.138458 ratio (the “Reverse Stock Split”). The amendment also increased the number of shares of common stock authorized for issuance to 250,000,000 shares and the number of shares of preferred stock authorized for issuance to 20,000,000. The par value of the common stock and preferred stock was not adjusted as a result of the Reverse Stock Split.
	All issued and outstanding common stock, preferred stock, and warrants for common stock or preferred stock, and the related per share amounts contained in the consolidated financial statements, have been retroactively adjusted to give effect to this Reverse Stock Split for all periods presented.

Initial_Public_Offering

Initial Public Offering	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Initial Public Offering	'
	20. Initial Public Offering
	In August 2013, the Company closed its initial public offering of 5,462,500 shares of its common stock (inclusive of 712,500 shares of common stock sold upon the exercise of the underwriters’ option to purchase additional shares). The public offering price of the shares sold in the offering was $12.00 per share. The total gross proceeds from the offering to the Company were $65,550,000, and after deducting underwriting discounts and commissions and offering expenses payable by the Company, the aggregate net proceeds received by the Company totaled approximately $56,105,000. In connection with the IPO:
		•	all outstanding shares of convertible preferred stock were converted into 8,514,000 shares of common stock, including 10,000 shares issued upon the cash exercise of Series B convertible preferred stock warrants;
		•	all outstanding principal and accrued interest of the convertible notes were converted into 3,741,000 shares of common stock;
		•	47,000 shares of common stock were issued upon the net exercise of common stock warrants;
		•	3,000 shares of common stock were issued upon the cash exercise of common stock warrants; and
		•	the Series A and Series C convertible preferred stock warrants were net exercised for 71,000 shares of common stock.
	After the closing of the IPO, the Company had 19,133,000 shares of common stock and 151,000 warrants to purchase common stock outstanding and there were no shares of convertible preferred stock, preferred stock warrants or balances related to convertible notes outstanding.

Quarterly_Financial_Informatio

Quarterly Financial Information	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly Financial Information	'
	21. Quarterly Financial Information (Unaudited)
		MARCH 31			JUNE 30			SEPTEMBER 30			DECEMBER 31
		(In thousands, except per share data)
	2013
	Total revenues	$	2,730		$	4,500		$	1,346		$	5,967
	Gross profit		935			1,102			269			1,501
	Net loss		(10,749	)		(1,639	)		(6,110	)		(9,991	)
	Deemed dividend on convertible notes		—			(1,378	)		—			—
	Net loss attributable to common stockholders		(10,749	)		(3,017	)		(6,110	)		(9,991	)
	Net loss per common share:
	Basic		(8.48	)		(2.36	)		(0.47	)		(0.52	)
	Diluted		(8.48	)		(2.67	)		(0.80	)		(0.52	)
	2012
	Total revenues	$	1,999		$	1,509		$	738		$	2,894
	Gross profit		1,139			825			217			626
	Net loss		(3,984	)		(3,912	)		(13,802	)		(17,096	)
	Deemed dividend on convertible notes		(1,253	)		—			—			(786	)
	Net loss attributable to common stockholders		(5,237	)		(3,912	)		(13,802	)		(17,882	)
	Net loss per common share:
	Basic		(4.20	)		(3.13	)		(10.94	)		(14.11	)
	Diluted		(4.20	)		(3.13	)		(10.94	)		(14.11	)
	In connection with the preparation of the consolidated financial statements for the year ended December 31, 2013, errors in the computation and disclosure of diluted net loss per share were identified for the three and nine months ended September 30, 2013 and for the three months ended June 30, 2013. This resulted from errors in the computation of how adjustments to the net loss attributable to common stockholders from the potentially dilutive securities were reflected in the diluted net loss per share computations and when identifying which potentially dilutive securities were determined to be dilutive or anti-dilutive. The errors affected both the net loss used in the numerator and the weighted average shares outstanding used in the denominator for diluted net loss per share. The Company evaluated the materiality of these errors in accordance with SEC Staff Accounting Bulletin No. 99, Materiality, and SEC Staff Accounting Bulletin No. 108, Considering the Effects of Prior Year Misstatements When Quantifying Misstatements in Current Year Financial Statements, and concluded that these errors, individually and in the aggregate, were immaterial to all prior periods impacted. While the adjustments were immaterial, the Company has elected to revise its previously reported diluted earnings per share as shown in the following table:
		THREE MONTHS ENDED						THREE MONTHS ENDED						NINE MONTHS ENDED
		30-Jun-13						30-Sep-13						30-Sep-13
		AS			AS REVISED			AS			AS REVISED			AS			AS REVISED
		REPORTED						REPORTED						REPORTED
		(In thousands, except per share data)
	Numerator:
	Net loss	$	(1,639	)	$	(1,639	)	$	(6,110	)	$	(6,110	)	$	(18,498	)	$	(18,498	)
	Deemed dividend on convertible notes		(1,378	)		(1,378	)		—			—			(1,378	)		(1,378	)
	Net loss attributable to common stockholders	$	(3,017	)	$	(3,017	)	$	(6,110	)	$	(6,110	)	$	(19,876	)	$	(19,876	)
	Effect of potentially dilutive securities:
	Convertible notes		—			—			(1,089	)		(4,392	)		(118	)		(4,392	)
	Warrants to purchase convertible preferred stock		—			(575	)		—			(264	)		—			(841	)
	Warrants to purchase common stock		—			—			(201	)		—			(201	)		—
	Net loss for diluted net loss per share	$	(3,017	)	$	(3,592	)	$	(7,400	)	$	(10,766	)	$	(20,195	)	$	(25,109	)
	Denominator:
	Shares used for basic net loss per share		1,277			1,277			12,888			12,888			5,187			5,187
	Effect of potentially dilutive securities:
	Convertible notes		—			—			1,043			503			20			169
	Warrants to purchase convertible preferred stock		—			70			—			31			—			61
	Warrants to purchase common stock		—			—			86			—			22			—
	Weighted average shares outstanding for diluted net loss per share		1,277			1,347			14,017			13,422			5,229			5,417
	Diluted net loss per share:	$	(2.36	)	$	(2.67	)	$	(0.53	)	$	(0.80	)	$	(3.86	)	$	(4.63	)
	The corrections have no impact on the Company’s consolidated balance sheets, net loss, net loss attributable to common stockholders, basic net loss per share, or the consolidated statements of comprehensive loss, convertible preferred stock and stockholders’ equity (deficit), and cash flows for any of the above mentioned periods.

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

'

Basis of Presentation

'

Basis of Presentation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

'

Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

'

Cash and Cash Equivalents

The Company considers all highly liquid financial instruments purchased with a maturity of three months or less to be cash equivalents. Cash and cash equivalents consist of cash on deposit, money market funds and certificates of deposit accounts (CDs) with U.S. financial institutions. The Company is exposed to credit risk in the event of default by financial institutions to the extent that cash and cash equivalents balances with financial institutions are in excess of amounts that are insured by the Federal Deposit Insurance Corporation. The Company has not experienced any losses on these deposits.

Restricted Cash

'

Restricted Cash

The Company’s restricted cash consisted of cash that the Company was contractually obligated as of December 31, 2012 to use to pay off the entire indebtedness of the promissory note entered into in April 2012 with an original principal balance of $10,000,000. The Company paid the outstanding balance of the promissory note in January 2013, and as of December 31, 2013, had no remaining contractual obligations which restricted the use of cash. See Note 8 for further discussion.

Short-Term Investments

'

Short-Term Investments

The Company’s short-term investments consist of certificates of deposit with original maturities less than one year but greater than three months which are classified as held-to-maturity. Certificates of deposit are stated at their amortized cost with realized gains or losses, if any, reported as other income or expenses in the consolidated statements of operations. The Company routinely evaluates the realizability of its short-term investments and recognizes an impairment charge when a decline in the estimated fair value of a short-term investment is below the amortized cost and determined to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the duration of time and the severity to which the fair value has been less than amortized cost, any adverse changes in the investee’s financial condition, and the Company’s intent and ability to hold the short-term investment for a period of time sufficient to allow for any anticipated recovery in market value. To date, the Company has not recognized any losses on its short-term investments.

The amortized cost and estimated fair values of short-term investments are summarized in the following table (in thousands):

31-Dec-13

AMORTIZED

GROSS

GROSS

ESTIMATED

COST

UNREALIZED

UNREALIZED

FAIR VALUE

GAINS

LOSSES

Securities Held-to-Maturity

Certificates of deposit, with maturities less than 1 year

$

13,677

$

—

$

(4

)

$

13,673

The short-term investments at December 31, 2013 were in inactive markets and, therefore, the estimated fair value is measured based on the Level 2 valuation hierarchy. The Company did not have any investments in securities as of December 31, 2012.

Fair Value of Financial Instruments

'

Fair Value of Financial Instruments

ASC 820, Fair Value Measurements (ASC 820), clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.

ASC 820 requires that the valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 establishes a three tier value hierarchy, which prioritizes inputs that may be used to measure fair value as follows:

•

Level 1—Quoted prices in active markets for identical assets or liabilities.

•

Level 2—Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

•

Level 3—Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability.

The following table presents the Company’s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2013 and 2012 (in thousands):

31-Dec-13

TOTAL

LEVEL 1

LEVEL 2

LEVEL 3

Assets

Money market funds

$

16,268

$

16,268

$

—

$

—

31-Dec-12

TOTAL

LEVEL 1

LEVEL 2

LEVEL 3

Assets

Money market funds

$

7,668

$

7,668

$

—

$

—

Liabilities

Common stock warrant liability

$

301

$

—

$

—

$

301

Preferred stock warrant liability

1,884

—

—

1,884

Convertible notes payable

41,860

—

—

41,860

Total liabilities at fair value

$

44,045

$

—

$

—

$

44,045

The money market funds held as of December 31, 2013 and 2012 were in active markets and, therefore, are measured based on the Level 1 valuation hierarchy.

The Company estimated the fair value of the common and preferred stock warrant liabilities as of December 31, 2012 using the Probability Weighted Expected Return Method (PWERM), which analyzes the returns afforded to common equity holders under multiple future scenarios. Under the PWERM, share value is based upon the probability-weighted present value of expected future net cash flows (distributions to stockholders), considering each of the possible future events and giving consideration to the rights and preferences of each share class. This method is most appropriate when the long-term outlook for an enterprise is largely known and multiple future scenarios can be reasonably estimated.

The common and preferred stock warrant liabilities were valued by a PWERM valuation using six scenarios, which included three initial public offering scenarios, two merger scenarios and a sale of the Company’s intellectual property. An annual discount rate of 35% was applied to the PWERM valuations as of December 31, 2012. The common stock warrant liability valuation also included an 18% discount for lack of marketability as of December 31, 2012. As the PWERM estimates the fair value of the common and preferred stock warrant liabilities using unobservable inputs, it is considered to be a Level 3 fair value measurement.

Effective on the date of the IPO, under ASC 815-40-15, Contracts in Entity’s Own Equity (ASC 815-40-15), the common and preferred stock warrant liabilities were considered to be indexed to the Company’s stock, and accordingly, the total warrants liability of $2,669,000 was reclassified and included in stockholders’ equity (deficit) as of December 31, 2013. The Company revalued the warrants immediately prior to the IPO. The fair value of the warrants which would have expired on the date of the IPO unless exercised was determined using the intrinsic method based on the IPO price of $12.00 per share, which is deemed a Level 2 fair value measurement. The fair value of the warrants that would not have expired on the date of the IPO regardless of whether or not they were exercised was determined using the Black-Scholes-Merton option-pricing model, which is deemed a Level 3 fair value measurement.

As a result of the change in estimated fair value between December 31, 2012 or the issuance dates of the warrants issued during the year ended December 31, 2013 and the closing of the IPO, the Company recognized a net gain from the total change in estimated fair value of the common and preferred stock warrant liabilities as shown in the tables below.

The following table provides a reconciliation of the beginning and ending balances for the common and preferred stock warrant liabilities measured at fair value using significant unobservable inputs (Level 3). The amounts included in the “Transfers out of Level 3” represent the beginning balance in the interim quarter during which it was transferred (in thousands):

COMMON

STOCK

WARRANT

LIABILITY

Fair value at December 31, 2012

$

301

Warrants issued

900

Change in fair value recorded in change in fair value of financial instruments

377

Transfers out of Level 3

(434

)

Reclassified to stockholders’ equity (deficit)

(1,144

)

Fair value at December 31, 2013

$

—

PREFERRED

STOCK

WARRANT

LIABILITY

Fair value at December 31, 2012

$

1,884

Change in fair value recorded in change in fair value of financial instruments

(823

)

Transfers out of Level 3

(140

)

Reclassified to stockholders’ equity (deficit)

(921

)

Fair value at December 31, 2013

$

—

Effective on the date of the IPO, all of the Company’s convertible notes were converted into shares of common stock. Prior to the IPO, convertible notes were valued by a PWERM valuation utilizing inputs similar to those used for estimating fair values of the common and preferred stock warrant liabilities described above. A discount rate of 25% was used for valuing the March and October 2012 Convertible Notes, defined in Note 9, as of December 31, 2012. A discount rate of 18% was used for valuing the October 2012 Subordinated Convertible Notes and the December 2012 Convertible Note, both defined in Note 9, as of December 31, 2012. These annual discount rates were applied in the PWERM valuation as of December 31, 2012. The Company revalued the convertible notes immediately prior to the IPO. As a result of the IPO, the number of shares to be issued became known and the Company estimated the fair value of the convertible notes using the intrinsic method based on the IPO price of $12.00 per share, which is deemed a Level 2 fair value measurement. Due to the change in estimated fair values between December 31, 2012 or the issuance dates of the convertible notes issued during the year ended December 31, 2013 and the closing of the IPO, the Company recognized a gain from the change in estimated fair value of the convertible notes as shown in the table below.

The following table provides a reconciliation of the beginning and ending balances for the convertible notes measured at fair value using significant unobservable inputs (Level 3). The amounts included in the “Transfers out of Level 3” represent the beginning balance in the interim quarter during which it was transferred (in thousands):

Fair value at December 31, 2012

$

41,860

Convertible notes issued

9,069

Convertible notes cancelled

(1,360

)

Accrued interest

1,299

Change in fair value recorded in change in fair value of financial instruments

(2,634

)

Transfers out of Level 3

(48,234

)

Fair value at December 31, 2013

$

—

During the year ended December 31, 2013, as noted above, there were $574,000 of preferred and common stock warrants and $48,234,000 of convertible notes transferred from the Level 3 to Level 2 category. There were no such transfers from the Level 3 to Level 2 category during the year ended December 31, 2012. Further, there were no transfers from the Level 2 to Level 1 category during the years ended December 31, 2013 or 2012.

Concentration of Credit Risk

'

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, short-term investments, accounts receivable and debt. The Company deposits its cash, cash equivalents and short-term investments with high credit quality domestic financial institutions with locations in the U.S. Such deposits may exceed federal deposit insurance limits. The Company believes the financial risks associated with these financial instruments are minimal.

The Company’s customer base is dispersed across many different geographic areas, and currently most customers are pest management distributors in the U.S. Generally, receivables are due up to 120 days from the invoice date and are considered past due after this date, although the Company may offer extended terms from time to time.

During the years ended December 31, 2013, 2012 and 2011, 8%, 20% and 7%, respectively, of the Company’s revenues were generated from international customers.

From inception through December 31, 2012, the Company’s principal source of revenues was its Regalia product line. During the year ended December 31, 2013, Grandevo and Regalia were the principal sources of the Company’s total revenues. During the years ended December 31, 2013, 2012 and 2011, these two product lines accounted for 97%, 96% and 96%, respectively, of the Company’s total revenues.

Customers with 10% or more of the Company’s total revenues consist of the following:

CUSTOMER

CUSTOMER

CUSTOMER

CUSTOMER

CUSTOMER

A

B (1)

C

D

E

For the years ended December 31,

2013

28

%

10

%

*

*

*

2012

33

%

*

13

%

12

%

*

2011

39

%

*

*

17

%

10

%

*

Represents less than 10% of total revenues

(1)

Represents related party revenues. See Note 18 for further discussion.

Customers with 10% or more of the Company’s outstanding accounts receivable consist of the following:

CUSTOMER

CUSTOMER

CUSTOMER

CUSTOMER

CUSTOMER

CUSTOMER

CUSTOMER

A

B (1)

C

D

E

F

G

December 31, 2013

19

%

13

%

12

%

11

%

*

*

*

December 31, 2012

*

*

*

33

%

17

%

11

%

11

%

*

Represents less than 10% of accounts receivable.

(1)

Represents accounts receivable from related parties. See Note 18 for further discussion.

Concentrations of Supplier Dependence

'

Concentrations of Supplier Dependence

The active ingredient in the Company’s Regalia product line is derived from the giant knotweed plant, which the Company obtains from China. The Company’s single supplier acquires raw knotweed from numerous regional sources and performs an extraction process on this plant, creating a dried extract that is shipped to the Company’s third- party manufacturer in the U.S. A disruption at this supplier’s manufacturing site or a disruption in trade between the U.S. and China could negatively impact sales of Regalia. The Company currently uses one supplier and does not have a long-term supply contract with this supplier. Although the Company has identified additional sources of knotweed, there can be no assurance that the Company will continue to be able to obtain dried extract from China at a competitive price.

Accounts Receivable

'

Accounts Receivable

The carrying value of the Company’s receivables represents their estimated net realizable values. The Company generally does not require collateral and estimates any required allowance for doubtful accounts based on historical collection trends, the age of outstanding receivables, and existing economic conditions. If events or changes in circumstances indicate that specific receivable balances may be impaired, further consideration is given to the collectibility of those balances and the allowance is recorded accordingly. Past-due receivable balances are written-off when the Company’s internal collection efforts have been unsuccessful in collecting the amount due. During the years ended December 31, 2013 and 2012, no receivable balances were written-off. As of December 31, 2013 and 2012, the Company had no allowance for doubtful accounts.

Inventories

'

Inventories

Inventories are stated at the lower of cost or market value (net realizable value or replacement cost) and include the cost of material and external labor and manufacturing costs. Cost is determined on the first-in, first-out basis. The Company provides for inventory reserves when conditions indicate that the selling price may be less than cost due to physical deterioration, obsolescence, changes in price levels, or other factors. Additionally, the Company provides reserves for excess and slow-moving inventory on hand that is not expected to be sold to reduce the carrying amount of excess slow-moving inventory to its estimated net realizable value. The reserves are based upon estimates about future demand from the Company’s customers and distributors and market conditions. As of December 31, 2013, the Company had $45,000 in reserves against its inventories. As of December 31, 2012, the Company had no reserves against its inventories. During the year ended December 31, 2013, the Company recorded, as a component of cost of product revenues, an inventory write-off of $205,000 primarily due to abnormal scrap and the identification of inventory that was not suitable for sale and an adjustment of $194,000 to write-down its Zequanox inventory to net realizable value. During the year ended December 31, 2012, the Company recorded, as a component of cost of product revenues, an inventory write-off of $913,000 primarily due to an early formulation of the Zequanox line of products that was not suitable for sale.

Inventories, net consist of the following (in thousands):

DECEMBER 31

2013

2012

Raw materials

$

5,355

$

3,204

Work in progress

2,917

607

Finished goods

3,394

1,061

$

11,666

$

4,872

Deferred Cost of Product Revenues

'

Deferred Cost of Product Revenues

Deferred cost of product revenues are stated at the lower of cost or net realizable value and include product sold where title has transferred but the criteria for revenue recognition have not been met. As of December 31, 2013, the Company recorded current deferred cost of product revenues of $418,000 which is included in prepaid expenses and other current assets in the consolidated balance sheets. As of December 31, 2012, the Company had no deferred cost of product revenues. During the year ended December 31, 2013, the Company recorded an adjustment of $174,000 to write down the carrying value of deferred cost of product revenues to net realizable value.

Property, Plant and Equipment

'

Property, Plant and Equipment

Property, plant and equipment are recorded at cost and are depreciated using the straight-line method over their estimated useful lives. The Company generally uses the following estimated useful lives for each asset category:

ASSET CATEGORY

ESTIMATED USEFUL LIFE

Building

30 years

Computer equipment

2-3 years

Machinery and equipment

3-20 years

Office equipment

3-5 years

Furniture

3-5 years

Leasehold improvements

Shorter of lease term or useful life

Software

3 years

Amortization of assets under capital leases is included in depreciation expense. Maintenance, repairs and minor renewals are expensed as incurred. Expenditures that substantially increase an asset’s useful life are capitalized.

Deferred Financing Costs

'

Deferred Financing Costs

Deferred financing costs, net include fees and costs incurred to obtain long-term financing. The costs are being amortized over the terms of the respective loans on a basis that approximates level yield. Unamortized deferred financing fees are written-off when debt is retired before the maturity date. Upon the amendment or termination of debt, unamortized deferred financing fees are accounted for in accordance with ASC 470-50-40, Debt Modifications and Extinguishments (ASC 470-50-40). As of December 31, 2013, $458,000 and $148,000 of the deferred financing costs were recorded as a component of current and non-current other assets, respectively, and are being amortized to interest expense. As of December 31, 2012, $145,000 and $261,000 of the deferred financing costs were recorded as a component of current and non-current other assets, respectively, and are being amortized to interest expense.

Impairment of Long-Lived Assets

'

Impairment of Long-Lived Assets

Impairment losses related to long-lived assets are recognized in the event the net carrying value of such assets is not recoverable and exceeds fair value. The Company evaluates the recoverability of its long-lived assets whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. The carrying amount of a long-lived asset (asset group) is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset (asset group). If an asset is considered is not recoverable, the impairment loss is measured as the amount by which the carrying value of the asset group exceeds its estimated fair value. To date, the Company has not recognized any such impairment loss associated with its long-lived assets.

Preferred Stock Warrant Liability

'

Preferred Stock Warrant Liability

The Company accounted for outstanding warrants exercisable into shares of its preferred stock as liability instruments as the preferred stock into which these warrants were convertible were contingently redeemable upon the occurrence of certain events or transactions. The Company adjusted the warrant instruments to fair value at each reporting period with the change in fair value recorded as a component of change in estimated fair value of financial instruments in the consolidated statements of operations. Effective on the date of the IPO, under ASC 815-40-15, the preferred stock warrant liabilities were considered to be indexed to the Company’s stock, and accordingly, the total warrants liability was reclassified and included in stockholders’ equity (deficit) as of December 31, 2013.

Common Stock Warrant Liability

'

Common Stock Warrant Liability

The Company issued detachable common stock warrants in connection with the October 2012 and April 2013 Junior Secured Promissory Notes as defined and discussed in Note 8 to purchase a variable number of the Company’s shares of common stock based on a fixed monetary amount. As the predominant settlement feature of these common stock warrants was to settle a fixed monetary amount in a variable number of shares, these common stock warrants fell within the scope of ASC 480, Distinguishing Liabilities from Equity (ASC 480). Accordingly, these common stock warrants were recorded at estimated fair value on their issuance date and were adjusted to their estimated fair value as of each reporting date with the change in estimated fair value recorded as a component of change in estimated fair value of financial instruments in the accompanying consolidated statements of operations. Effective on the date of the IPO, under ASC 815-40-15, the common stock warrant liabilities were considered to be indexed to the Company’s stock, and accordingly, the total warrants liability was reclassified and included in stockholders’ equity (deficit) as of December 31, 2013.

Revenue Recognition

'

Revenue Recognition

The Company recognizes revenues when persuasive evidence of an arrangement exists, delivery and transfer of title has occurred or services have been rendered, the price is fixed or determinable, and collectability is reasonably assured, unless contractual obligations, acceptance provisions or other contingencies exist. If such obligations or provisions exist, revenue is recognized after such obligations or provisions are fulfilled or expire.

Product revenues consist of revenues generated from sales to distributors and from sales of the Company’s products to direct customers, net of rebates and cash discounts. For sales of products made to distributors, the Company considers a number of factors in determining whether revenue is recognized upon transfer of title to the distributor, or when payment is received. These factors include, but are not limited to, whether the payment terms offered to the distributor in comparison to the Company’s historical terms are considered to be longer than normal payment terms, the distributor history of adhering to the terms of its contractual arrangements with the Company, whether the Company has a pattern of granting concessions for the benefit of the distributor, and whether there are other conditions that may indicate that the sale to the distributor is not substantive. When the Company offers payment terms that are considered to be extended in comparison to the Company’s historical terms, the Company considers the arrangement not to be fixed or determinable, and accordingly, revenue is deferred until payment is due. The costs associated with such deferral are also deferred and classified in prepaid expenses and other current assets in the consolidated balance sheets. The Company currently recognizes revenue primarily on the sell-in method with its distributors. Distributors do not have price protection or return rights.

As of December 31, 2013, the Company recorded current deferred product revenues of $1,016,000. As of December 31, 2012, the Company had no deferred product revenues.

From time to time, the Company offers certain product rebates, which are recorded as reductions to product revenues. An accrued liability for these product rebates is recorded at the time the revenues are recorded.

The Company recognizes license revenues pursuant to strategic collaboration and distribution agreements under which the Company receives payments for the achievement of testing validation, regulatory progress and commercialization events. As these activities and payments are associated with exclusive rights that the Company provides in connection with strategic collaboration and distribution agreements over the term of the agreements, revenues related to the payments received are deferred and recognized over the term of the exclusive distribution period of the respective agreement. For the years ended December 31, 2012 and 2011, the Company received payments totaling $1,533,000 and $833,000, respectively, of which $1,000,000 was received from a related party for the year ended December 31, 2012. No payments were received under these agreements during the year ended December 31, 2013. For the years ended December 31, 2013, 2012 and 2011, the Company recognized $193,000, $179,000 and $57,000, respectively, as license revenues, excluding related party revenues, in the accompanying consolidated statements of operations.

For the year ended December 31, 2013, the Company recognized $131,000 of related party revenues under these agreements based on the terms of the Company’s commercial agreement with Syngenta, an affiliate of one of our 5% stockholders. In addition, in connection with the December 2012 Convertible Note issued to a related party in December 2012, which is described in Note 9, the Company recorded a reduction of license revenues included in related party revenues of $110,000 for the year ended December 31, 2012. There were no related party license revenues recognized for the years ended December 31, 2012 and 2011.

At December 31, 2013, the Company recorded current and non-current deferred revenues of $324,000 and $1,372,000, respectively, related to payments received under these agreements, of which $131,000 and $628,000, respectively, related to deferred revenues from related parties based on the terms of the Company’s commercial agreement with Syngenta. At December 31, 2012, the Company recorded current and non-current deferred revenues of $324,000 and $1,696,000, respectively, related to payments received under these agreements, of which $131,000 and $759,000, respectively, related to deferred revenues from related parties based on the terms of the Company’s commercial agreement with Syngenta.

Research, Development and Patent Expenses

'

Research, Development and Patent Expenses

Research and development expenditures, which primarily consist of payroll-related expenses, toxicology costs, regulatory costs, consulting costs and lab costs, and patent expenses, which primarily consist of legal costs relating to the patents and patent filing costs, are expensed to operations as incurred. For the years ended December 31, 2013, 2012 and 2011, research and development expenses totaled $16,827,000, $12,140,000 and $9,133,000, respectively, and patent expenses totaled $987,000, $601,000 and $277,000, respectively. Grants received from third parties for research and development activities are recorded as reductions of expense over the term of the agreement as the related activities are conducted. For the years ended December 31, 2012 and 2011, the Company received payments under grants totaling $140,000 and $164,000, respectively. There were no grants received for the year ended December 31, 2013. Of these amounts, $31,000 was recorded in accrued liabilities as accrued grant proceeds for which the underlying grant services had not been provided as of December 31, 2011. There were no accrued grant proceeds for the years ended December 31, 2013 and 2012. For the years ended December 31, 2012 and 2011, the Company reduced research and development expenses by $171,000 and $195,000, respectively, as services were performed under the grants. There was no reduction to research and development expenses for services performed under grants for the year ended December 31, 2013.

Shipping and Handling Costs

'

Shipping and Handling Costs

Amounts billed for shipping and handling are included as a component of product revenues. Related costs for shipping and handling have been included as a component of cost of product revenues.

Advertising

'

Advertising

The Company expenses advertising costs as incurred. Advertising costs for the years ended December 31, 2013, 2012 and 2011, were $760,000, $609,000 and $286,000, respectively.

Share-Based Compensation

'

Share-Based Compensation

The Company recognizes share-based compensation expense for all stock options made to employees and directors based on estimated fair values.

The Company estimates the fair value of stock options on the date of grant using an option-pricing model. The value of the portion of the stock options that is ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

For purposes of determining the Company’s historical share-based compensation expense, it used the Black-Scholes-Merton (BSM) option-pricing model to calculate the estimated fair value of stock options on the measurement date (generally, the grant date). This model requires inputs for the expected life of the stock options, estimated volatility factor, risk-free interest rate, and expected dividend yield. The Company’s estimates of forfeiture rates also affect the amount of aggregate compensation expense. These inputs are subjective and generally require significant judgment. For the years ended December 31, 2013, 2012 and 2011, the Company calculated the fair value of stock options granted using the following assumptions:

YEAR ENDED DECEMBER 31

2013

2012

2011

Expected life (years)

5.29-7.71

5.00-6.08

5.00-6.28

Estimated volatility factor

0.70-0.75

0.72-0.76

0.7

Risk-free interest rate

1.27%-2.11%

0.74%-1.16%

0.86%-2.40%

Expected dividend yield

—

—

—

Expected Life—The Company’s expected life represents the period that its share-based payment awards are expected to be outstanding. The Company uses the “simplified method” in accordance with Staff Accounting Bulletin (SAB) No. 107, Share-Based Payment, and SAB No. 110, Simplified Method for Plain Vanilla Share Options, to develop the expected term of options determined to be “plain vanilla.” Under this approach, the expected term is presumed to be the midpoint between the vesting date and the contractual end of the option grant. For stock options granted with an exercise price not equal to the determined fair market value, the Company estimates the expected life based on historical data and management’s expectations about exercises and post-vesting termination behavior.

Estimated Volatility Factor—The Company uses the calculated volatility based upon the trading history and calculated volatility of the common stock of comparable agricultural biotechnology companies in determining an estimated volatility factor.

Risk-Free Interest Rate—The Company bases the risk-free interest rate on the implied yield currently available on U.S. Treasury constant-maturity securities with the same or substantially equivalent remaining term.

Expected Dividend Yield—The Company has not declared dividends nor does it expect to in the foreseeable future. Therefore, a zero value was assumed for the expected dividend yield.

Estimated Forfeitures—When estimating forfeitures, the Company considers voluntary and involuntary termination behavior and actual option forfeitures.

If in the future the Company determines that other methods are more reasonable, or other methods for calculating these assumptions are prescribed by authoritative guidance, the fair value calculated for the Company’s stock options could change significantly. Higher volatility and longer expected lives result in an increase to share-based compensation expense determined at the grant date. Share-based compensation expense affects the Company’s research, development and patent expense and selling, general and administrative expense.

Other Income (Expense), Net

'

Other Income (Expense), Net

Other income (expense), net included net losses resulting from foreign currency transactions in the amount of $53,000 and $54,000 for the years ended December 31, 2013 and 2012, respectively. There were no losses from foreign currency transactions for the year ended December 31, 2011. In addition, in 2013, other income (expense), net included a loss on disposal of fixed assets totaling $231,000. There were no losses on disposals of fixed assets during the years ended December 31, 2012 and 2011.

Income Taxes

'

Income Taxes

The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. To the extent deferred tax assets cannot be recognized under the preceding criteria, the Company establishes valuation allowances as necessary to reduce deferred tax assets to the amounts expected to be realized. As of December 31, 2013 and 2012, all deferred tax assets were fully offset by a valuation allowance. Realization of deferred tax assets is dependent upon future federal, state, and foreign taxable income. The Company’s judgments regarding deferred tax assets may change as the Company expands into international jurisdictions, due to future market conditions, changes in U.S. or international tax laws, and other factors. These changes, if any, may require possible material adjustments to these deferred tax assets, resulting in a reduction in net income or an increase in net loss in the period when such determinations are made.

The Company recognizes liabilities for uncertain tax positions based upon a two-step process. To the extent a tax position does not meet a more-likely-than-not level of certainty; no benefit is recognized in the consolidated financial statements. If a position meets the more-likely-than-not level of certainty, it is recognized in the consolidated financial statements at the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company’s policy is to analyze the Company’s tax positions taken with respect to all applicable income tax issues for all open tax years (in each respective jurisdiction). As of December 31, 2013 and 2012, the Company has concluded that no uncertain tax positions were required to be recognized in its consolidated financial statements. It is the Company’s practice to recognize interest and penalties related to income tax matters in income tax expense. No amounts were recognized for interest and penalties during the years ended December 31, 2013, 2012 and 2011.

Comprehensive Loss

'

Comprehensive Loss

Comprehensive loss represents the net loss for the period plus the results of certain changes to stockholders’ equity (deficit) that are not reflected in the consolidated statements of operations, if applicable. The only component of the Company’s comprehensive loss for the periods presented is net loss.

Net Loss Per Share

'

Net Loss Per Share

Basic net loss per share, which excludes dilution, is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock, such as stock options, convertible notes, convertible preferred stock and warrants, result in the issuance of common stock which share in the losses of the Company. Certain potential shares of common stock have been excluded from the computation of diluted net loss per share for certain periods as their effect would be anti-dilutive. Such potentially dilutive shares are excluded when the effect would be to reduce the loss per share. The treasury stock method has been applied to determine the dilutive effect of warrants. See Note 4 for further discussion.

Segment Information

'

Segment Information

The Company is organized as a single operating segment, whereby its chief operating decision maker assesses the performance of and allocates resources to the business as a whole.

Recently Issued Accounting Pronouncements

'

Recently Issued Accounting Pronouncements

There have been no new accounting pronouncements issued during the year ended December 31, 2013 that are of significance, or potential significance, to the Company.

Reclassifications

'

Reclassifications

Certain amounts in 2012 and 2011 have been reclassified to conform with the 2013 financial statement presentations. These reclassifications have no effect on previously reported net income.

Significant_Accounting_Policie2

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Amortized Cost and Estimated Fair Values of Short-Term Investments	'
	The amortized cost and estimated fair values of short-term investments are summarized in the following table (in thousands):
			31-Dec-13
			AMORTIZED			GROSS			GROSS			ESTIMATED
			COST			UNREALIZED			UNREALIZED			FAIR VALUE
						GAINS			LOSSES
	Securities Held-to-Maturity
	Certificates of deposit, with maturities less than 1 year		$	13,677		$	—		$	(4	)	$	13,673
Assets and Liabilities Measured at Fair Value on Recurring Basis	'
	The following table presents the Company’s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2013 and 2012 (in thousands):
			31-Dec-13
			TOTAL			LEVEL 1			LEVEL 2			LEVEL 3
	Assets
	Money market funds		$	16,268		$	16,268		$	—		$	—
			31-Dec-12
			TOTAL			LEVEL 1			LEVEL 2			LEVEL 3
	Assets
	Money market funds		$	7,668		$	7,668		$	—		$	—
	Liabilities
	Common stock warrant liability		$	301		$	—		$	—		$	301
	Preferred stock warrant liability			1,884			—			—			1,884
	Convertible notes payable			41,860			—			—			41,860
	Total liabilities at fair value		$	44,045		$	—		$	—		$	44,045
Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)	'
	The following table provides a reconciliation of the beginning and ending balances for the common and preferred stock warrant liabilities measured at fair value using significant unobservable inputs (Level 3). The amounts included in the “Transfers out of Level 3” represent the beginning balance in the interim quarter during which it was transferred (in thousands):
			COMMON
			STOCK
			WARRANT
			LIABILITY
	Fair value at December 31, 2012		$	301
	Warrants issued			900
	Change in fair value recorded in change in fair value of financial instruments			377
	Transfers out of Level 3			(434	)
	Reclassified to stockholders’ equity (deficit)			(1,144	)
	Fair value at December 31, 2013		$	—
			PREFERRED
			STOCK
			WARRANT
			LIABILITY
	Fair value at December 31, 2012		$	1,884
	Change in fair value recorded in change in fair value of financial instruments			(823	)
	Transfers out of Level 3			(140	)
	Reclassified to stockholders’ equity (deficit)			(921	)
	Fair value at December 31, 2013		$	—
	The following table provides a reconciliation of the beginning and ending balances for the convertible notes measured at fair value using significant unobservable inputs (Level 3). The amounts included in the “Transfers out of Level 3” represent the beginning balance in the interim quarter during which it was transferred (in thousands):
	Fair value at December 31, 2012		$	41,860
	Convertible notes issued			9,069
	Convertible notes cancelled			(1,360	)
	Accrued interest			1,299
	Change in fair value recorded in change in fair value of financial instruments			(2,634	)
	Transfers out of Level 3			(48,234	)
	Fair value at December 31, 2013		$	—
Schedule of Concentration of Credit Risk Percentage	'
	Customers with 10% or more of the Company’s total revenues consist of the following:
			CUSTOMER			CUSTOMER			CUSTOMER			CUSTOMER			CUSTOMER
			A			B (1)			C			D			E
	For the years ended December 31,
	2013			28	%		10	%		*			*			*
	2012			33	%		*			13	%		12	%		*
	2011			39	%		*			*			17	%		10	%
	*	Represents less than 10% of total revenues
	(1)	Represents related party revenues. See Note 18 for further discussion.
	Customers with 10% or more of the Company’s outstanding accounts receivable consist of the following:
			CUSTOMER			CUSTOMER			CUSTOMER			CUSTOMER			CUSTOMER			CUSTOMER			CUSTOMER
			A			B (1)			C			D			E			F			G
	December 31, 2013			19	%		13	%		12	%		11	%		*			*			*
	December 31, 2012			*			*			*			33	%		17	%		11	%		11	%
	*	Represents less than 10% of accounts receivable.
	(1)	Represents accounts receivable from related parties. See Note 18 for further discussion.
Schedule of Inventories, net	'
	Inventories, net consist of the following (in thousands):
			DECEMBER 31
			2013			2012
	Raw materials		$	5,355		$	3,204
	Work in progress			2,917			607
	Finished goods			3,394			1,061
			$	11,666		$	4,872
Summary of Property, Plant and Equipment Estimated Useful Lives	'
	The Company generally uses the following estimated useful lives for each asset category:
	ASSET CATEGORY		ESTIMATED USEFUL LIFE
	Building		30 years
	Computer equipment		2-3 years
	Machinery and equipment		3-20 years
	Office equipment		3-5 years
	Furniture		3-5 years
	Leasehold improvements		Shorter of lease term or useful life
	Software		3 years
Fair Value Assumptions of Stock Options Granted	'
	For the years ended December 31, 2013, 2012 and 2011, the Company calculated the fair value of stock options granted using the following assumptions:
			YEAR ENDED DECEMBER 31
			2013		2012	2011
	Expected life (years)		5.29-7.71		5.00-6.08	5.00-6.28
	Estimated volatility factor		0.70-0.75		0.72-0.76	0.7
	Risk-free interest rate		1.27%-2.11%		0.74%-1.16%	0.86%-2.40%
	Expected dividend yield		—		—	—

Property_Plant_and_Equipment_T

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property Plant And Equipment [Abstract]	'
Schedule of Property, Plant and Equipment	'
	Property, plant and equipment consist of the following (in thousands):
		31-Dec
		2013			2012
	Land	$	1		$	1
	Buildings		—			—
	Computer equipment and software		459			355
	Furniture, fixtures and office equipment		293			192
	Machinery and equipment		4,624			2,446
	Leasehold improvements		497			472
	Construction in progress		6,503			2,103
			12,377			5,569
	Less accumulated depreciation		(2,957	)		(2,041	)
		$	9,420		$	3,528
Summary of Estimated Fair Value of Assets Acquired	'
	The following table summarizes the estimated fair value of the assets acquired as of the Acquisition Date, which were determined using Level 2 and 3 inputs as described above (in thousands):
		JULY 19,
		2012
	Land	$	1
	Building		314
	Equipment		1,144
	Assets acquired	$	1,459

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss Per Share	'
	The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented (in thousands). Such potentially dilutive shares are excluded when the effect would be to reduce the loss per share. The treasury stock method has been applied to determine the dilutive effect of warrants.
			DECEMBER 31
			2013			2012			2011
	Convertible preferred stock			—			8,504			8,504
	Convertible notes (1)			—			—			—
	Stock options outstanding			2,608			2,067			1,384
	Warrants to purchase convertible preferred stock			—			207			36
	Warrants to purchase common stock (2)			151			—			5
	(1)	As of December 31, 2012, the Company had approximately $41,860,000, in contingently convertible notes payable and related accrued interest for which the contingencies related to conversion had not been met as of December 31, 2012. Therefore, it would have no dilutive or anti-dilutive impact until the contingency had been met effective upon the IPO in August 2013. All convertible notes converted to common stock in connection with the IPO. See Note 9 for further discussion.
	(2)	In October 2012 and April 2013, the Company issued warrants to purchase a number of shares of common stock equal to 15% of the funded principal amount of the October 2012 and April 2013 Junior Secured Promissory Notes as defined in Note 8, divided by 70% of the value of common stock in a sale of the Company or a qualified initial public offering (Qualified IPO), with an exercise price of 70% of the value of common stock in a sale of the Company or a Qualified IPO. In June 2013, the Company issued warrants to purchase a number of shares of common stock equal to 10% of the total committed amount of the June 2013 Credit Facility as defined in Note 8, divided by 70% of the value of common stock in a sale of the Company or a Qualified IPO, with an exercise price of 70% of the value of common stock in a sale of the Company or a Qualified IPO. These warrants were contingently exercisable for which the contingencies related to exercise had not been met until the IPO in August 2013. Therefore, they would have no dilutive or anti-dilutive impact until the contingency had been met in August 2013. See Note 8 for further discussion.
Computation of Common Shares Upon Exercise of Warrants and Basic and Diluted Net Loss Per Share	'
	The numbers of shares of common stock issuable upon the exercise of warrants to purchase convertible preferred stock and upon the conversion of convertible preferred stock were at a ratio of one-to-one.
			YEAR ENDED DECEMBER 31
			2013			2012			2011
			(In thousands, except per share data)
	Numerator:
	Net loss		$	(28,489	)	$	(38,794	)	$	(13,180	)
	Deemed dividend on convertible notes			(1,378	)		(2,039	)		—
	Net loss attributable to common stockholders		$	(29,867	)	$	(40,833	)	$	(13,180	)
	Effect of potentially dilutive securities:
	Convertible notes			(4,392	)		—			—
	Warrants to purchase preferred stock			(840	)		—			—
	Net loss for diluted net loss per share		$	(35,099	)	$	(40,833	)	$	(13,180	)
	Denominator
	Weighted average shares used for basic net loss per share			8,731			1,257			1,239
	Effect of potentially dilutive securities:
	Convertible notes			127			—			—
	Warrants to purchase preferred stock			53			—			—
	Weighted average shares outstanding for diluted net loss per share			8,911			1,257			1,239
	Basic net loss per share:		$	(3.42	)	$	(32.48	)	$	(10.64	)
	Diluted net loss per share:		$	(3.94	)	$	(32.48	)	$	(10.64	)

Other_Assets_Tables

Other Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]	'
Summary of Other Assets	'
	Other assets consist of the following (in thousands):
		DECEMBER 31
		2013		2012
	Prepaid initial public offering costs	$	—	$	2,257
	Prepaid distribution fees		125		134
	Deferred financing costs, less current portion		148		261
	Deposits for equipment		256		—
	Deposits on equipment leases		177		43
	Other assets		100		90
		$	806	$	2,785

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2013
Payables And Accruals [Abstract]	'
Schedule of Accrued Liabilities	'
	Accrued liabilities consist of the following (in thousands):
		DECEMBER 31
		2013		2012
	Accrued compensation	$	2,040	$	1,342
	Accrued severance		100		—
	Accrued expenses		1,630		1,295
	Accrued inventory costs		610		—
	Accrued product rebates		—		386
		$	4,380	$	3,023

Debt_Tables

Debt (Tables)	12 Months Ended
	Dec. 31, 2013
Schedule of Debt	'
	Debt consists of the following (in thousands):
			31-Dec
			2013			2012
	Promissory note bearing interest at 6.25% per annum, which is payable monthly through May 2013, collateralized by all of the Company’s inventories, chattel paper, accounts receivable, equipment and general intangibles (excluding certain financed equipment and intellectual property). The Promissory Note was repaid in May 2013 (1)		$	—		$	35
	Term Loan (Term Loan) bearing interest at 7.00% per annum which is payable monthly through April 2016. The Term Loan is collateralized by all of the Company’s inventories, chattel paper, accounts receivable, equipment and general intangibles (excluding certain financed equipment and intellectual property) pledged as collateral under the Term Loan, subordinated (1)			309			426
	Promissory note bearing interest at 7.00% per annum which is payable monthly through November 2014, collateralized by all of the Company’s inventories, chattel paper, accounts receivable, equipment and general intangibles (excluding certain financed equipment and intellectual property), net of unamortized debt discount at December 31, 2013 of $2, subordinated (1)			123			261
	Senior secured promissory note (April 2012 Senior Secured Promissory Note) bearing interest at 15.00% per annum which is payable monthly through April 2017, collateralized by substantially all of the Company’s assets. The April 2012 Senior Secured Promissory Note was repaid in January 2013			—			8,374
	Junior secured promissory notes (October 2012 and April 2013 Junior Secured Promissory Notes) bearing interest at 12.00% per annum which are payable monthly through October 2015, collateralized by substantially all of the Company’s assets, net of unamortized debt discount at December 31, 2013 of $445 (1)			12,005			7,242
	Debt			12,437			16,338
	Less current portion			(157	)		(8,572	)
			$	12,280		$	7,766
	(1)	The lender’s security interest was subordinate to the holders of the April 2012 Senior Secured Promissory Note with the exception of its interest in equipment.
Schedule of Aggregate Contractual Future Principal Payments Due on Company's Debt	'
	As of December 31, 2013, aggregate contractual future principal payments on the Company’s debt, by year, are due as follows (in thousands):
	Years ending December 31:
	2014		$	251
	2015			12,585
	2016			48
	Total future principal payments		$	12,884
Consideration Received, Fair Values of Notes, Common Stock Warrants Issued and Calculation of the Gain on Extinguishment of Debt	'
	The following table shows the consideration received, fair values of the notes and common stock warrants issued and calculation of the gain on extinguishment of debt for the $3,750,000 Notes (in thousands):
	Consideration received
	Fair Value of October 2012 Subordinated Convertible Note		$	1,360
	Cash			2,500
	Total Consideration Received (a)		$	3,860
	Notes and Warrants Issued
	Principal Balance of Notes Issued		$	3,750
	Debt Discount (1)			(291	)
	Fair Value of Notes Issued			3,459
	Fair Value of Additional Common Stock Warrants Issued			352
	Total Fair Value of Notes and Warrants Issued (b)		$	3,811
	Gain on Extinguishment of Debt (a—b)		$	49
	(1)	The amortization of this account is being recorded in interest expense in the consolidated statements of operations over the term of the arrangement.
April 2012 Senior Secured Promissory Note [Member]	'
Activity Related to Secured Promissory Note	'
	Activity related to the April 2012 Senior Secured Promissory Note from December 31, 2012 through December 31, 2013 consisted of the following (in thousands):
			DECEMBER 31,			AMORTIZATION			PRINCIPAL			DECEMBER 31,
			2012			OF DEBT			PAYMENTS			2013
						DISCOUNT
	Principal		$	9,139		$	—		$	(9,139	)	$	—
	Discount related to Series C Warrant (1)			(251	)		251			—			—
	Discount related to financing costs (1)			(514	)		514			—			—
			$	8,374		$	765		$	(9,139	)	$	—
	(1)	The amortization of this account is included in interest expense in the consolidated statements of operations and non-cash interest expense in the consolidated statements of cash flows.
October 2012 Junior secured promissory notes [Member]	'
Activity Related to Secured Promissory Note	'
	Activity related to the October 2012 and April 2013 Junior Secured Promissory Notes from December 31, 2012 through December 31, 2013 consisted of the following (in thousands):
			DECEMBER 31,			ADDITIONS			AMORTIZATION			PRINCIPAL		DECEMBER 31,
			2012						OF DEBT			PAYMENTS		2013
									DISCOUNT
	Principal		$	7,500		$	4,950		$	—		$	—	$	12,450
	Debt discount related to issuance of common stock warrants (1)			(258	)		(113	)		130			—		(241	)
	Discount related to the $3,750,000 Notes (1)			—			(291	)		87			—		(204	)
			$	7,242		$	4,546		$	217		$	—	$	12,005
	(1)	The amortization of this account is included in interest expense in the consolidated statements of operations and as non-cash interest expense in the consolidated statements of cash flows.

Convertible_Notes_Payable_Tabl

Convertible Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Summary of Convertible Notes Payable	'
	Convertible notes payable consists of the following (in thousands):
		MATURITY	DECEMBER 31
		DATE	2013		2012
	Convertible notes (March 2012 Convertible Notes) bearing interest at 10.00% per annum issued in March and April 2012. The convertible notes were converted to common stock in August 2013.	September 2013	$	—	$	20,204
	Convertible note (October 2012 Convertible Note) bearing interest at 10.00% per annum issued in October 2012. The convertible note was converted to common stock in August 2013	September 2013		—		2,314
	Convertible notes payable, current portion			—		22,518
	Convertible note (October 2012 Subordinated Convertible Note) bearing interest at 12.00% per annum issued in October 2012. The convertible note was converted to common stock in August 2013	Oct-15		—		2,797
	Convertible note (December 2012 Convertible Note) bearing interest at 10.00% per annum issued in December 2012. The convertible note was converted to common stock in August 2013	Oct-15		—		16,545
	Convertible notes (First May 2013 Convertible Notes) bearing interest at 10.00% per annum issued in May 2013. The convertible notes were converted to common stock in August 2013	May-16		—		—
	Convertible note (Second May 2013 Convertible Note) bearing interest at 10.00% per annum issued in May 2013. The convertible note was converted to common stock in August 2013	May-16		—		—
	Total convertible notes payable		$	—	$	41,860

Warrants_Tables

Warrants (Tables)	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Summary of Information about Common Stock Warrants Outstanding	'
	The following table summarizes information about the Company’s common stock warrants outstanding as of December 31, 2013 (in thousands, except exercise price data):
	DESCRIPTION		ISSUE DATE	EXPIRATION	NUMBER OF		EXERCISE
				DATE (1)	SHARES		PRICE
					SUBJECT TO
					WARRANTS
					ISSUED
	In connection with April 2013 Junior Secured Promissory Note (Additional Common Stock Warrants)		April 2013	October 2015		118	$	8.4
	In connection with June 2013 Credit Facility (June 2013 Warrants)		Jun-13	Jun-23		33	$	8.4
						151
	(1)	Both the common stock warrants expire upon the earlier to occur of (i) the date listed above; (ii) the acquisition of the Company by another entity by means of any transaction or series of related transactions (including, without limitation, any transfer of more than 50% of the voting power of the Company, reorganization, merger or consolidation, but excluding any merger effected exclusively for the purpose of changing the domicile of the Company) or (iii) a sale of all or substantially all of the assets of the Company; unless the Company’s stockholders of record as constituted immediately prior to such acquisition or sale will, immediately after such acquisition or sale (by virtue of securities issued as consideration for the Company’s acquisition or sale or otherwise) hold at least fifty percent (50%) of the voting power of the surviving or acquiring entity.
Summary of Information about Convertible Preferred Stock and Common Stock Warrants Outstanding	'
	The following table summarizes information about the Company’s convertible preferred stock and common stock warrants outstanding as of December 31, 2012 (in thousands, except exercise price data):
	DESCRIPTION		ISSUE DATE	EXPIRATION	NUMBER OF		EXERCISE		ESTIMATED
				DATE	SHARES		PRICE		FAIR
					SUBJECT TO				VALUE AS
					WARRANTS				OF
					ISSUED				DECEMBER
									31, 2012 (2)
	In connection with loan agreement (Series A convertible preferred stock)		April 2007	April 2014		6	$	2.608	$	68
	In connection with promissory note and revolving line of credit (Series B convertible preferred stock)		August 2008	May 2013		3	$	4.849		34
	In connection with promissory note (Series B convertible preferred stock)		March 2009	March 2014		7	$	4.849		72
	In connection with April 2012 Senior Secured Promissory Note (Series C convertible preferred stock)		Apr-12	Apr-22		191	$	7.846		1,710
	In connection with October 2012 Junior Secured Promissory Note (Common stock) (1)		October 2012	October 2015		—	$	—		301
						207			$	2,185
	(1)	As of December 31, 2012, the Company had issued warrants to purchase shares of common stock equal to 15% of the funded principal amount of the October 2012 Junior Secured Promissory Notes (See Note 8) divided by 70% of the value of common stock in a sale of the Company or an IPO, with an exercise price of 70% of the value of common stock in a sale of the Company or IPO. These warrants were contingently exercisable for which the contingencies related to exercise had not been met as of December 31, 2012.
	(2)	See Note 2 for discussion of the methods used to determine the estimated fair values of the preferred stock warrants and common stock warrants.

Common_Stock_Tables

Common Stock (Tables)	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Reserved Shares of Common Stock for Future Issuances	'
	As of December 31, 2013, the Company had reserved shares of common stock for future issuances as follows (in thousands):
		SHARES
	Stock options available for future grant		1,194
	Stock options outstanding		2,608
	Warrants to purchase common stock		151
			3,953

Stock_Option_Plans_Tables

Stock Option Plans (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Summary of Activity under Company's Stock Option Plans	'
	The following table summarizes the activity under the Company’s stock option plans for the year ended December 31, 2013 (in thousands, except exercise price and remaining contractual life data):
		SHARES			SHARES			WEIGHTED-		WEIGHTED-		AGGREGATE
		AVAILABLE			OUTSTANDING			AVERAGE		AVERAGE		INTRINSIC
		FOR						EXERCISE		REMAINING		VALUE
		GRANT						PRICE		CONTRACTUAL
										LIFE
										(IN YEARS)
	Balances at December 31, 2012		352			2,067		$	3.86		7.7	$	14,380
	Options authorized		1,600			—
	Options granted		(1,036	)		1,036		$	15.76
	Options exercised		—			(217	)	$	1.18
	Options canceled		278			(278	)	$	6.24
	Balances at December 31, 2013		1,194			2,608		$	8.56		8.1	$	24,158
	Vested and expected to vest at December 31, 2013					2,409		$	8.25		8	$	23,061
	Exercisable at December 31, 2013					1,054		$	2.97		6.5	$	15,610

Capital_Leases_Tables

Capital Leases (Tables)	12 Months Ended
	Dec. 31, 2013
Leases [Abstract]	'
Aggregate Contractual Future Minimum Lease Payments	'
	As of December 31, 2013, aggregate contractual future minimum lease payments on the capital leases are due as follows (in thousands):
		CAPITAL
		LEASES
	Years ending December 31:
	2014	$	1,520
	2015		1,120
	2016		54
	Total minimum payments required		2,694
	Less: amount representing interest		(159	)
	Present value of future payments		2,535
	Less: current portion		(1,401	)
		$	1,134

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Schedule of Non-Cancelable Lease Agreements	'
	At December 31, 2013, the Company’s aggregate commitment under non-cancelable lease agreements is as follows (in thousands):
		OPERATING
		LEASES
	Years ending December 31:
	2014	$	965
	2015		753
	2016		666
	2017		606
	2018 and beyond		822
	Total minimum payments required	$	3,812

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Deferred Tax Assets	'
	The temporary timing differences that give rise to the deferred tax assets are as follows (in thousands):
		31-Dec
		2013			2012
	Components of deferred taxes:
	Net operating loss carryforwards	$	30,258		$	19,966
	Research and development tax credit		1,577			1,002
	Other, net		2,415			1,432
	Net deferred tax assets		34,250			22,400
	Less: valuation allowance		(34,250	)		(22,400	)
	Net deferred tax assets	$	—		$	—
Reconciliation of Effective Income Tax Rate to US Federal Income Tax Statutory Rate	'
	The provision for income taxes is different than the amount computed using the applicable statutory federal income tax rate with the difference for each year summarized below:
		DECEMBER 31
		2013			2012
	Federal tax benefit at statutory rate		34	%		34	%
	State tax benefit, net of federal benefit		5			5
	Interest expense		(5	)		—
	Mark-to-market accounting		9			(12	)
	Deemed dividend		(2	)		(6	)
	Share-based compensation expense		(2	)		—
	Other		1			(1	)
	Adjustment due to change in valuation allowance		(40	)		(20	)
	Provision for income taxes		—	%		—	%
Reconciliation of Beginning and Ending Unrecognized Tax Benefits	'
	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):
		2013			2012
	Balance at January 1	$	340		$	305
	Increase related to prior year tax positions		79			—
	Increase related to current year tax positions		106			35
	Balance at December 31	$	525		$	340

Quarterly_Financial_Informatio1

Quarterly Financial Information (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Summary of Quarterly Financial Information	'
		MARCH 31			JUNE 30			SEPTEMBER 30			DECEMBER 31
			(In thousands, except per share data)
	2013
	Total revenues	$	2,730		$	4,500		$	1,346		$	5,967
	Gross profit		935			1,102			269			1,501
	Net loss		(10,749	)		(1,639	)		(6,110	)		(9,991	)
	Deemed dividend on convertible notes		—			(1,378	)		—			—
	Net loss attributable to common stockholders		(10,749	)		(3,017	)		(6,110	)		(9,991	)
	Net loss per common share:
	Basic		(8.48	)		(2.36	)		(0.47	)		(0.52	)
	Diluted		(8.48	)		(2.67	)		(0.80	)		(0.52	)
	2012
	Total revenues	$	1,999		$	1,509		$	738		$	2,894
	Gross profit		1,139			825			217			626
	Net loss		(3,984	)		(3,912	)		(13,802	)		(17,096	)
	Deemed dividend on convertible notes		(1,253	)		—			—			(786	)
	Net loss attributable to common stockholders		(5,237	)		(3,912	)		(13,802	)		(17,882	)
	Net loss per common share:
	Basic		(4.20	)		(3.13	)		(10.94	)		(14.11	)
	Diluted		(4.20	)		(3.13	)		(10.94	)		(14.11	)
Schedule of Error Corrections	'
	THREE MONTHS ENDED						THREE MONTHS ENDED						NINE MONTHS ENDED
	30-Jun-13						30-Sep-13						30-Sep-13
		AS			AS REVISED			AS			AS REVISED			AS			AS REVISED
		REPORTED						REPORTED						REPORTED
		(In thousands, except per share data)
	Numerator:
	Net loss	$	(1,639	)	$	(1,639	)	$	(6,110	)	$	(6,110	)	$	(18,498	)	$	(18,498	)
	Deemed dividend on convertible notes		(1,378	)		(1,378	)		—			—			(1,378	)		(1,378	)
	Net loss attributable to common stockholders	$	(3,017	)	$	(3,017	)	$	(6,110	)	$	(6,110	)	$	(19,876	)	$	(19,876	)
	Effect of potentially dilutive securities:
	Convertible notes		—			—			(1,089	)		(4,392	)		(118	)		(4,392	)
	Warrants to purchase convertible preferred stock		—			(575	)		—			(264	)		—			(841	)
	Warrants to purchase common stock		—			—			(201	)		—			(201	)		—
	Net loss for diluted net loss per share	$	(3,017	)	$	(3,592	)	$	(7,400	)	$	(10,766	)	$	(20,195	)	$	(25,109	)
	Denominator:
	Shares used for basic net loss per share		1,277			1,277			12,888			12,888			5,187			5,187
	Effect of potentially dilutive securities:
	Convertible notes		—			—			1,043			503			20			169
	Warrants to purchase convertible preferred stock		—			70			—			31			—			61
	Warrants to purchase common stock		—			—			86			—			22			—
	Weighted average shares outstanding for diluted net loss per share		1,277			1,347			14,017			13,422			5,229			5,417
	Diluted net loss per share:	$	(2.36	)	$	(2.67	)	$	(0.53	)	$	(0.80	)	$	(3.86	)	$	(4.63	)

Summary_of_Business_Additional

Summary of Business - Additional Information (Detail) (USD $)	1 Months Ended	12 Months Ended
	Aug. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'	'	'	'	'
Shares issued under initial public offering	5,462,500	'	'	'	'
Issuance of common stock under IPO to underwriters by selling stockholders	712,500	'	'	'	'
Public offering price of the shares sold in the offering	$12	'	'	'	'
Total gross proceeds from IPO	$65,550,000	'	'	'	'
Aggregate net proceeds received	56,105,000	56,105,000	'	'	'
Accumulated deficit	'	-105,436,000	-75,569,000	'	'
Working capital	'	46,915,000	'	'	'
Cash and cash equivalents	'	24,455,000	10,006,000	2,215,000	4,287,000
Short-term investments	'	$13,677,000	'	'	'
Reverse stock split	'1-for-3.138458	'	'	'	'

Significant_Accounting_Policie3

Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Aug. 31, 2013
Significant Accounting Policies [Line Items]	'	'	'	'
Restricted cash	'	$9,139,000	'	'
Investments in securities	'	0	'	'
Fair value discount rate	'	35.00%	'	'
Discount for lack of marketability	'	18.00%	'	'
Warrants liability reclassified	2,669,000	'	'	'
Public offering price of the shares sold	'	'	'	$12
Concentration risk, supplier	'The Company currently uses one supplier and does not have a long-term supply contract with this supplier.	'	'	'
Receivables, written-off	0	0	'	'
Allowance for doubtful accounts	0	0	'	'
Reserves against inventories	45,000	0	'	'
Inventory write-off	205,000	913,000	'	'
Inventory write-down to net realizable value	194,000	'	'	'
Deferred financing cost current	458,000	145,000	'	'
Write down of carrying value of deferred cost	174,000	'	'	'
Deferred financing cost non-current other assets	148,000	261,000	'	'
Current deferred product revenues	1,209,000	193,000	'	'
Deferred payments received	0	1,533,000	833,000	'
Recognized license revenues	193,000	179,000	57,000	'
Affiliate revenues percent	5.00%	'	'	'
Non-current deferred revenues	744,000	937,000	'	'
Deferred revenues related parties current	131,000	131,000	'	'
Deferred revenues related parties non current	628,000	759,000	'	'
Payments received under grants	0	140,000	164,000	'
Reduction in research and development expenses	0	171,000	195,000	'
Advertising costs	760,000	609,000	286,000	'
Other income (expense), net	-282,000	-45,000	9,000	'
Loss on disposal of fixed assets	-231,000	'	'	'
Percentage of recognized uncertain tax position upon ultimate settlement	50.00%	'	'	'
Uncertain tax positions	0	0	'	'
Interest and penalties related to income tax	0	0	0	'
Strategic collaboration and distribution agreements [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Current deferred product revenues	324,000	324,000	'	'
Non-current deferred revenues	1,372,000	1,696,000	'	'
Deferred revenues related parties current	131,000	131,000	'	'
Deferred revenues related parties non current	628,000	759,000	'	'
Accrued Liabilities [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Current deferred product revenues	0	0	31,000	'
Prepaid expenses and other current assets [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Deferred financing cost current	418,000	0	'	'
Series C warrant [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Public offering price of the shares sold	$12	'	'	'
Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | International [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Customers accounted for percentage of company's total revenues and accounts receivable	8.00%	20.00%	7.00%	'
Certificates of deposit [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Short-term investments original maturity description	'Short-term investments consist of certificates of deposit with original maturities less than one year but greater than three months which are classified as held-to-maturity.	'	'	'
Short-term investments original maturity period maximum	'1 year	'	'	'
Short-term investments original maturity period minimum	'3 months	'	'	'
March 2012 and October 2012 Convertible Notes [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Fair value discount rate	'	25.00%	'	'
Subordinated Convertible Notes [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Fair value discount rate	'	18.00%	'	'
Public offering price of the shares sold	'	$12	'	'
December 2012 convertible note [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Recognized license revenues	'	0	0	'
Reduction in license revenue	'	110,000	'	'
Grandevo and Regalia [Member] | Sales Revenue, Net [Member] | Product Concentration Risk [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Customers accounted for percentage of company's total revenues and accounts receivable	97.00%	96.00%	96.00%	'
Revenue Recognition [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Current deferred product revenues	1,016,000	0	'	'
Research and development expenses [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Research and development expense	16,827,000	12,140,000	9,133,000	'
Foreign currency transactions [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Other income (expense), net	53,000	54,000	0	'
Other income (expense), net [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Loss on disposal of fixed assets	231,000	0	0	'
Preferred and common stock warrants [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Transfer from Level 3 to Level 2 category	574,000	0	'	'
Transfer from Level 2 to Level 1 category	0	0	'	'
Convertible notes payable [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Transfer from Level 3 to Level 2 category	48,234,000	0	'	'
Transfer from Level 2 to Level 1 category	0	0	'	'
Patent expenses [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Patent expenses	987,000	601,000	277,000	'
Related party revenues [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Deferred payments received	'	1,000,000	'	'
Recognized license revenues	131,000	'	'	'
April 2012 Senior Secured Promissory Note [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Promissory note original principal balance	10,000,000	'	'	'
Restricted cash	$0	'	'	'
Maximum [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Receivables due period	'120 days	'	'	'
Maximum [Member] | Sales Revenue, Net [Member] | Customer Concentration Risk [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Customers accounted for percentage of company's total revenues and accounts receivable	'	10.00%	'	'

Significant_Accounting_Policie4

Significant Accounting Policies - Amortized Cost and Estimated Fair Values of Short-Term Investments (Detail) (Certificates of deposit [Member], USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Certificates of deposit [Member]	'
Schedule of Held-to-maturity Securities [Line Items]	'
Amortized Cost	$13,677
Gross Unrealized Gains	'
Gross Unrealized Losses	-4
Estimated Fair value	$13,673

Significant_Accounting_Policie5

Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Liabilities	'	'
Liabilities at fair value	'	$44,045
Common stock warrant liability [Member]	'	'
Liabilities	'	'
Liabilities at fair value	'	301
Preferred stock warrant liability [Member]	'	'
Liabilities	'	'
Liabilities at fair value	'	1,884
Convertible notes payable [Member]	'	'
Liabilities	'	'
Liabilities at fair value	'	41,860
Money market funds [Member]	'	'
Assets	'	'
Assets at fair value	16,268	7,668
Level 1 [Member]	'	'
Liabilities	'	'
Liabilities at fair value	'	'
Level 1 [Member] | Common stock warrant liability [Member]	'	'
Liabilities	'	'
Liabilities at fair value	'	'
Level 1 [Member] | Preferred stock warrant liability [Member]	'	'
Liabilities	'	'
Liabilities at fair value	'	'
Level 1 [Member] | Convertible notes payable [Member]	'	'
Liabilities	'	'
Liabilities at fair value	'	'
Level 1 [Member] | Money market funds [Member]	'	'
Assets	'	'
Assets at fair value	16,268	7,668
Level 2 [Member]	'	'
Liabilities	'	'
Liabilities at fair value	'	'
Level 2 [Member] | Common stock warrant liability [Member]	'	'
Liabilities	'	'
Liabilities at fair value	'	'
Level 2 [Member] | Preferred stock warrant liability [Member]	'	'
Liabilities	'	'
Liabilities at fair value	'	'
Level 2 [Member] | Convertible notes payable [Member]	'	'
Liabilities	'	'
Liabilities at fair value	'	'
Level 2 [Member] | Money market funds [Member]	'	'
Assets	'	'
Assets at fair value	'	'
Level 3 [Member]	'	'
Liabilities	'	'
Liabilities at fair value	'	44,045
Level 3 [Member] | Common stock warrant liability [Member]	'	'
Liabilities	'	'
Liabilities at fair value	'	301
Level 3 [Member] | Preferred stock warrant liability [Member]	'	'
Liabilities	'	'
Liabilities at fair value	'	1,884
Level 3 [Member] | Convertible notes payable [Member]	'	'
Liabilities	'	'
Liabilities at fair value	'	41,860
Level 3 [Member] | Money market funds [Member]	'	'
Assets	'	'
Assets at fair value	'	'

Significant_Accounting_Policie6

Significant Accounting Policies - Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3) (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Convertible notes payable [Member]	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Transfers out of Level 3	($48,234,000)	$0
Level 3 [Member] | Common stock warrant liability [Member]	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Beginning balance	301,000	'
Warrants issued\ Convertible notes issued	900,000	'
Change in fair value recorded in change in fair value of financial instruments	377,000	'
Transfers out of Level 3	-434,000	'
Reclassified to stockholders' equity (deficit)	-1,144,000	'
Ending balance	'	'
Level 3 [Member] | Preferred stock warrant liability [Member]	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Beginning balance	1,884,000	'
Change in fair value recorded in change in fair value of financial instruments	-823,000	'
Transfers out of Level 3	-140,000	'
Reclassified to stockholders' equity (deficit)	-921,000	'
Ending balance	'	'
Level 3 [Member] | Convertible notes payable [Member]	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Beginning balance	41,860,000	'
Warrants issued\ Convertible notes issued	9,069,000	'
Convertible notes cancelled	-1,360,000	'
Accrued interest	1,299,000	'
Change in fair value recorded in change in fair value of financial instruments	-2,634,000	'
Transfers out of Level 3	-48,234,000	'
Ending balance	'	'

Significant_Accounting_Policie7

Significant Accounting Policies - Schedule of Concentration of Credit Risk Percentage (Detail) (Customer Concentration Risk [Member])	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Sales Revenue, Net [Member] | Customer A [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Customers accounted for percentage of company's total revenues and accounts receivable	28.00%	33.00%	39.00%
Sales Revenue, Net [Member] | Customer B [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Customers accounted for percentage of company's total revenues and accounts receivable	10.00%	'	'
Sales Revenue, Net [Member] | Customer C [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Customers accounted for percentage of company's total revenues and accounts receivable	'	13.00%	'
Sales Revenue, Net [Member] | Customer D [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Customers accounted for percentage of company's total revenues and accounts receivable	'	12.00%	17.00%
Sales Revenue, Net [Member] | Customer E [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Customers accounted for percentage of company's total revenues and accounts receivable	'	'	10.00%
Accounts receivable [Member] | Customer A [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Customers accounted for percentage of company's total revenues and accounts receivable	19.00%	'	'
Accounts receivable [Member] | Customer B [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Customers accounted for percentage of company's total revenues and accounts receivable	13.00%	'	'
Accounts receivable [Member] | Customer C [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Customers accounted for percentage of company's total revenues and accounts receivable	12.00%	'	'
Accounts receivable [Member] | Customer D [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Customers accounted for percentage of company's total revenues and accounts receivable	11.00%	33.00%	'
Accounts receivable [Member] | Customer E [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Customers accounted for percentage of company's total revenues and accounts receivable	'	17.00%	'
Accounts receivable [Member] | Customer F [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Customers accounted for percentage of company's total revenues and accounts receivable	'	11.00%	'
Accounts receivable [Member] | Customer G [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Customers accounted for percentage of company's total revenues and accounts receivable	'	11.00%	'

Significant_Accounting_Policie8

Significant Accounting Policies - Schedule of Concentration of Credit Risk Percentage (Parenthetical) (Detail) (Maximum [Member], Customer Concentration Risk [Member])	12 Months Ended
	Dec. 31, 2012
Sales Revenue, Net [Member]	'
Concentration Risk [Line Items]	'
Customers accounted for percentage of company's total revenues and accounts receivable	10.00%
Accounts receivable [Member]	'
Concentration Risk [Line Items]	'
Customers accounted for percentage of company's total revenues and accounts receivable	10.00%

Significant_Accounting_Policie9

Significant Accounting Policies - Schedule of Inventories (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw materials	$5,355	$3,204
Work in progress	2,917	607
Finished goods	3,394	1,061
Inventories, total	$11,666	$4,872

Recovered_Sheet1

Significant Accounting Policies - Summary of Property, Plant and Equipment Estimated Useful Lives (Detail)	12 Months Ended
	Dec. 31, 2013
Buildings [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Property, plant and equipment, estimated useful life	'30 years
Leasehold improvements [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Property, plant and equipment, estimated useful life, description	'Shorter of lease term or useful life
Software [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Property, plant and equipment, estimated useful life	'3 years
Minimum [Member] | Computer equipment and software [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Property, plant and equipment, estimated useful life	'2 years
Minimum [Member] | Machinery and equipment [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Property, plant and equipment, estimated useful life	'3 years
Minimum [Member] | Office equipment [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Property, plant and equipment, estimated useful life	'3 years
Minimum [Member] | Furniture, fixtures and office equipment [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Property, plant and equipment, estimated useful life	'3 years
Maximum [Member] | Computer equipment and software [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Property, plant and equipment, estimated useful life	'3 years
Maximum [Member] | Machinery and equipment [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Property, plant and equipment, estimated useful life	'20 years
Maximum [Member] | Office equipment [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Property, plant and equipment, estimated useful life	'5 years
Maximum [Member] | Furniture, fixtures and office equipment [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Property, plant and equipment, estimated useful life	'5 years

Recovered_Sheet2

Significant Accounting Policies - Fair Value Assumptions of Stock Options Granted (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Minimum [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Expected life (years)	'5 years 3 months 15 days	'5 years	'5 years
Estimated volatility factor	70.00%	72.00%	'
Risk-free interest rate	1.27%	0.74%	0.86%
Maximum [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Expected life (years)	'7 years 8 months 16 days	'6 years 29 days	'6 years 3 months 11 days
Estimated volatility factor	75.00%	76.00%	70.00%
Risk-free interest rate	2.11%	1.16%	2.40%
Expected dividend yield	'	'	'

Property_Plant_and_Equipment_S

Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	$12,377	$5,569
Less accumulated depreciation	-2,957	-2,041
Property, plant and equipment, net	9,420	3,528
Land [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	1	1
Buildings [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	'	'
Computer equipment and software [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	459	355
Furniture, fixtures and office equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	293	192
Machinery and equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	4,624	2,446
Leasehold improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	497	472
Construction in progress [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	$6,503	$2,103

Property_Plant_and_Equipment_A

Property, Plant and Equipment - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Jul. 19, 2012
Property Plant And Equipment [Abstract]	'	'	'	'
Depreciation and amortization expense	$976,000	$613,000	$499,000	'
Company acquired land, building and equipment	'	'	'	1,459,000
Transaction costs of acquisition	'	'	'	341,000
Fair value in excess of purchase price of the asset acquired	'	'	'	257,000
Interest expense	$801,000	$106,000	'	'

Property_Plant_and_Equipment_S1

Property, Plant and Equipment - Summary of Estimated Fair Value of Assets Acquired (Detail) (USD $)	Jul. 19, 2012
In Thousands, unless otherwise specified
Business Combinations [Abstract]	'
Land	$1
Building	314
Equipment	1,144
Assets acquired	$1,459

Net_Loss_Per_Share_Schedule_of

Net Loss Per Share - Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Detail)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Convertible preferred stock [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Anti-dilutive securities excluded from computation of earning per share	'	8,504	8,504
Convertible notes payable [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Anti-dilutive securities excluded from computation of earning per share	'	'	'
Stock options outstanding [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Anti-dilutive securities excluded from computation of earning per share	2,608	2,067	1,384
Warrants to purchase convertible preferred stock [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Anti-dilutive securities excluded from computation of earning per share	'	207	36
Warrants to purchase common stock [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Anti-dilutive securities excluded from computation of earning per share	151	'	5

Net_Loss_Per_Share_Schedule_of1

Net Loss Per Share - Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Parenthetical) (Detail) (USD $)	1 Months Ended
	Jun. 30, 2013	Apr. 30, 2013	Oct. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Jun. 30, 2012
Earnings Per Share [Abstract]	'	'	'	'	'	'
Contingently convertible notes payable	'	'	'	'	$41,860,000	$514,000
Warrants issued to purchase a percentage of common stock	10.00%	15.00%	15.00%	'	'	'
Value of common stock in a sale of the Company or an initial public offering	70.00%	70.00%	70.00%	'	70.00%	'
Percentage of exercise price on the value of common stock	70.00%	70.00%	70.00%	'	70.00%	'

Net_Loss_Per_Share_Additional_

Net Loss Per Share - Additional Information (Detail)	1 Months Ended	12 Months Ended
	Aug. 31, 2013	Dec. 31, 2013
Earnings Per Share [Abstract]	'	'
Conversion of convertible preferred stock ratio	1	1

Net_Loss_Per_Share_Computation

Net Loss Per Share - Computation of Common Shares Upon Exercise of Warrants and Basic and Diluted Net Loss Per Share (Detail) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

In Thousands, except Per Share data, unless otherwise specified

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Numerator

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

($9,991)

($6,110)

($1,639)

($10,749)

($17,096)

($13,802)

($3,912)

($3,984)

($18,498)

($28,489)

($38,794)

($13,180)

Deemed dividend on convertible notes

'

'

-1,378

'

-786

'

'

-1,253

-1,378

-1,378

-2,039

'

Net loss attributable to common stockholders

-9,991

-6,110

-3,017

-10,749

-17,882

-13,802

-3,912

-5,237

-19,876

-29,867

-40,833

-13,180

Effect of potentially dilutive securities

'

'

'

'

'

'

'

'

'

'

'

'

Net loss for diluted net loss per share

'

-10,766

-3,592

'

'

'

'

'

-25,109

-35,099

-40,833

-13,180

Denominator

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average shares used for basic net loss per share

'

12,888

1,277

'

'

'

'

'

5,187

8,731

1,257

1,239

Effect of potentially dilutive securities

'

'

'

'

'

'

'

'

'

'

'

'

Convertible notes

'

503

'

'

'

'

'

'

169

127

'

'

Warrants to purchase preferred stock

'

'

'

'

'

'

'

'

'

53

'

'

Weighted average shares outstanding for diluted net loss per share

'

13,422

1,347

'

'

'

'

'

5,417

8,911

1,257

1,239

Basic net loss per share

($0.52)

($0.47)

($2.36)

($8.48)

($14.11)

($10.94)

($3.13)

($4.20)

'

($3.42)

($32.48)

($10.64)

Diluted net loss per share

($0.52)

($0.80)

($2.67)

($8.48)

($14.11)

($10.94)

($3.13)

($4.20)

($4.63)

($3.94)

($32.48)

($10.64)

Convertible notes [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Effect of potentially dilutive securities

'

'

'

'

'

'

'

'

'

'

'

'

Effect of potentially dilutive securities

'

-4,392

'

'

'

'

'

'

-4,392

-4,392

'

'

Warrants to purchase preferred stock [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Effect of potentially dilutive securities

'

'

'

'

'

'

'

'

'

'

'

'

Effect of potentially dilutive securities

'

($264)

($575)

'

'

'

'

'

($841)

($840)

'

'

Other_Assets_Summary_of_Other_

Other Assets - Summary of Other Assets (Detail) (USD $)	Dec. 31, 2013	Apr. 10, 2013	Dec. 31, 2012
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]	'	'	'
Prepaid initial public offering costs	'	'	$2,257,000
Prepaid distribution fees	125,000	'	134,000
Deferred financing costs, less current portion	148,000	24,000	261,000
Deposits for equipment	256,000	'	'
Deposits on equipment leases	177,000	'	43,000
Other assets	100,000	'	90,000
Other assets, total	$806,000	'	$2,785,000

Accrued_Liabilities_Schedule_o

Accrued Liabilities - Schedule of Accrued Liabilities (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Payables And Accruals [Abstract]	'	'
Accrued compensation	$2,040	$1,342
Accrued severance	100	'
Accrued expenses	1,630	1,295
Accrued inventory costs	610	'
Accrued product rebates	'	386
Accrued liabilities, total	$4,380	$3,023

Accrued_Liabilities_Additional

Accrued Liabilities - Additional Information (Detail) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Payables And Accruals [Abstract]	'
Accrued severance expenses	$100

Factoring_and_Security_Agreeme1

Factoring and Security Agreement - Additional Information (Detail) (USD $)	1 Months Ended
	Jun. 13, 2013	Dec. 31, 2013
Receivables [Abstract]	'	'
Sales of interest in accounts receivable	$5,000,000	'
Sales of interest in accounts receivables, percentage	15.00%	'
Accounts receivable transferred	'	$479,000

Debt_Schedule_of_Debt_Detail

Debt - Schedule of Debt (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Debt Instrument [Line Items]	'	'
Debt	$12,437	$16,338
Less current portion	-157	-8,572
Debt, less current portion	12,280	7,766
Promissory note bearing interest at 6.25% [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt	'	35
Term loan bearing interest at 7.00% [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt	309	426
Promissory note bearing interest at 7.00% [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt	123	261
April 2012 Senior Secured Promissory Note [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt	'	8,374
October 2012 Junior secured promissory notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt	$12,005	$7,242

Debt_Schedule_of_Debt_Parenthe

Debt - Schedule of Debt (Parenthetical) (Detail) (USD $)

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

31-May-08

Dec. 31, 2013

Dec. 31, 2012

Mar. 31, 2012

Mar. 31, 2009

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Apr. 13, 2013

Dec. 31, 2013

Dec. 31, 2012

Promissory note bearing interest at 6.25% [Member]

Promissory note bearing interest at 6.25% [Member]

Promissory note bearing interest at 6.25% [Member]

Term loan bearing interest at 7.00% [Member]

Term loan bearing interest at 7.00% [Member]

Term loan bearing interest at 7.00% [Member]

Promissory note bearing interest at 7.00% [Member]

Promissory note bearing interest at 7.00% [Member]

Promissory note bearing interest at 7.00% [Member]

April 2012 Senior Secured Promissory Note [Member]

April 2012 Senior Secured Promissory Note [Member]

April 2012 Senior Secured Promissory Note [Member]

October 2012 Junior secured promissory notes [Member]

October 2012 Junior secured promissory notes [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, interest rate

6.25%

6.25%

6.25%

7.00%

7.00%

7.00%

7.00%

7.00%

7.00%

15.00%

15.00%

15.00%

12.00%

12.00%

Debt instrument, payment terms

'Payable monthly through May 2013

'Payable monthly through May 2012

'

'Payable monthly through April 2016

'Payable monthly through April 2016

'

'Six monthly interest only payments starting May 1, 2009, followed by 60 equal monthly installments of $13,000 commencing November 1, 2009, with the final payment due on November 1, 2014.

'Payable monthly through November 2014

'Payable monthly through November 2014

'Payable monthly through April 2017

'Payable monthly through April 2017

'

'Payable monthly through October 2015

'Payable monthly through October 2015

Unamortized debt discount

'

'

'

'

'

'

'

$2

'

'

'

'

$445

'

Debt_Schedule_of_Aggregate_Con

Debt - Schedule of Aggregate Contractual Future Principal Payments Due on Company's Debt (Detail) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Debt Disclosure [Abstract]	'
2014	$251
2015	12,585
2016	48
Total future principal payments	$12,884

Debt_Additional_Information_De

Debt - Additional Information (Detail) (USD $)

1 Months Ended

6 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Apr. 10, 2013

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Apr. 30, 2013

Oct. 31, 2012

Jun. 30, 2012

Dec. 31, 2013

Dec. 31, 2013

Apr. 10, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Apr. 10, 2013

Dec. 31, 2013

Dec. 31, 2012

Oct. 31, 2012

Dec. 31, 2013

Apr. 10, 2013

Oct. 16, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

31-May-08

Dec. 31, 2013

Dec. 31, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Mar. 31, 2009

Dec. 31, 2013

Dec. 31, 2012

Apr. 13, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Revolving line of credit [Member]

Series C warrant [Member]

Common stock warrants [Member]

Series C convertible preferred stock [Member]

Series C convertible preferred stock [Member]

June 2013 credit facility [Member]

June 2013 warrants [Member]

June 2013 warrants [Member]

April 2013 junior secured promissory note [Member]

April 2013 junior secured promissory note [Member]

April 2013 junior secured promissory note [Member]

October 2012 subordinated convertible note [Member]

October 2012 subordinated convertible note [Member]

October 2012 subordinated convertible note [Member]

October 2012 subordinated convertible note [Member]

Level 3 [Member]

Minimum [Member]

Maximum [Member]

Promissory note bearing interest at 6.25% [Member]

Promissory note bearing interest at 6.25% [Member]

Promissory note bearing interest at 6.25% [Member]

Term loan bearing interest at 7.00% [Member]

Term loan bearing interest at 7.00% [Member]

Term loan bearing interest at 7.00% [Member]

Promissory note bearing interest at 7.00% [Member]

Promissory note bearing interest at 7.00% [Member]

Promissory note bearing interest at 7.00% [Member]

April 2012 Senior Secured Promissory Note [Member]

April 2012 Senior Secured Promissory Note [Member]

April 2012 Senior Secured Promissory Note [Member]

October 2012 Junior secured promissory notes [Member]

October 2012 Junior secured promissory notes [Member]

October 2012 Junior secured promissory notes [Member]

October 2012 Junior secured promissory notes [Member]

October 2012 Junior secured promissory notes [Member]

October 2012 Junior secured promissory notes [Member]

Common stock warrants [Member]

Installment

Installment

Installment

Debt instrument maturity period year three [Member]

Extended fourth year [Member]

Extended fifth year [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of debt

'

'

'

'

'

'

'

'

$306,000

'

'

'

'

'

'

'

'

'

'

'

'

'

$13,950,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated market rate of interest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument borrowing amount

'

'

6,529,000

24,076,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

400,000

'

'

'

'

'

650,000

'

'

10,000,000

'

'

7,500,000

'

'

'

'

'

Debt instrument, interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12.00%

'

12.00%

'

'

'

6.25%

6.25%

6.25%

7.00%

7.00%

7.00%

7.00%

7.00%

7.00%

15.00%

15.00%

15.00%

12.00%

12.00%

'

12.00%

13.00%

14.00%

Number of installments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

60

'

'

'

'

'

60

'

'

59

'

'

'

'

'

'

'

'

Amount paid in each installment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,785

'

'

'

'

'

13,000

'

'

238,000

'

'

'

'

'

'

'

'

Installment payment commencing date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1-Jun-08

1-Jun-08

'

'

'

'

1-Nov-09

'

'

1-May-12

'

'

'

'

'

'

'

'

Percentage of borrowings limited to qualifying accounts receivable

'

'

'

'

'

'

'

75.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Credit facility maximum borrowing capacity

'

'

'

'

'

'

'

500,000

'

'

'

'

7,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument maturity date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

16-Oct-15

'

'

'

'

'

'

'

'

1-Apr-16

'

'

1-Nov-14

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, payment terms

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'Payable monthly through May 2013

'Payable monthly through May 2012

'

'Payable monthly through April 2016

'Payable monthly through April 2016

'Six monthly interest only payments starting May 1, 2009, followed by 60 equal monthly installments of $13,000 commencing November 1, 2009, with the final payment due on November 1, 2014.

'Payable monthly through November 2014

'Payable monthly through November 2014

'

'Payable monthly through April 2017

'Payable monthly through April 2017

'Payable monthly through October 2015

'Payable monthly through October 2015

'

'

'

'

Non-refundable loan fees

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

625,000

'

'

'

'

'

'

'

'

Installment payment final date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2017-04-01

'

'

'

'

'

'

'

'

Warrant issued to lender for of purchase preferred stock

'

'

'

'

'

'

'

'

'

'

191,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant exercise price

'

'

'

'

'

'

'

'

'

'

$7.85

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant expiration period

'

'

'

'

'

'

'

'

'

'

'The Series C Warrant would expire, unless exercised, on the earlier to occur of April 2022 or one year after the Company successfully completes a Qualified IPO

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fees amount

'

'

'

'

'

'

'

'

625,000

'

'

'

'

'

'

'

502,000

270,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Termination fee, percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

3.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible note repayment terms

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'35 days

'

'

'

'

'

'

'

Total repayment debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9,451,000

'

'

'

'

'

'

'

Principal amount of repayment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9,139,000

'

'

'

'

'

'

'

Principal amount of repayment, accrued interest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

34,000

'

'

'

'

'

'

'

Termination fee payment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

278,000

'

'

'

'

'

'

'

Debt instrument borrowing terms

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'The October 2012 Junior Secured Promissory Notes have an initial term of three years and can be extended for an additional two years in one year increments. During the initial three-year term, the October 2012 Junior Secured Promissory Notes bear interest at 12% per annum. If the term of the October 2012 Junior Secured Promissory Notes is extended an additional year, the interest rate increases to 13% during the fourth year. If the term of the October 2012 Junior Secured Promissory Notes is extended for an additional two years, the interest rate is 14% during the fifth year. Interest on the October 2012 Junior Secured Promissory Notes is payable monthly through the initial maturity date of the loan which is October 2, 2015 or through any extension period. The principal and all unpaid interest are due on the maturity date, as may be extended.

'

'

'

'

'

Agent Fee percentage

'

'

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.00%

'

'

'

'

'

Additional fee percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.00%

'

'

'

'

'

Unpaid Agent Fee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

172,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

261,000

'

'

'

'

'

Additional costs related to legal fees

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

66,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants issued to purchase common stock funded principal percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15.00%

'

'

'

'

'

Value of common stock in a sale of the Company or an initial public offering

'

70.00%

'

70.00%

70.00%

70.00%

'

'

'

'

'

'

'

70.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

70.00%

'

'

'

'

'

Fair value of Common Stock Warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

282,000

'

'

'

'

'

Exercise price of the Common Stock Warrants

'

'

8.4

'

'

'

'

'

'

'

'

7.846

'

8.4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8.4

'

'

'

'

'

Covenant requirements minimum cash balance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

'

'

'

'

'

Additional debt cash balance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

'

'

'

Increase in amount available under loan agreement

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional debt issued under amendment

4,950,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt issued in partial consideration for cash

3,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt issued in partial conversion for cancellation of principal balance

1,250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount borrowed under amended loan agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,500,000

12,450,000

'

'

'

Accrued interest on promissory notes

'

74,000

74,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants exercise price percentage

'

'

70.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price of warrants as percentage of common stock

'

'

70.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock warrants issued to purchase common stock percentage

'

'

20.00%

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of Common Stock Warrants

'

'

465,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible debt instrument, face value

'

'

'

41,860,000

'

'

514,000

'

'

'

'

'

'

'

'

'

'

'

'

'

1,250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible debt, fair value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,459,000

'

'

1,360,000

1,360,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, additional borrowings

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,500,000

2,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Promissory Notes issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,750,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,750,000

'

'

'

'

'

Gain on extinguishment of debt

'

'

49,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt discount

'

'

'

'

'

'

'

'

'

113,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value of Additional Common Stock Warrants Issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

352,000

352,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Funds borrowed

'

'

3,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

4,950,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional unpaid Agent Fee, percentage

'

'

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred finance costs

24,000

'

148,000

261,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

87,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount permit to draw

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Credit facility expiry date

'

'

'

'

'

'

'

'

'

'

'

'

30-Jun-14

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Credit facility accrued interest

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Credit facility fee

'

'

'

'

'

'

'

'

'

'

'

'

2.00%

'

'

'

'

'

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Credit facility financing-related costs and primarily legal fees

'

'

'

'

'

'

'

'

'

'

'

'

10,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants expire date

'

'

'

'

'

'

'

'

'

'

'

'

'

14-Jun-23

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of the Warrants at the date of issuance as deferred financing cost

'

'

435,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding amount

'

'

'

'

'

'

'

'

'

'

'

'

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt_Activity_Related_to_Secur

Debt - Activity Related to Secured Promissory Note (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
In Thousands, unless otherwise specified			October 2012 Junior secured promissory notes [Member]	October 2012 Junior secured promissory notes [Member]	October 2012 Junior secured promissory notes [Member]	October 2012 Junior secured promissory notes [Member]	April 2012 Senior Secured Promissory Note [Member]	April 2012 Senior Secured Promissory Note [Member]	April 2012 Senior Secured Promissory Note [Member]	April 2012 Senior Secured Promissory Note [Member]
				Debt discount related to issuance of common stock warrants [Member]	Discount related to the $3,750,000 Notes [Member]	Principal [Member]		Principal [Member]	Discount related to Series C Warrant [Member]	Discount related to financing costs [Member]
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'	'
Debt, beginning balance	$12,437	$16,338	$7,242	($258)	'	$7,500	$8,374	$9,139	($251)	($514)
Amortization of debt discount	'	'	217	130	87	'	765	'	251	514
Debt, ending balance	12,437	16,338	12,005	-241	-204	12,450	'	'	'	'
Principal payments	'	'	'	'	'	'	-9,139	-9,139	'	'
Additions	'	'	$4,546	($113)	($291)	$4,950	'	'	'	'

Debt_Consideration_Received_Fa

Debt - Consideration Received, Fair Values of Notes, Common Stock Warrants Issued and Calculation of the Gain on Extinguishment of Debt (Detail) (USD $)	12 Months Ended				1 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2013	Apr. 10, 2013	Dec. 31, 2012	Apr. 10, 2013	Dec. 31, 2013
		October 2012 subordinated convertible note [Member]	October 2012 subordinated convertible note [Member]	October 2012 subordinated convertible note [Member]	April 2013 junior secured promissory note [Member]	April 2013 junior secured promissory note [Member]
Consideration received	'	'	'	'	'	'
Fair Value of Notes	'	$1,360,000	$1,360,000	'	'	$3,459,000
Cash	'	'	'	'	2,500,000	2,500,000
Total Consideration Received	3,860,000	'	'	'	'	'
Notes and Warrants Issued	'	'	'	'	'	'
Principal Balance of Notes Issued	'	1,250,000	'	1,703,000	'	3,750,000
Debt Discount	'	'	'	'	'	-291,000
Fair Value of Notes	'	1,360,000	1,360,000	'	'	3,459,000
Fair Value of Additional Common Stock Warrants Issued	'	'	'	'	352,000	352,000
Total Fair Value of Notes and Warrants Issued	3,811,000	'	'	'	'	'
Gain on extinguishment of debt	$49,000	'	'	'	'	'

Debt_Activity_Related_to_Secur1

Debt - Activity Related to Secured Promissory Note (Parenthetical) (Detail) (October 2012 Junior secured promissory notes [Member], USD $)	Dec. 31, 2013
October 2012 Junior secured promissory notes [Member]	'
Debt Instrument [Line Items]	'
Promissory notes, issued	$3,750,000

Convertible_Notes_Payable_Summ

Convertible Notes Payable - Summary of Convertible Notes Payable (Detail) (USD $)

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Apr. 10, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

March 2012 convertible notes [Member]

March 2012 convertible notes [Member]

October 2012 convertible notes [Member]

October 2012 convertible notes [Member]

October 2012 subordinated convertible note [Member]

October 2012 subordinated convertible note [Member]

October 2012 subordinated convertible note [Member]

December 2012 convertible note [Member]

December 2012 convertible note [Member]

First may 2013 convertible notes [Member]

Second may 2013 convertible note [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible notes payable, current portion

'

$22,518,000

'

'

$20,204,000

'

$2,314,000

'

'

'

'

'

'

'

Convertible notes payable, noncurrent portion

'

19,342,000

'

'

'

'

'

'

'

2,797,000

'

16,545,000

'

'

Total convertible notes payable

'

$41,860,000

$514,000

'

'

'

'

'

$1,250,000

'

'

'

'

'

Convertible_Notes_Payable_Summ1

Convertible Notes Payable - Summary of Convertible Notes Payable (Parenthetical) (Detail)	12 Months Ended				0 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Oct. 16, 2012	Dec. 06, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
	March 2012 convertible notes [Member]	October 2012 convertible notes [Member]	October 2012 subordinated convertible note [Member]	October 2012 subordinated convertible note [Member]	December 2012 convertible note [Member]	December 2012 convertible note [Member]	First may 2013 convertible notes [Member]	Second may 2013 convertible note [Member]
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'
Maturity Date	30-Sep-13	30-Sep-13	16-Oct-15	'	16-Oct-15	16-Oct-15	22-May-16	30-May-16
Convertible note interest rate	10.00%	10.00%	12.00%	12.00%	10.00%	10.00%	10.00%	10.00%

Convertible_Notes_Payable_Conv

Convertible Notes Payable - Convertible Notes - Additional Information (Detail) (USD $)

1 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

Aug. 31, 2013

28-May-13

Dec. 31, 2013

Dec. 31, 2013

28-May-13

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Common stock [Member]

Common stock [Member]

Equity securities [Member]

March 2012 convertible notes [Member]

March 2012 convertible notes [Member]

October 2012 convertible notes [Member]

October 2012 convertible notes [Member]

October 2012 convertible notes [Member]

March 2012 and October 2012 Convertible Notes [Member]

March 2012 and October 2012 Convertible Notes [Member]

March 2012 and October 2012 Convertible Notes [Member]

March 2012 and October 2012 Convertible Notes [Member]

March 2012 and October 2012 Convertible Notes [Member]

Equity securities [Member]

Common stock [Member]

Equity securities [Member]

Maximum [Member]

Minimum [Member]

Common stock [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issued and sold convertible notes

'

'

'

'

'

'

$8,076,000

'

$1,000,000

'

'

'

'

'

'

'

Maturity Date

'

'

'

'

'

'

30-Sep-13

'

30-Sep-13

'

'

'

'

'

'

'

Convertible note interest rate

'

'

'

'

'

'

10.00%

'

10.00%

'

'

'

'

'

'

'

Proceeds from issuance of public offering

56,105,000

'

56,105,000

30,000,000

'

5,000,000

'

'

'

'

'

'

'

'

'

'

Business acquisition voting transfer

'

'

'

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Notes convert into equity securities of purchase price

'

'

'

'

70.00%

'

'

80.00%

'

80.00%

85.00%

'

'

'

'

70.00%

Discount on conversion price

'

'

'

'

'

'

'

'

'

'

'

'

'

30.00%

20.00%

'

Public offering price of the shares sold

$12

'

'

'

'

'

'

'

'

'

'

$12

'

'

'

'

Estimated fair value of Convertible Notes as of issuance dates

'

'

'

'

'

'

9,343,000

'

1,772,000

'

'

14,599,000

22,518,000

'

'

'

Proceeds from issuance of Convertible Notes

'

3,000,000

'

'

'

'

'

'

'

'

'

9,076,000

'

'

'

'

Excess of estimated fair value of Convertible Notes

'

'

'

'

'

'

'

'

'

'

'

2,039,000

'

'

'

'

Increase of estimated fair value of Convertible Notes

'

'

'

'

'

'

'

'

'

'

'

$8,516,000

$10,721,000

'

'

'

Convertible_Notes_Payable_Octo

Convertible Notes Payable - October 2012 Subordinated Convertible Note - Additional Information (Detail) (USD $)

1 Months Ended

6 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

28-May-13

Jun. 30, 2013

Dec. 31, 2013

Aug. 31, 2013

Apr. 10, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Oct. 31, 2012

Oct. 16, 2012

Dec. 31, 2013

Apr. 10, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Non-current other liabilities [Member]

Current and non-current other assets [Member]

Legal fees [Member]

October 2012 subordinated convertible note [Member]

October 2012 subordinated convertible note [Member]

October 2012 subordinated convertible note [Member]

October 2012 subordinated convertible note [Member]

October 2012 subordinated convertible note [Member]

October 2012 subordinated convertible note [Member]

October 2012 subordinated convertible note [Member]

October 2012 subordinated convertible note [Member]

October 2012 subordinated convertible note [Member]

Agent fee [Member]

Conversion adjusted rate [Member]

Maximum [Member]

Minimum [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Company borrowed convertible note

'

'

'

'

'

'

'

'

'

'

$2,500,000

'

'

'

'

'

'

'

Convertible Note initial maturity term

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

'

Convertible Note additional maturity term

'

'

'

'

'

'

'

'

'

'

'2 years

'

'

'

'

'

'

'

Convertible Note interest percentage per annum

'

'

'

'

'

'

'

'

'

'

12.00%

12.00%

'

'

'

'

'

'

Outstanding principal balance

'

'

'

'

'

'

'

'

'

'

'

1,250,000

'

1,703,000

'

'

'

'

Accrued interest on promissory notes

'

74,000

74,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible debt, fair value

'

'

'

'

'

'

'

'

'

'

'

1,360,000

1,360,000

'

'

'

'

'

Gain on extinguishment of debt

'

'

49,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Converted Agent Fee

'

'

'

'

'

'

48,000

39,000

'

'

'

'

'

'

'

'

'

'

Agent Fee, percentage

'

'

'

'

'

'

'

'

'

5.00%

'

'

'

'

'

'

'

'

Additional agent fee, percentage

'

'

'

'

'

'

'

'

'

1.00%

'

'

'

'

'

'

'

'

Deferred financing costs

'

'

148,000

'

24,000

261,000

'

'

22,000

87,000

'

'

'

'

89,000

'

'

'

Convertible into share of common stock per share

'

'

'

'

'

'

'

'

'

'

'

85.00%

'

'

'

80.00%

'

'

Discount on conversion price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20.00%

15.00%

Public offering price of the shares sold

'

'

'

$12

'

'

'

'

'

'

'

$12

'

'

'

'

'

'

Estimated fair value of Convertible Notes as of issuance dates

'

'

'

'

'

'

'

'

'

'

2,662,000

2,500,000

'

2,797,000

'

'

'

'

Proceeds from issuance of Convertible Notes

3,000,000

'

'

'

'

'

'

'

'

'

2,500,000

'

'

'

'

'

'

'

Excess of estimated fair value of Convertible Notes

'

'

'

'

'

'

'

'

'

'

162,000

'

'

'

'

'

'

'

Increase of estimated fair value of Convertible Notes

'

'

'

'

'

'

'

'

'

'

'

$133,000

'

'

'

'

'

'

Convertible_Notes_Payable_Dece

Convertible Notes Payable - December 2012 Convertible Note - Additional Information (Detail) (USD $)

Jun. 30, 2013

Jun. 30, 2013

Dec. 06, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 06, 2012

Dec. 06, 2012

Dec. 06, 2012

Dec. 06, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Prior to June 30 2013 [Member]

After June 30 2013 [Member]

December 2012 convertible note [Member]

December 2012 convertible note [Member]

December 2012 convertible note [Member]

December 2012 convertible note [Member]

December 2012 convertible note [Member]

December 2012 convertible note [Member]

December 2012 convertible note [Member]

December 2012 convertible note [Member]

December 2012 convertible note [Member]

December 2012 convertible note [Member]

December 2012 convertible note [Member]

December 2012 convertible note [Member]

December 2012 convertible note [Member]

December 2012 convertible note [Member]

Non-Qualified financing [Member]

Non-Qualified financing [Member]

Operating expense [Member]

Cost of license revenue [Member]

Product [Member]

Distributor [Member]

Minimum [Member]

Maximum [Member]

Qualified financing [Member]

Prior to June 30 2013 [Member]

Prior to June 30 2013 [Member]

After June 30 2013 [Member]

After June 30 2013 [Member]

Qualified financing [Member]

Qualified financing [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Company borrowed convertible note

'

'

$12,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Note initial maturity term

'

'

'2 years 10 months

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Note additional maturity term

'

'

'1 year

'

'

'

'

'

'

'

'

'

'

'

'

'

Maturity Date

'

'

16-Oct-15

16-Oct-15

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Note interest percentage

'

'

10.00%

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

Transfer of voting power percentage

'

'

'

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding principal balance

'

'

'

120,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Conversion price percentage on a sale transaction

'

'

'

'

'

'

'

'

'

'

'

'

133.33%

'

142.86%

'

Gross proceeds qualified for conversion

'

'

'

'

'

'

'

'

'

'

'

20,000,000

'

'

'

'

Convertible invested holder of the Company's equity, strategic investors

'

'

'

'

'

'

'

'

'

'

'

50.00%

'

'

'

'

Convertible into share of common stock per share

75.00%

70.00%

'

'

'

'

'

'

'

'

'

'

'

75.00%

'

70.00%

Discount on conversion price

'

'

'

'

'

'

'

'

'

25.00%

30.00%

'

'

'

'

'

Estimated fair value of Convertible Notes as of issuance dates

'

'

16,355,000

19,072,000

16,545,000

'

'

'

'

'

'

'

'

'

'

'

Excess of estimated fair value of Convertible Notes

'

'

3,855,000

'

'

3,610,000

110,000

135,000

245,000

'

'

'

'

'

'

'

Change in estimated fair value of financial instruments

'

'

'

1,767,000

'

'

'

'

'

'

'

'

'

'

'

'

Increase of estimated fair value of Convertible Notes

'

'

'

'

$100,000

'

'

'

'

'

'

'

'

'

'

'

Convertible_Notes_Payable_Firs

Convertible Notes Payable - First and Second May 2013 Convertible Notes - Additional Information (Detail) (USD $)	1 Months Ended		12 Months Ended
	22-May-13	28-May-13	Dec. 31, 2013
Debt Instrument [Line Items]	'	'	'
Sale of convertible note	$3,529,000	'	'
Convertible note interest rate description	'On May 22, 2013, the Company completed the sale of convertible notes under a convertible note purchase agreement in the amount of $3,529,000 in a private placement to 22 investors (First May 2013 Convertible Notes). The First May 2013 Convertible Notes accrued interest at a rate of 10% per annum and would have matured on May 22, 2016.	'On May 28, 2013, the Company completed the sale of a convertible note under a separate convertible note purchase agreement in the amount of $3,000,000 in a private placement (Second May 2013 Convertible Note). The Second May 2013 Convertible Note accrued interest at a rate of 10% per annum and would have matured on May 30, 2016.	'
Proceeds from issuance of Convertible Notes	'	3,000,000	'
Notes converted at discount into common stock percentage	'	'	142.86%
Amount of additional Non-Qualified Financing	'	'	2,000,000
Percentage of proceeds from Non-Qualified Financing	'	'	50.00%
Common stock [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Convertible into share of common stock per share	'	70.00%	'
First and second May 2013 convertible notes [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Payment due under convertible notes	'	0	'
Discount on conversion price	'	'	30.00%
First may 2013 convertible notes [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Proceeds from issuance of Convertible Notes	3,529,000	'	'
Estimated fair value of Convertible Notes as of issuance dates	4,907,000	'	5,147,000
Excess of estimated fair value of Convertible Notes	1,378,000	'	'
Increase of estimated fair value of Convertible Notes	'	'	166,000
Second may 2013 convertible note [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Proceeds from issuance of Convertible Notes	3,000,000	'	'
Estimated fair value of Convertible Notes as of issuance dates	4,162,000	'	4,369,000
Excess of estimated fair value of Convertible Notes	1,162,000	'	'
Increase of estimated fair value of Convertible Notes	'	'	$149,000

Preferred_Stock_Additional_Inf

Preferred Stock - Additional Information (Detail) (USD $)

12 Months Ended

Share data in Thousands, except Per Share data, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Aug. 31, 2013

Jun. 30, 2012

Dec. 31, 2013

31-May-12

31-May-12

Dec. 31, 2013

Dec. 31, 2012

31-May-12

Apr. 30, 2007

Dec. 31, 2013

Dec. 31, 2012

31-May-12

Aug. 31, 2008

Dec. 31, 2013

Dec. 31, 2012

31-May-12

Jun. 30, 2011

IPO [Member]

Pre Amendment [Member]

Post Amendment [Member]

Series A convertible preferred stock [Member]

Series A convertible preferred stock [Member]

Series A convertible preferred stock [Member]

Series A convertible preferred stock [Member]

Series B convertible preferred stock [Member]

Series B convertible preferred stock [Member]

Series B convertible preferred stock [Member]

Series B convertible preferred stock [Member]

Series C convertible preferred stock [Member]

Series C convertible preferred stock [Member]

Series C convertible preferred stock [Member]

Series C convertible preferred stock [Member]

Class of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, shares issued

0

0

'

'

'

'

'

0

1,484

'

1,484

0

2,242

'

2,242

0

4,778

'

4,778

Preferred stock, par value

$0.00

'

'

'

'

'

'

$0.00

$0.00

'

$2.61

$0.00

$0.00

'

$4.85

$0.00

$0.00

'

$5.32

Convertible notes payable

'

$41,860,000

'

$514,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued interest

'

'

'

5,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares authorized

250,000

12,936

250,000

'

'

12,745

12,936

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, shares authorized

20,000

0

20,000

'

20,000

8,632

8,823

0

1,489

1,489

'

0

2,252

2,252

'

0

5,082

5,082

'

Basis conversion of outstanding convertible preferred stock into common stock

'1-for-1 basis

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividends declared

$0

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants_Summary_of_Informatio

Warrants - Summary of Information about Common Stock Warrants Outstanding (Detail)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013
In Thousands, unless otherwise specified			Additional Common Stock Warrant [Member]	June 2013 Warrants [Member]
			April 2013 junior secured promissory note [Member]	June 2013 credit facility [Member]
Class of Warrant or Right [Line Items]	'	'	'	'
Issue date	'	'	'April 2013	'June 2013
Expiration date	'	'	'October 2015	'June 2023
Number of shares subject to warrant issued	151	207	118	33
Exercise price	8.4	'	8.4	8.4

Warrants_Summary_of_Informatio1

Warrants - Summary of Information about Common Stock Warrants Outstanding (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2013
Other Liabilities Disclosure [Abstract]	'
Voting power percentage	50.00%

Warrants_Additional_Informatio

Warrants - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2013
Other Liabilities Disclosure [Abstract]	'
Additional Common Stock Warrants, exercisable	'18 months

Warrants_Summary_of_Informatio2

Warrants -Summary of Information about Convertible Preferred Stock and Common Stock Warrants Outstanding (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2012
In Thousands, unless otherwise specified			Common stock [Member]	Series A convertible preferred stock [Member]	Series C convertible preferred stock [Member]	Promissory note and revolving line of credit [Member]	Promissory note [Member]
						Series B convertible preferred stock [Member]	Series B convertible preferred stock [Member]
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Issue date	'	'	'October 2012	'April 2007	'April 2012	'August 2008	'March 2009
Expiration date	'	'	'October 2015	'April 2014	'April 2022	'May 2013	'March 2014
Number of shares subject to warrant issued	151	207	'	6	191	3	7
Exercise price	8.4	'	'	2.608	7.846	4.849	4.849
Estimated fair value as of December 31, 2012	'	$2,185	$301	$68	$1,710	$34	$72

Warrants_Summary_of_Informatio3

Warrants -Summary of Information about Convertible Preferred Stock and Common Stock Warrants Outstanding (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2012	Jun. 30, 2013	Apr. 30, 2013	Oct. 31, 2012
Other Liabilities Disclosure [Abstract]	'	'	'	'
Percentage on funded principal amount	15.00%	'	'	'
Percentage on value of common stock in sale of company or an initial public offering	70.00%	70.00%	70.00%	70.00%
Percentage of exercise price on value of common stock	70.00%	70.00%	70.00%	70.00%

Common_Stock_Additional_Inform

Common Stock - Additional Information (Detail) (USD $)	Dec. 31, 2013	Aug. 31, 2013	Dec. 31, 2012
In Thousands, except Per Share data, unless otherwise specified
Equity [Abstract]	'	'	'
Common stock, shares authorized	250,000	250,000	12,936
Common stock, par value	$0.00	$0.00	$0.00

Common_Stock_Reserved_Shares_o

Common Stock - Reserved Shares of Common Stock for Future Issuances (Detail)	Dec. 31, 2013
In Thousands, unless otherwise specified
Class of Stock [Line Items]	'
Reserved shares of common stock for future issuances	3,953
Stock options available for future grant [Member]	'
Class of Stock [Line Items]	'
Reserved shares of common stock for future issuances	1,194
Stock options outstanding [Member]	'
Class of Stock [Line Items]	'
Reserved shares of common stock for future issuances	2,608
Warrants to purchase common stock [Member]	'
Class of Stock [Line Items]	'
Reserved shares of common stock for future issuances	151

Stock_Option_Plans_Additional_

Stock Option Plans - Additional Information (Detail) (USD $)	12 Months Ended							12 Months Ended		12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Jul. 31, 2006	Dec. 31, 2013	Jul. 31, 2011	Dec. 31, 2013
				Donald Glidewell [Member]	2006 Equity incentive plan [Member]	2006 Equity incentive plan [Member]	2006 Equity incentive plan [Member]	2011 Stock plan [Member]	2011 Stock plan [Member]	Stock incentive plan 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Common stock shares authorized	'	'	'	'	'	'	1,434,000	'	1,167,000	1,600,000
Number of shares available for grant	1,194,000	352,000	'	'	0	0	'	0	0	'
Number of stock options exercised, subject to repurchase	'	'	'	'	0	0	'	'	'	'
Number of options outstanding	2,608,000	2,067,000	'	'	705,000	'	'	1,131,000	'	772,000
Number of options weighted average exercise price	$8.56	$3.86	'	'	$1.04	'	'	$7.67	'	$16.74
Number of options vested	'	'	'	'	624,000	'	'	420,000	'	11,000
Number of options exercised	217,000	'	'	'	204,000	'	'	13,000	'	0
Number of options canceled	278,000	'	'	'	116,000	'	'	120,000	'	42,000
Exercise of incentive stock options	'	'	'	'	'	'	'	'	2,446,000	'
Percentage increase by number of shares of common stock outstanding	'	'	'	'	'	'	'	'	'	3.50%
Options vesting percentage	25.00%	'	'	'	'	'	'	'	'	'
Vesting of options, description	'Generally, options vest 25% on the first anniversary from the date of grant and 1/48 per month thereafter	'	'	'	'	'	'	'	'	'
Total intrinsic value of options exercised	$2,801,000	$93,000	$7,000	'	'	'	'	'	'	'
Estimated fair value of options vested	1,314,000	489,000	228,000	'	'	'	'	'	'	'
Weighted-average estimated fair value of options granted	$10.35	$4.24	$0.78	'	'	'	'	'	'	'
Share-based compensation expense	2,300,000	662,000	271,000	266,000	'	'	'	'	'	'
Tax benefit not recognized	0	0	0	'	'	'	'	'	'	'
Unvested options granted to employees stock option plans	$10,454,000	'	'	$444,000	'	'	'	'	'	'
Weighted-average remaining term	'3 years 3 months 18 days	'	'	'3 months 18 days	'	'	'	'	'	'

Stock_Option_Plans_Summary_of_

Stock Option Plans - Summary of Activity under Company's Stock Option Plans (Detail) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'
Shares available for grant, Beginning balance	352	'
Shares available for grant, Options authorized	1,600	'
Shares available for grant, Options granted	-1,036	'
Shares available for grant, Options exercised	'	'
Shares available for grant, Options canceled	278	'
Shares available for grant, Ending balance	1,194	352
Shares outstanding, Beginning balance	2,067	'
Shares outstanding, Options granted	1,036	'
Shares outstanding, Options exercised	-217	'
Shares outstanding, Options canceled	-278	'
Shares outstanding, Ending balance	2,608	2,067
Shares outstanding, Vested and expected to vest	2,409	'
Shares outstanding, Exercisable	1,054	'
Weighted Average Exercise Price, Beginning balance	$3.86	'
Weighted Average Exercise Price, Options granted	$15.76	'
Weighted Average Exercise Price, Options exercised	$1.18	'
Weighted Average Exercise Price, Options canceled	$6.24	'
Weighted Average Exercise Price, Ending balance	$8.56	$3.86
Weighted Average Exercise Price, Vested and expected to vest	$8.25	'
Weighted Average Exercise Price, Exercisable	$2.97	'
Weighted-Average remaining contractual life	'8 years 1 month 6 days	'7 years 8 months 12 days
Weighted-Average remaining contractual life, Vested and expected to vest	'8 years	'
Weighted-Average remaining contractual life, Exercisable	'6 years 6 months	'
Aggregate intrinsic value, Beginning balance	$14,380	'
Aggregate intrinsic value, Ending balance	24,158	14,380
Aggregate intrinsic value, Vested and expected to vest	23,061	'
Aggregate intrinsic value, Exercisable	$15,610	'

Capital_Leases_Additional_Info

Capital Leases - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Capital Leased Assets [Line Items]	'	'	'
Amortization of capital leases	$470,000	$175,000	$143,000
Machinery and equipment [Member]	'	'	'
Capital Leased Assets [Line Items]	'	'	'
Property plant and equipment under capital leases	3,046,000	939,000	'
Property plant and equipment, accumulated amortization under capital leases	$935,000	$465,000	'

Capital_Leases_Aggregate_Contr

Capital Leases - Aggregate Contractual Future Minimum Lease Payments (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Leases [Abstract]	'	'
2014	$1,520	'
2015	1,120	'
2016	54	'
Total minimum payments required	2,694	'
Less: amount representing interest	-159	'
Present value of future payments	2,535	'
Less: current portion	-1,401	-207
Capital lease obligations, less current portion	$1,134	$195

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)	0 Months Ended	12 Months Ended
	Sep. 09, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	sqft
Operating Leased Assets [Line Items]	'	'	'	'
Office facility lease agreement	28,700	'	'	'
Lease termination date	'	'2015-02	'	'
Lease renewal period	'5 years	'	'	'
Lease agreement period	'60 months	'	'	'
Monthly base rent	$46,000	'	'	'
Percentage of annual increase in base rent	3.00%	'	'	'
Rental expense	'	691,000	484,000	412,000
Legal proceedings	'	$0	'	'
Minimum [Member]	'	'	'	'
Operating Leased Assets [Line Items]	'	'	'	'
Leased office facilities expiration period	'	28-Feb-14	'	'
Maximum [Member]	'	'	'	'
Operating Leased Assets [Line Items]	'	'	'	'
Leased office facilities expiration period	'	31-Oct-16	'	'
Office and laboratory [Member]	'	'	'	'
Operating Leased Assets [Line Items]	'	'	'	'
Lease start date	9-Sep-13	'	'	'
Office space [Member]	'	'	'	'
Operating Leased Assets [Line Items]	'	'	'	'
Office facility lease agreement	'	24,500	'	'
Lease renewal period	'	'5 years	'	'

Commitments_and_Contingencies_2

Commitments and Contingencies - Schedule of Non-Cancelable Lease Agreements (Detail) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Commitments And Contingencies Disclosure [Abstract]	'
2014	$965
2015	753
2016	666
2017	606
2018 and beyond	822
Total minimum payments required	$3,812

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Contingency [Line Items]	'	'	'
Net deferred tax assets	$34,250,000	$22,400,000	'
Change in valuation allowance	11,850,000	8,134,000	5,211,000
Federal research and development credits	151,000	'	'
Deferred tax liabilities	0	0	'
Income tax expense (benefit)	'	'	'
Unrecognized tax benefits	525,000	340,000	305,000
Maximum [Member]	'	'	'
Income Tax Contingency [Line Items]	'	'	'
Limitations on carry-forwards	493,000	'	'
Income tax examination year	'2013	'	'
Minimum [Member]	'	'	'
Income Tax Contingency [Line Items]	'	'	'
Income tax examination year	'2006	'	'
Federal income tax [Member]	'	'	'
Income Tax Contingency [Line Items]	'	'	'
Net operating loss carry-forwards	77,682,000	'	'
Net operating loss carry-forwards, expiry period	'2026	'	'
Research and development tax credit carry-forwards	1,414,000	'	'
Tax credit carry-forwards, expiry period	'2026	'	'
State [Member]	'	'	'
Income Tax Contingency [Line Items]	'	'	'
Research and development tax credit carry-forwards	1,274,000	'	'
Various other state [Member]	'	'	'
Income Tax Contingency [Line Items]	'	'	'
Net operating loss carry-forwards	13,656,000	'	'
Net operating loss carry-forwards, expiry period	'2031	'	'
California [Member] | State [Member]	'	'	'
Income Tax Contingency [Line Items]	'	'	'
Net operating loss carry-forwards	$59,829,000	'	'
Net operating loss carry-forwards, expiry period	'2016	'	'

Income_Taxes_Schedule_of_Defer

Income Taxes - Schedule of Deferred Tax Assets (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Components of deferred taxes:	'	'
Net operating loss carryforwards	$30,258	$19,966
Research and development tax credit	1,577	1,002
Other, net	2,415	1,432
Net deferred tax assets	34,250	22,400
Less: valuation allowance	-34,250	-22,400
Net deferred tax assets	'	'

Income_Taxes_Reconciliation_of

Income Taxes - Reconciliation of Effective Income Tax Rate to US Federal Income Tax Statutory Rate (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]	'	'
Federal tax benefit at statutory rate	34.00%	34.00%
State tax benefit, net of federal benefit	5.00%	5.00%
Interest expense	-5.00%	'
Mark-to-market accounting	9.00%	-12.00%
Deemed dividend	-2.00%	-6.00%
Share-based compensation expense	-2.00%	'
Other	1.00%	-1.00%
Adjustment due to change in valuation allowance	-40.00%	-20.00%
Provision for income taxes	'	'

Income_Taxes_Reconciliation_of1

Income Taxes - Reconciliation of Beginning and Ending Unrecognized Tax Benefits (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]	'	'
Beginning balance	$340	$305
Increase related to prior year tax positions	79	'
Increase related to current year tax positions	106	35
Ending balance	$525	$340

Employee_Benefit_Plan_Addition

Employee Benefit Plan - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Defined contribution plan, maximum employers contribution	3.00%	'	'
Defined contribution plan, additional matching contribution	50.00%	'	'
Defined contribution plan, vesting percentage	100.00%	'	'
Defined contribution plan, matching contribution amount	$294,000	$229,000	$190,000
Minimum [Member]	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Defined contribution plan, additional matching contribution percentage	3.00%	'	'
Maximum [Member]	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Defined contribution plan, additional matching contribution percentage	5.00%	'	'

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Related Party Transaction [Line Items]	'	'	'
Products purchased for further distribution and resale	$1,693,000	$184,000	$150,000
Tremont Group, Inc [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Products purchased for further distribution and resale	1,446,000	'	'
Outstanding accounts receivable due	903,000	'	'
Accounts receivable due date	'2014-04	'	'
Syngenta [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Products purchased for further distribution and resale	116,000	'	'
Outstanding accounts receivable due	0	'	'
Convertible note issued	'	12,500,000	'
Convertible note converted into shares, outstanding balance	0	'	'
License revenue recognized	$131,000	'	'

Reverse_Stock_Split_Additional

Reverse Stock Split - Additional Information (Detail)	1 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Aug. 31, 2013	Dec. 31, 2013	Dec. 31, 2012
Equity [Abstract]	'	'	'
Conversion of convertible preferred stock ratio	1	1	'
Reverse stock split	'1-for-3.138458	'	'
Reverse stock split, ratio	3.138458	'	'
Increased number of shares of common stock authorized for issuance	250,000	250,000	12,936
Increased number of shares of preferred stock authorized for issuance	20,000	20,000	0

Initial_Public_Offering_Additi

Initial Public Offering - Additional Information (Detail) (USD $)	1 Months Ended	12 Months Ended
	Aug. 31, 2013	Dec. 31, 2013	Dec. 31, 2012
Subsidiary, Sale of Stock [Line Items]	'	'	'
Shares issued under initial public offering	5,462,500	'	'
Issuance of common stock under IPO to underwriters by selling stockholders	712,500	'	'
Public offering price of the shares sold in the offering	$12	'	'
Total gross proceeds from IPO	$65,550,000	'	'
Aggregate net proceeds received	$56,105,000	$56,105,000	'
Convertible preferred stock and warrants to common stock	8,514,000	'	'
Common stock issued upon cash exercise of common stock warrants	3,000	'	'
Convertible notes converted into common stock	3,741,000	'	'
Common stock issued upon net exercise of common stock warrants	47,000	'	'
Common stock, shares outstanding	19,133,000	19,323,000	1,267,000
Warrants to purchase common stock outstanding	151,000	'	'
Series B convertible preferred stock warrants [Member]	'	'	'
Subsidiary, Sale of Stock [Line Items]	'	'	'
Common stock issued upon cash exercise of common stock warrants	10,000	'	'
Series A and Series C convertible preferred stock warrants [Member]	'	'	'
Subsidiary, Sale of Stock [Line Items]	'	'	'
Convertible preferred stock and warrants to common stock	71,000	'	'

Quarterly_Financial_Informatio2

Quarterly Financial Information - Summary of Quarterly Financial Information (Detail) (USD $)	3 Months Ended								9 Months Ended	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly Financial Information Disclosure [Abstract]	'	'	'	'	'	'	'	'	'	'	'	'
Total revenues	$5,967	$1,346	$4,500	$2,730	$2,894	$738	$1,509	$1,999	'	$14,543	$7,140	$5,251
Gross profit	1,501	269	1,102	935	626	217	825	1,139	'	3,807	2,807	3,079
Net loss	-9,991	-6,110	-1,639	-10,749	-17,096	-13,802	-3,912	-3,984	-18,498	-28,489	-38,794	-13,180
Deemed dividend on convertible notes	'	'	-1,378	'	-786	'	'	-1,253	-1,378	-1,378	-2,039	'
Net loss attributable to common stockholders	($9,991)	($6,110)	($3,017)	($10,749)	($17,882)	($13,802)	($3,912)	($5,237)	($19,876)	($29,867)	($40,833)	($13,180)
Net loss per common share:	'	'	'	'	'	'	'	'	'	'	'	'
Basic	($0.52)	($0.47)	($2.36)	($8.48)	($14.11)	($10.94)	($3.13)	($4.20)	'	($3.42)	($32.48)	($10.64)
Diluted	($0.52)	($0.80)	($2.67)	($8.48)	($14.11)	($10.94)	($3.13)	($4.20)	($4.63)	($3.94)	($32.48)	($10.64)

Quarterly_Financial_Informatio3

Quarterly Financial Information - Schedule of Error Corrections - Computation of Common Shares Upon Exercise of Warrants and Basic and Diluted Net Loss Per Share (Detail) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

In Thousands, except Per Share data, unless otherwise specified

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Numerator:

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

($9,991)

($6,110)

($1,639)

($10,749)

($17,096)

($13,802)

($3,912)

($3,984)

($18,498)

($28,489)

($38,794)

($13,180)

Deemed dividend on convertible notes

'

'

-1,378

'

-786

'

'

-1,253

-1,378

-1,378

-2,039

'

Net loss attributable to common stockholders

-9,991

-6,110

-3,017

-10,749

-17,882

-13,802

-3,912

-5,237

-19,876

-29,867

-40,833

-13,180

Effect of potentially dilutive securities:

'

'

'

'

'

'

'

'

'

'

'

'

Net loss for diluted net loss per share

'

-10,766

-3,592

'

'

'

'

'

-25,109

-35,099

-40,833

-13,180

Denominator:

'

'

'

'

'

'

'

'

'

'

'

'

Shares used for basic net loss per share

'

12,888

1,277

'

'

'

'

'

5,187

8,731

1,257

1,239

Effect of potentially dilutive securities:

'

'

'

'

'

'

'

'

'

'

'

'

Convertible notes

'

503

'

'

'

'

'

'

169

127

'

'

Warrants to purchase convertible preferred stock

'

31

70

'

'

'

'

'

61

'

'

'

Warrants to purchase common stock

'

'

'

'

'

'

'

'

'

53

'

'

Weighted average shares outstanding for diluted net loss per share

'

13,422

1,347

'

'

'

'

'

5,417

8,911

1,257

1,239

Diluted net loss per share

($0.52)

($0.80)

($2.67)

($8.48)

($14.11)

($10.94)

($3.13)

($4.20)

($4.63)

($3.94)

($32.48)

($10.64)

Convertible notes [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Effect of potentially dilutive securities:

'

'

'

'

'

'

'

'

'

'

'

'

Effect of potentially dilutive securities

'

-4,392

'

'

'

'

'

'

-4,392

-4,392

'

'

Warrants to purchase preferred stock [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Effect of potentially dilutive securities:

'

'

'

'

'

'

'

'

'

'

'

'

Effect of potentially dilutive securities

'

-264

-575

'

'

'

'

'

-841

-840

'

'

As reported [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Numerator:

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

'

-6,110

-1,639

'

'

'

'

'

-18,498

'

'

'

Deemed dividend on convertible notes

'

'

-1,378

'

'

'

'

'

-1,378

'

'

'

Net loss attributable to common stockholders

'

-6,110

-3,017

'

'

'

'

'

-19,876

'

'

'

Effect of potentially dilutive securities:

'

'

'

'

'

'

'

'

'

'

'

'

Warrants to purchase common stock

'

-201

'

'

'

'

'

'

-201

'

'

'

Net loss for diluted net loss per share

'

-7,400

-3,017

'

'

'

'

'

-20,195

'

'

'

Denominator:

'

'

'

'

'

'

'

'

'

'

'

'

Shares used for basic net loss per share

'

12,888

1,277

'

'

'

'

'

5,187

'

'

'

Effect of potentially dilutive securities:

'

'

'

'

'

'

'

'

'

'

'

'

Convertible notes

'

1,043

'

'

'

'

'

'

20

'

'

'

Warrants to purchase common stock

'

86

'

'

'

'

'

'

22

'

'

'

Weighted average shares outstanding for diluted net loss per share

'

14,017

1,277

'

'

'

'

'

5,229

'

'

'

Diluted net loss per share

'

($0.53)

($2.36)

'

'

'

'

'

($3.86)

'

'

'

As reported [Member] | Convertible notes [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Effect of potentially dilutive securities:

'

'

'

'

'

'

'

'

'

'

'

'

Effect of potentially dilutive securities

'

($1,089)

'

'

'

'

'

'

($118)

'

'

'